<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Saudi J Biol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Saudi J Biol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2150</journal-id><journal-id journal-id-type="pmc-domain">sjbs</journal-id><journal-title-group><journal-title>Saudi Journal of Biological Sciences</journal-title></journal-title-group><issn pub-type="ppub">1319-562X</issn><issn pub-type="epub">2213-7106</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9073025</article-id><article-id pub-id-type="pmcid-ver">PMC9073025.1</article-id><article-id pub-id-type="pmcaid">9073025</article-id><article-id pub-id-type="pmcaiid">9073025</article-id><article-id pub-id-type="pmid">35531220</article-id><article-id pub-id-type="doi">10.1016/j.sjbs.2022.01.006</article-id><article-id pub-id-type="pii">S1319-562X(22)00006-7</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Strategies for successful designing of immunocontraceptive vaccines and recent updates in vaccine development against sexually transmitted infections - A review</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name name-style="western"><surname>Vickram</surname><given-names initials="AS">A.S.</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au010"><name name-style="western"><surname>Dhama</surname><given-names initials="K">Kuldeep</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au015"><name name-style="western"><surname>Thanigaivel</surname><given-names initials="S">S.</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au020"><name name-style="western"><surname>Chakraborty</surname><given-names initials="S">Sandip</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au025"><name name-style="western"><surname>Anbarasu</surname><given-names initials="K">K.</given-names></name><xref rid="af020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au030"><name name-style="western"><surname>Dey</surname><given-names initials="N">Nibedita</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au035"><name name-style="western"><surname>Karunakaran</surname><given-names initials="R">Rohini</given-names></name><email>rohini@aimst.edu.my</email><xref rid="af025" ref-type="aff">e</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="af005"><label>a</label>Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Tamil Nadu, India</aff><aff id="af010"><label>b</label>Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh 243122, India</aff><aff id="af015"><label>c</label>Department of Veterinary Microbiology, College of Veterinary Sciences &amp;amp, Animal Husbandry, R.K.Nagar, West Tripura, Pin- 799008, India</aff><aff id="af020"><label>d</label>Department of Bioinformatics, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Tamil Nadu, India</aff><aff id="af025"><label>e</label>Unit of Biochemistry, Faculty of Medicine, AIMST University, Semeling, Bedong, Kedah, Malaysia</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>rohini@aimst.edu.my</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>07</day><month>1</month><year>2022</year></pub-date><volume>29</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">407044</issue-id><fpage>2033</fpage><lpage>2046</lpage><history><date date-type="received"><day>18</day><month>8</month><year>2021</year></date><date date-type="rev-recd"><day>30</day><month>12</month><year>2021</year></date><date date-type="accepted"><day>2</day><month>1</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>01</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>07</day><month>05</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-12 20:25:19.570"><day>12</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 The Authors. Published by Elsevier B.V. on behalf of King Saud University.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab005"><sec><title>Background</title><p>The world population is continuously growing. It has been estimated that half of the world&#8217;s population is from the Asian continent, mainly from China and India. Overpopulation may lead to many societal problems as well as to changes in the habitat. Birth control measures are thus needed to control this growth. However, for the last 50&#8211;60&#160;years, there have not been any improvements in the field of contraception. Nevertheless, the immunocontraceptive vaccine is an emerging field, and it might be the only replacement for the existing mode of contraception for the next millennium. Sexually transmitted infections (STIs) are frequent, and their transmission rate increases yearly. As antibiotics are the prevailing treatment for this kind of infections, resistance in humans has increased; therefore, having effective antibiotic treatments for STIs is now a concern. Vaccines against STIs are now needed. It is thought that the improvements in the fields of proteomics, immunomics, metabolomics, and other omics will help in the successful development of vaccines.</p></sec><sec><title>Objective</title><p>To collect and review the literature about recent advancements in immunocontraception and vaccines against sexually transmitted diseases/infections.</p></sec><sec><title>Methods</title><p>Reliable scientific databases, such as PubMed Central, PubMed, Scopus, Science Direct, and Goggle Scholar, were consulted. Publications bearing important information on targeted antigens/immunogens for contraceptive vaccine design and advancements in vaccine development for STIs were gathered and tabulated, and details were analyzed as per the theme of each study.</p></sec><sec><title>Results</title><p>Important antigens that have a specific role in fertility have been studied extensively for their contraceptive nature. Additionally, the advancements in the screening for the best antigens, according to their antigenic nature and how they elicit immune responses for an extended period were also studied. Herd immunity for STIs and advancements in the development of vaccines for syphilis, gonorrhea, and herpes simplex virus were also studied and tabulated in this review. An extensive knowledge on STIs vaccines was gained.</p></sec><sec><title>Conclusion</title><p>This extensive review is aimed to provide insights for active researchers in vaccinology, immunology, and reproductive biology. Advancements in the development of vaccines for different STIs can be gathered as a wholesome report.</p></sec></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Vaccine</kwd><kwd>Immunocontraception</kwd><kwd>Sexually transmitted infections</kwd><kwd>Herd immunity</kwd><kwd>Syphilis</kwd><kwd>Herpes simplex virus</kwd><kwd>Antigens</kwd><kwd>Immunogens</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0005">The world population is growing at an alarming rate each year (<xref rid="b0005" ref-type="bibr">Moore et al., 2016</xref>), and this growth rate in developing countries is two times the rate in developed nations (<xref rid="b0010" ref-type="bibr">Uniyal et al., 2016</xref>). Half of the world&#8217;s population is contributed by Asian countries, specifically by India and China. Besides, contraceptive usage and research are in their infancy till 1960 (<xref rid="b0015" ref-type="bibr">Pohjoranta et al., 2020</xref>). This leads to 46 million abortions each year in the developing nations (<xref rid="b0020" ref-type="bibr">Ganatra et al., 2017</xref>), which are also due to a lack of proper temporary contraceptive practices (<xref rid="b0025" ref-type="bibr">Dahal et al., 2017 2(1):1005</xref>). Government agencies only promote condom usage for men as an effective contraception method in the developing nations (<xref rid="b0030" ref-type="bibr">Kidan and Azeze, 2017</xref>, <xref rid="b0035" ref-type="bibr">Girma et al., 2017</xref>). But condom usage is not 100% effective for birth control (<xref rid="b0040" ref-type="bibr">Magnani et al., 2007</xref>). Once again, this lack of effectivity leads to abortions and further consequences that must be faced by women in the developing countries (<xref rid="b0045" ref-type="bibr">Barroso and Babanto, 2016</xref>). Birth control methods available in developed nations include birth control implants (<xref rid="b0050" ref-type="bibr">Cromer et al., 1994</xref>), patches (<xref rid="b0055" ref-type="bibr">Hampton, 2016</xref>, <xref rid="b0060" ref-type="bibr">Kuehn, 2008</xref>), pills (<xref rid="b0065" ref-type="bibr">Delavande, 2008</xref>), birth control shots (<xref rid="b0070" ref-type="bibr">Jayaraman, 2018</xref>), sponges (for vaginal sex) (<xref rid="b0075" ref-type="bibr">Reed, 2014</xref>), vaginal rings (<xref rid="b0080" ref-type="bibr">Murphy et al., 2016</xref>), breastfeeding as an alternate type of birth control (<xref rid="b0085" ref-type="bibr">Houv&#232;ssou et al., 2020</xref>), cervical caps (<xref rid="b0090" ref-type="bibr">Zapata et al., 2015</xref>), condoms (<xref rid="b0095" ref-type="bibr">Clark et al., 2014</xref>), diaphragms (<xref rid="b0100" ref-type="bibr">Beksinska, 2016</xref>), female condoms (<xref rid="b0105" ref-type="bibr">Wiyeh et al., 2020</xref>), fertility awareness programs (<xref rid="b0110" ref-type="bibr">Malarcher et al., 2016</xref>), intrauterine devices (IUDs) (<xref rid="b0115" ref-type="bibr">Lopez et al., 2015</xref>), outercourse and abstinence (<xref rid="b0120" ref-type="bibr">Bakaroudis, 2014</xref>), spermicides (<xref rid="b0125" ref-type="bibr">Susmiarsih et al., 2017</xref>), and vasectomy (<xref rid="b0130" ref-type="bibr">Mandell et al., 2021</xref>). However, developing nations are widely using condoms as sole contraceptives, which are only 70% effective for birth control. Countries like India and China are strongly recommending controlling overpopulation given that food and clean water supplies are limited and that fulfilling people&#8217;s basic needs often leads to habitat and environmental destruction (<xref rid="b0135" ref-type="bibr">Edet</xref>). Therefore, modern or novel contraception methods with a 100% success rate for birth control are still needed; they would reduce unnecessary abortions, protecting women&#8217;s health (<xref rid="b0140" ref-type="bibr">Hanna et al., 2016</xref>). Although cost affordable, effective methods of contraception are available in the market in both developed and developing countries, pharmaceutical companies are still investing much money in search for new contraceptive methods (<xref rid="b0145" ref-type="bibr">Rubin, 2017</xref>). Moreover, existing methods are still not affordable for people in rural areas of countries like India and China, and governments should focus in reducing the unmet demand. For the last 30 or 40&#160;years, numerous reproductive biologists and immunologists have been trying to develop a contraceptive vaccine with a 100% success rate in birth control. Immunocontraception might be the novel contraceptive method for the next millennium (<xref rid="b0150" ref-type="bibr">Talwar et al., 2015</xref>. <xref rid="f0005" ref-type="fig">Fig. 1</xref>, <xref rid="t0005" ref-type="table">Tables 1</xref> and <xref rid="t0010" ref-type="table">2</xref>.<fig id="f0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>Strategies for contraceptive vaccine design.</bold> 1. Disturbing the hormone axis leading to inappropriate secretions results in contraception. 2. Sperm cell needs to bind to prostasomes for motility and establishing fertility. Target antigens can prevent this binding and works as contraception. 3. Targeting immunogenic proteins responsible for an ovum may result in anovulation. 4. Thus, an essential step in the fertilisation process- binding sperm cell with egg and its further fusion can be prevented, and contraception is achieved. 5. A large number of immunogenic proteins are involved in suppressing maternal response to sperm cell and embryo. Targeting any of those proteins can successfully prevent implantation of the fetus, so pregnancy can be avoided.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p>Important and explored antigens/immunogens for contraception.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"><bold>Targeted Immunogens/Antigens</bold></th><th colspan="1" rowspan="1"><bold>Species</bold></th><th colspan="1" rowspan="1"><bold>Mechanism</bold></th><th colspan="1" rowspan="1"><bold>Author studied and year</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Porcine zona pellucida (pZPC)</td><td colspan="1" rowspan="1">Wallaby<break/>White-tailed deer, Wild horses</td><td colspan="1" rowspan="1">It stops the attachment of sperm with egg and thus the fertilization</td><td colspan="1" rowspan="1"><xref rid="b0370" ref-type="bibr">Curtis et al., 2002</xref>, <xref rid="b0370" ref-type="bibr">Curtis et al., 2002</xref>, <xref rid="b0375" ref-type="bibr">Turner et al., 2002</xref>, <xref rid="b0375" ref-type="bibr">Turner et al., 2002</xref>, <xref rid="b0380" ref-type="bibr">Shideler et al., 2002</xref>, <xref rid="b0380" ref-type="bibr">Shideler et al., 2002</xref>, <xref rid="b0385" ref-type="bibr">Kirkpatrick et al., 1996 50,</xref> (<xref rid="b0385" ref-type="bibr">Kirkpatrick et al., 1996 50</xref>)<break/> (<xref rid="b0345" ref-type="bibr">Tumova et al., 2021</xref>)</td></tr><tr><td colspan="1" rowspan="1">Virally vectored zona pellucida</td><td colspan="1" rowspan="1">Rabbit<break/>vertebrate Pests<break/>Mouse<break/></td><td colspan="1" rowspan="1">Produces Follicular damage after immunisation and thus prevent the meeting of sperm and egg for fertilization</td><td colspan="1" rowspan="1"><xref rid="b0390" ref-type="bibr">Hardy et al., 2006</xref>, <xref rid="b0390" ref-type="bibr">Hardy et al., 2006</xref>, <xref rid="b0395" ref-type="bibr">Lloyd et al., 2003</xref>, <xref rid="b0395" ref-type="bibr">Lloyd et al., 2003</xref>, <xref rid="b0400" ref-type="bibr">Hardy, 2007</xref>, <xref rid="b0400" ref-type="bibr">Hardy, 2007</xref>, <xref rid="b0405" ref-type="bibr">Redwood et al., 2008</xref> (<xref rid="b0405" ref-type="bibr">Redwood et al., 2008</xref>)<break/><xref rid="b0410" ref-type="bibr">McLeod et al., 2008</xref>, <xref rid="b0410" ref-type="bibr">McLeod et al., 2008</xref></td></tr><tr><td colspan="1" rowspan="1">Gonadotropin-releasing hormone (GnRH)</td><td colspan="1" rowspan="1">Swine<break/>Mouse<break/>Horse<break/>White-Tailed Deer</td><td colspan="1" rowspan="1">Stops or lessens the production of LH and FSH hormone, which helps in controlling the gamete production and also the secondary sexual characteristics in both male and female</td><td colspan="1" rowspan="1"><xref rid="b0415" ref-type="bibr">Killian et al., 2006</xref>, <xref rid="b0415" ref-type="bibr">Killian et al., 2006</xref>, <xref rid="b0420" ref-type="bibr">Miller et al., 2008</xref>, <xref rid="b0420" ref-type="bibr">Miller et al., 2008</xref>, <xref rid="b0425" ref-type="bibr">Han et al., 2016</xref>, <xref rid="b0425" ref-type="bibr">Han et al., 2016</xref>, <xref rid="b0430" ref-type="bibr">Goodwin et al., 2015</xref>, <xref rid="b0430" ref-type="bibr">Goodwin et al., 2015</xref>, <xref rid="b0435" ref-type="bibr">Barranco et al., 2015</xref>, <xref rid="b0435" ref-type="bibr">Barranco et al., 2015</xref><break/> (<xref rid="b0440" ref-type="bibr">Madbouly et al., 2021</xref>) <break/><xref rid="b0445" ref-type="bibr">Pinna et al., 2015</xref>, <xref rid="b0445" ref-type="bibr">Pinna et al., 2015</xref></td></tr><tr><td colspan="1" rowspan="1">SP-17</td><td colspan="1" rowspan="1">Domestic kittens<break/>mice<break/></td><td colspan="1" rowspan="1">Stops the sperm capacitation and sperm motility, steps adherence of prostasomes and sperm cell which is much needed for fertilisation</td><td colspan="1" rowspan="1"><xref rid="b0450" ref-type="bibr">Minhas et al., 2016</xref>, <xref rid="b0450" ref-type="bibr">Minhas et al., 2016</xref>, <xref rid="b0455" ref-type="bibr">Kaur and Prabha, 2014</xref>, <xref rid="b0455" ref-type="bibr">Kaur and Prabha, 2014</xref>, <xref rid="b0190" ref-type="bibr">Lea et al., 1997</xref>, <xref rid="b0190" ref-type="bibr">Lea et al., 1997</xref><break/></td></tr><tr><td colspan="1" rowspan="1">Rodent epididymal protein, DE, belongs to cysteine-rich<break/>secretory protein (CRISP)</td><td colspan="1" rowspan="1">Rodents<break/></td><td colspan="1" rowspan="1">It prevents the sperm and egg fusion</td><td colspan="1" rowspan="1"><xref rid="b0460" ref-type="bibr">Da Ros et al., 2015</xref>, <xref rid="b0460" ref-type="bibr">Da Ros et al., 2015</xref>, <xref rid="b0465" ref-type="bibr">Yu et al., 2015</xref>, <xref rid="b0465" ref-type="bibr">Yu et al., 2015</xref>, <xref rid="b0470" ref-type="bibr">Ellerman et al., 1998</xref>, <xref rid="b0470" ref-type="bibr">Ellerman et al., 1998</xref><break/></td></tr><tr><td colspan="1" rowspan="1">Eppin- Male reproductive traced antigen</td><td colspan="1" rowspan="1">Mice<break/>Monkey</td><td colspan="1" rowspan="1">Stops sperm motility and engages in entrapment of sperm cell even after liquefaction</td><td colspan="1" rowspan="1"><xref rid="b0475" ref-type="bibr">Wang et al., 2007</xref>, <xref rid="b0475" ref-type="bibr">Wang et al., 2007</xref><break/> (<xref rid="b0480" ref-type="bibr">O'rand et al., 2006</xref>) <break/><xref rid="b0485" ref-type="bibr">O'rand et al., 2004</xref>, <xref rid="b0485" ref-type="bibr">O'rand et al., 2004</xref>, <xref rid="b0490" ref-type="bibr">O'Rand et al., 2009</xref>, <xref rid="b0490" ref-type="bibr">O'Rand et al., 2009</xref>, <xref rid="b0495" ref-type="bibr">Michael et al., 2016</xref>, <xref rid="b0495" ref-type="bibr">Michael et al., 2016</xref><break/> (<xref rid="b0500" ref-type="bibr">Nieschlag</xref>)</td></tr><tr><td colspan="1" rowspan="1">Bovine bone morphogenetic protein 15 (BMP15)</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Inhibition of normal ovarian<break/>follicular development and also anovulation</td><td colspan="1" rowspan="1"><xref rid="b0505" ref-type="bibr">Persani et al., 2014</xref>, <xref rid="b0505" ref-type="bibr">Persani et al., 2014</xref>, <xref rid="b0510" ref-type="bibr">Otsuka et al., 2011</xref>, <xref rid="b0510" ref-type="bibr">Otsuka et al., 2011</xref></td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0010" orientation="portrait"><label>Table 2</label><caption><p>Importance of Vaccine development for various sexually transmitted infections.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"><bold>Sexually transmitted diseases</bold></th><th colspan="1" rowspan="1"><bold>Vaccine development strategies done</bold></th><th colspan="1" rowspan="1"><bold>The key factor that needs to be addressed</bold></th><th colspan="1" rowspan="1"><bold>The author studied and year</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Syphilis</td><td colspan="1" rowspan="1">Gaps in current biomedical knowledge and technologies for syphilis treatment should be focused on. The development of a vaccine for syphilis should be very safe and effective against transmission between sexually active population as well as it should protect against complications including congenital and neurosyphilis</td><td colspan="1" rowspan="1">Epidemiologic data and implications<break/>on infection and<break/>disease for syphilis</td><td colspan="1" rowspan="1"><xref rid="b0870" ref-type="bibr">Kersh and Lukehart, 2018</xref>, <xref rid="b0865" ref-type="bibr">Sood et al., 2017</xref>, <xref rid="b0875" ref-type="bibr">Ambrose, 2016</xref>, <xref rid="b0870" ref-type="bibr">Kersh and Lukehart, 2018</xref>, <xref rid="b0610" ref-type="bibr">Gottlieb et al., 2016</xref>, <xref rid="b0610" ref-type="bibr">Gottlieb et al., 2016</xref>, <xref rid="b0880" ref-type="bibr">Lithgow et al., 2017</xref>, <xref rid="b0875" ref-type="bibr">Ambrose, 2016</xref><break/></td></tr><tr><td colspan="1" rowspan="1">Gonorrhoea</td><td colspan="1" rowspan="1">New vaccine approaches need gonococcal subversion of immune responses, antigenic variations, and gender pose difference should be the best option for effective vaccine design for Gonorrhea, key knowledge about the epidemiology of the gonococcal subversion, advancing basic knowledge to translational research for an effective vaccine.</td><td colspan="1" rowspan="1">Pitiable natural immunity, antigen variations, the evolution of gonococcal subversion are the key challenges that need to be addressed for an effective vaccine</td><td colspan="1" rowspan="1"><xref rid="b0885" ref-type="bibr">Jerse et al., 2014</xref>, <xref rid="b0880" ref-type="bibr">Lithgow et al., 2017</xref>, <xref rid="b0890" ref-type="bibr">Zielke et al., 2016</xref>, <xref rid="b0885" ref-type="bibr">Jerse et al., 2014</xref>, <xref rid="b1260" ref-type="bibr">Ratto-Kim et al., 2018</xref>, <xref rid="b0900" ref-type="bibr">Wetzler et al., 2016</xref> (<xref rid="b0890" ref-type="bibr">Zielke et al., 2016</xref>) <break/><xref rid="b0900" ref-type="bibr">Wetzler et al., 2016</xref>, <xref rid="b0895" ref-type="bibr">Russell, 2018</xref><break/></td></tr><tr><td colspan="1" rowspan="1">HSV</td><td colspan="1" rowspan="1">The unique nature of HSV infection, need to analyse the biological feasibility for vaccine development, Prime-pull strategy as an effective vaccine development for HSV, the evolution of HSV 1 and 2 subversions are found to be the essential things that need to be focused on for the development of a vaccine for HSV 1 and 2.</td><td colspan="1" rowspan="1">Protective genital mucosal immunity, focus on preventive vaccine rather than therapeutic vaccine</td><td colspan="1" rowspan="1"><xref rid="b0905" ref-type="bibr">Dubensky et al., 2018</xref>, <xref rid="b0900" ref-type="bibr">Wetzler et al., 2016</xref>, <xref rid="b0910" ref-type="bibr">Dubensky et al., 2017</xref>, <xref rid="b0905" ref-type="bibr">Dubensky et al., 2018</xref><break/> (<xref rid="b0910" ref-type="bibr">Dubensky et al., 2017</xref>)<break/> (<xref rid="b0915" ref-type="bibr">Johnston et al., 2016</xref>) <break/><xref rid="b0925" ref-type="bibr">Hensel et al., 2017</xref>, <xref rid="b0920" ref-type="bibr">Long et al.</xref>, <xref rid="b0930" ref-type="bibr">Dooling et al., 2018</xref>, <xref rid="b0925" ref-type="bibr">Hensel et al., 2017</xref><break/></td></tr><tr><td colspan="1" rowspan="1">HPV</td><td colspan="1" rowspan="1">The difference between precancerous lesions and HPV led cancer is different to understand, focusing on a quadrivalent vaccine for HPV will be an important move for the HPV vaccine, arranging of large sexual education programs in the young girls will also promote the vaccine, the development and advancement in DNA type vaccine for HPV will be another focus</td><td colspan="1" rowspan="1">Obtaining recovered<break/>epidemiologic information<break/>on infection and<break/>disease worldwide and facilitating clinical<break/>evaluation and<break/>vaccine<break/>introduction in male and female will be the key challenge</td><td colspan="1" rowspan="1"><xref rid="b0935" ref-type="bibr">Brekke et al., 2018</xref>, <xref rid="b0930" ref-type="bibr">Dooling et al., 2018</xref>, <xref rid="b0940" ref-type="bibr">Di Mario et al., 2015</xref>, <xref rid="b0935" ref-type="bibr">Brekke et al., 2018</xref>, <xref rid="b0945" ref-type="bibr">Hsieh et al., 2015</xref>, <xref rid="b0940" ref-type="bibr">Di Mario et al., 2015</xref>, <xref rid="b0950" ref-type="bibr">Schiller, 2016</xref>, <xref rid="b0945" ref-type="bibr">Hsieh et al., 2015</xref>, <xref rid="b0955" ref-type="bibr">Agarwal et al., 2018</xref>, <xref rid="b0950" ref-type="bibr">Schiller, 2016</xref><break/>(<xref rid="b0955" ref-type="bibr">Agarwal et al., 2018</xref>)<break/><xref rid="b0965" ref-type="bibr">Best &amp; Pai, 2015</xref> (<xref rid="b0960" ref-type="bibr">Oh et al</xref>)</td></tr></tbody></table></table-wrap></p><p id="p0010">The development of contraceptive vaccines is the core work for many immunologists. Still, the anti-human chorionic gonadotrophin (hCG) vaccine is the only immunocontraceptive vaccine that might enter clinical trials (<xref rid="b0150" ref-type="bibr">Talwar et al., 2015</xref>). For better vaccine development, the target antigen should be competitive and good enough for controlling human fertility. Besides, the vaccine should be completely antigenic and elicit long-lasting immunogenic responses in the female or male bodies to be infertile. The vaccine should also be affordable, be very safe for human use, compete with already existing techniques with a near or 100% success rate for birth control, be reversible, and meet the unmet demand for contraception (<xref rid="b0155" ref-type="bibr">Samoylova et al., 2017</xref>). All the above-mentioned modes of contraception may prevent unnecessary abortions or pregnancies, but they do not prevent the spread of sexually transmitted infections (STIs) (<xref rid="b0160" ref-type="bibr">Steiner et al., 2016</xref>). Therefore, designing a suitable vaccine against STIs is in need as a preventive measure. The number of studies aiming to develop vaccines against STIs is rapidly growing; however, slow progress and a lot of disappointments have been faced (<xref rid="b0165" ref-type="bibr">Brotman et al., 2014</xref>). There is a lack of understanding regarding STI causing organisms and the transmission mechanisms during sexual intercourse. The development of vaccines for herpes simplex virus (HSV), human papillomavirus (HPV), and Hepatitis B found success even in human trials. However, we have not been able to design successful vaccines for syphilis, <italic toggle="yes">Neisseria</italic>, or HIV, for example (<xref rid="b0170" ref-type="bibr">Almeida and Borges, 2015</xref>). Until a vaccine for these infections is successful, they would remain transmissible to healthy individuals who are sexually active and have multiple sexual partners. Therefore, preventive rather than therapeutic vaccines are needed (<xref rid="b0175" ref-type="bibr">Strauss and Madan, 2016</xref>). Nearly three decades ago, the vaccine for hepatitis B was developed. However, the prevalence of this disease is still high in rural areas, especially among adolescents who are highly active in sexual intercourse. This proves that, even after identifying and developing a vaccine for an STI, the governments have to take the necessary steps to ensure the availability of such vaccines in rural areas; they should also conduct awareness programs about STIs and immunization. Accordingly, there is a need for both novel contraceptive vaccines for temporal birth control and for STIs for adolescents and preadolescents. This review emphasizes on significant targeted antigens for immunocontraception, crucial strategies for screening and identifying antigenic targets, STIs, and advancements in vaccine development for various STIs.</p></sec><sec id="s0010"><label>2</label><title>Target antigens in sperm and male reproductive tract for human contraception use</title><p id="p0015">It has been very long believed that semen, especially sperm cells, are highly immunogenic in both genders. In 1932, Baskin and colleagues worked with immunizing women with whole semen from their partners for a prescribed time to check whether it would lead to infertility over a prolonged period (<xref rid="b0180" ref-type="bibr">Dominiak et al., 2016</xref>). After this, many researchers started working with human semen as a contraceptive; the work on immunocontraception started blooming. Almost 7% of infertile men and 75% of vasectomized men have anti-sperm antibodies in their sera, confirming that there are many chances of developing immunocontraception for human use based on whole semen, defined sperm cells, and/or sperm-specific antigens (<xref rid="b0185" ref-type="bibr">Hull; M.G., C.M. Glazener; N.J. Kelly; D.L. Conway; P.A. Foster and R.A. Hinton, , 1985</xref>). Nowadays, many sperm antigens (proteins) have been identified as useful for developing immunocontraceptive vaccines. Among these antigens, SP17 was an important antigen in which many researchers worked to elucidate its immunocontraceptive properties (<xref rid="b0190" ref-type="bibr">Lea et al., 1997</xref>, <xref rid="b0195" ref-type="bibr">Mortazavi et al., 2021</xref>, <xref rid="b0200" ref-type="bibr">Diekman and Herr, 1997</xref>, <xref rid="b0205" ref-type="bibr">O'Donnell et al., 2021</xref>, <xref rid="b0210" ref-type="bibr">Mirandola et al., 2015</xref>). SP10 (<xref rid="b0215" ref-type="bibr">Mortazavi et al., 2021</xref>) and SP56 (<xref rid="b0220" ref-type="bibr">Bleil and Wassarman, 1990</xref>) have also been studied for their role and use in immunocontraception (<xref rid="b0225" ref-type="bibr">Frayne and Hall, 1999</xref>, <xref rid="b0230" ref-type="bibr">Jalalvandi et al., 2021</xref>, <xref rid="b0235" ref-type="bibr">Naz, 2005</xref>, <xref rid="b0240" ref-type="bibr">Kerr et al., 1998</xref>, <xref rid="b0245" ref-type="bibr">Sharma et al., 2017</xref>). Other antigens like tNASP (nuclear autoantigenic sperm protein) (<xref rid="b0250" ref-type="bibr">Wang et al., 2009</xref>, <xref rid="b0255" ref-type="bibr">Nagatomo et al., 2016</xref>), FA-1 (<xref rid="b0260" ref-type="bibr">Naz and Wolf, 1994</xref>), SOB-2 (<xref rid="b0265" ref-type="bibr">Lefevre et al., 1997</xref>, <xref rid="b0270" ref-type="bibr">Hay et al., 2014</xref>), SPAM1 (<xref rid="b0275" ref-type="bibr">McLaughlin et al., 2003</xref>, <xref rid="b0280" ref-type="bibr">Tecle and Gagneux, 2015</xref>), and sperm associated antigen 9 (<xref rid="b0285" ref-type="bibr">Jagadish et al., 2006</xref>, <xref rid="b0290" ref-type="bibr">Lou et al., 2016</xref>) have also shown promising results for immunocontraception. These antigens have some spermicidal activity, which also inhibits sperm cell-egg interactions (<xref rid="b0295" ref-type="bibr">Archana et al., 2021</xref>). This inhibitory effect leads to simultaneous infertility in the female partner when used as immunocontraception or immunotherapy (<xref rid="b0300" ref-type="bibr">Shetty et al., 2017</xref>).</p><p id="p0020">Izumo, a sperm plasma membrane protein, proved to have many molecular-based functions in the fusion of sperm cell and egg. Izumo protein is also a particularly good target antigen that may act as an immunocontraceptive vaccine for women after immunization (<xref rid="b0305" ref-type="bibr">Ellerman et al., 2009</xref>). The immunizing Izumo antigen exhibits inhibition of sperm-egg interactions in mouse models. Inoue <italic toggle="yes">et al.</italic> studied whether human Izumo was also involved in sperm and egg fusion (<xref rid="b0310" ref-type="bibr">Inoue et al., 2005</xref>, <xref rid="b0315" ref-type="bibr">Naz, 2014</xref>). They observed that sperm and egg fusion mechanisms were significantly impaired. They have also shown that this phenomenon is species specific given that it occurs between the sperm and the zona pellucida (<xref rid="b0320" ref-type="bibr">Rubinstein et al., 2006</xref>). Inoue <italic toggle="yes">et al.</italic> produced an anti-human-Izumo (a polyclonal antibody),mixed it with a sperm and egg mixture, and incubated it for 45&#160;min. This resulted in no fusion between the sperm and egg because of Izumo inhibition (<xref rid="b0315" ref-type="bibr">Naz, 2014</xref>). However, if sperm is treated with a standard IgG, the fusion happens. On average, six sperms were able to bind an egg in experiments <italic toggle="yes">in vitro</italic> (<xref rid="b0310" ref-type="bibr">Inoue et al., 2005</xref>). CD46, DE, and SAMP32 (<xref rid="b0325" ref-type="bibr">Hao et al., 2002</xref>) are other antigens found on the sperm surface plasma membrane that are not much significant in sperm cell and egg fusion. Out of all antigens on the sperm cell plasma membrane that have been tested, Izumo is the only one found to have a significant role in fusion. Additionally, it can be used as immunocontraception, as evidence by various <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> studies (<xref rid="b0330" ref-type="bibr">Wang et al., 2008</xref>, <xref rid="b0335" ref-type="bibr">Wang et al., 2009</xref>). An <italic toggle="yes">et al.</italic> studied the recombinant plasmid pCXN2-mIzumo as an immunocontraceptive vaccine. <italic toggle="yes">In vitro</italic> fertilization was found to be around 11.07% in mice immunized with pCXN2-mIzumo, whereas it was 36% in the control group (<xref rid="b0340" ref-type="bibr">An et al., 2009</xref>). This study concluded that pCXN2-mIzumo would be a candidate target for designing a proper immunocontraceptive vaccine (<xref rid="b0340" ref-type="bibr">An et al., 2009</xref>).</p><p id="p0025">Various studies done in a variety of animal models have reported many potential sperm antigens. However, no single sperm antigen has been authorized for use as a human vaccine since they have their limitations (<xref rid="b0345" ref-type="bibr">Tumova et al., 2021</xref>). Therefore, researchers are now working with multi antigens to combat the single-antigen effect and to produce a proper immunocontraception method (<xref rid="b0350" ref-type="bibr">Ferro and Garside, 2011</xref>, <xref rid="b0355" ref-type="bibr">Hardy et al., 2008</xref>, <xref rid="b0360" ref-type="bibr">Naz, 2011</xref>). Hardy <italic toggle="yes">et al.</italic> used a multi-antigen single recombinant polypeptide bearing SP56 and ZP1, 2, and 3 to immunize female mice. This resulted in a reduced fertility rate when compared to the control group. In addition, Naz and Aleem combined six different sperm-specific antigens into a single recombinant polypeptide. This recombinant protein, when administrated, was proved to be successful in controlling the fertility rate. Another study utilized acrosomal proteins as multi antigens and succeeded in reducing the fertility rate in monkeys (<xref rid="b0365" ref-type="bibr">Kurth et al., 2008</xref>).</p></sec><sec id="s0015"><label>3</label><title>Screening novel antigens for effective contraception</title><p id="p0030">It has been observed that, approximately, 5% to 10% of human male infertility is due to anti-sperm antibodies in the sera (<xref rid="b0515" ref-type="bibr">Marconi and Weidner, 2017</xref>), and that 70% of the vasectomized men also have anti-sperm antibodies (<xref rid="b0520" ref-type="bibr">Brubaker et al., 2018</xref>). Based on these reports, a phage display antibody library for infertile patients with positive anti-sperm antibodies and for vasectomized men was created. This library was used to detect antibodies specific to sperm antigens and, among the many clones obtained, only four were strongly reactive. These four clones bear novel sequences and unique complementary sequences. FAB-7 and AFA-1 antibodies reacted with fertilization antigen 1 (<xref rid="b0525" ref-type="bibr">Shrestha et al., 2021</xref>), whereas those for YLP20 reacted with a sperm protein that has a molecular weight of around 50&#160;kDa. In addition, AS16 antibodies reacted with another sperm protein and caused agglutination. All these antibodies resulted in the inhibition of various sperm functions, leading to infertility. These advancements may lead to the detection of novel sperm-specific antigens for a prompt design of an immunocontraceptive vaccine.</p><p id="p0035">Major detection or identification of novel antigens can be done by tracking genitally transmitted microorganisms (<xref rid="b0530" ref-type="bibr">Sturm, 1978</xref>) from females to males during intercourse (<xref rid="b0535" ref-type="bibr">Shi et al., 2007</xref>). This exchange may sometimes cause immune-related infertility in men (<xref rid="b0540" ref-type="bibr">Weissenbacher et al., 2014</xref>, <xref rid="b0545" ref-type="bibr">Beagley et al., 1998</xref>, <xref rid="b0550" ref-type="bibr">Taylor-Robinson, 1986</xref>). Therefore, peptides derived from microorganisms identified as infertility causative agents may be grouped, after the construction of a library, and screened for unique determination sequences. Clones or proper antigens could then be derived. This method can be used as an effective alternative strategy to develop an immunocontraceptive vaccine (<xref rid="b0535" ref-type="bibr">Shi et al., 2007</xref>).</p></sec><sec id="s0020"><label>4</label><title>Vaccines for sexually transmitted diseases (STDs)</title><p id="p0040">Vaccine development against STDs or organisms is multiplying year by year. To develop a vaccine for an STD, the first thing is to understand the biology of the sexually transmitted organism and then the underlying mechanism (<xref rid="b0555" ref-type="bibr">Gottlieb and Johnston, 2017</xref>, <xref rid="b0560" ref-type="bibr">Velan and Yadgar, 2017</xref>). Unraveling the mechanism behind the infection and its transmission to the male or female partner is the most significant task in generating an excellent vaccine (<xref rid="b0565" ref-type="bibr">Kahle et al., 2012</xref>). To produce or to make global sustainable, STI control is in need (<xref rid="b0570" ref-type="bibr">Korenromp et al., 2016</xref>). To achieve this, vaccines against STIs are being evolved by researchers worldwide (<xref rid="b0575" ref-type="bibr">Low et al., 2017</xref>). However, producing vaccines against STIs is difficult. Moreover, production is hindered by the fact that infections are spreading worldwide and interfere with each other. Vaccines against Hepatitis B virus (HBV) and HPV have been shown to be highly effective for prevention in humans (<xref rid="b0580" ref-type="bibr">Kurosky et al., 2017</xref>, <xref rid="b0585" ref-type="bibr">Van Damme et al., 2017</xref>, <xref rid="b0590" ref-type="bibr">Gupta et al., 2017</xref>, <xref rid="b0595" ref-type="bibr">Borch et al., 2017</xref>). This was complemented by frequent public awareness programs (<xref rid="b0600" ref-type="bibr">Wilson, 2017</xref>, <xref rid="b0605" ref-type="bibr">Hasan et al., 2017</xref>) regarding the use of these two vaccines. Nowadays, these two infections are under control all over the world, and guide researchers in their work for developing new STI vaccines to control other infections (<xref rid="b0610" ref-type="bibr">Gottlieb et al., 2016</xref>). HSV-1 and 2 are the most frequently transmitted viruses via sexual interaction (<xref rid="b0615" ref-type="bibr">Nahmias et al., 1989</xref>). An estimated population of 420 million people is globally affected or infected with HSV-2 (<xref rid="b0620" ref-type="bibr">Looker et al., 2008</xref>) or herpes, the most common genital infection, whereas HSV-1 contributes with 100 million infected people (<xref rid="b0625" ref-type="bibr">Stingley et al., 2000</xref>). In 2012, the World Health Organization (WHO) reported that around 400 million people in the world were infected with curable STIs; among these, <italic toggle="yes">Neisseria gonorrhoeae</italic> and <italic toggle="yes">Treponema pallidum</italic> (syphilis) were found to be prevalent. In 2013, the WHO and National Institutes of Health (NIH) decided to develop new strategies to overcome the limitations of STI vaccines. These resulted in high priority research strategies to produce vaccines against <italic toggle="yes">N. gonorrhoeae</italic> (<xref rid="b0630" ref-type="bibr">Moncada et al., 2017</xref>); <italic toggle="yes">T. pallidum</italic> (<xref rid="b0635" ref-type="bibr">Smolak et al., 2017</xref>), and HSV-1 and &#8722;2 by various researchers in 2014. Since then, studies have also focused on modelling the theoretical impact of STIs, analyzing cost-effectiveness of STI vaccine development, understanding the history of STIs, obtaining extensive and updated epidemiological data for various STIs, conducing translational clinical studies for STIs, encouraging both investors and pharmaceutical companies to invest in STI vaccine development with various promotion programs, and creating awareness in the public by conducing programs in rural and township areas through local public health ministries (<xref rid="b0610" ref-type="bibr">Gottlieb et al., 2016</xref>).</p></sec><sec id="s0025"><label>5</label><title>Herd immunity and its effects against vaccines for STDs</title><p id="p0045">In a group of populations, the acquired immunity that helps reduce the risk of spreading or adapting infections among vulnerable individuals is called herd immunity (<xref rid="b0640" ref-type="bibr">Anderson et al., 1992</xref>). Individually, immunity can be acquired by natural infections and/or vaccination. Herd immunity can be best understood by understanding the reproductive infection number (R). R<sub>0</sub> is defined as the basic reproductive number that determines the spread of an infection; it is the average number of new infections spread by one infected human being within an entirely susceptible population (<xref rid="b0645" ref-type="bibr">Smith et al., 1984</xref>, <xref rid="b0650" ref-type="bibr">Garnett, 2002</xref>). Acquired immunity plays a major role in the determination of this number; when acquired immunity is present in a population, such population is no longer entirely susceptible. R<sub>t</sub> is the average number of very new infections caused in a susceptible population at time interval &#8220;t&#8221;. Thus, the product is said to be R<sub>0,</sub> when the whole population is susceptible, but R<sub>t</sub> may be proportionally smaller as the number of immune individuals within the population increases (<xref rid="b0655" ref-type="bibr">McLean and Blower, 1995</xref>).</p></sec><sec id="s0030"><label>6</label><title>Herd immunity in STIS</title><p id="p0050">There are two major reasons for which vaccination programs against STIs are being organized (<xref rid="b0660" ref-type="bibr">Linares</xref>). First, the risk of transmitting and acquiring infections is increasing because of their complex heterogeneity. Second, STIs affect the population of sexually active adults and are restricted to minorities; STIs most commonly affect women than men (<xref rid="b0665" ref-type="bibr">Hamilton and Morris, 2015</xref>). Sexually, both men and women are the reason, but the blame and the cause are usually attributed to women (<xref rid="b0670" ref-type="bibr">Badawi et al., 2021</xref>). Thus, vaccination programs should be conducted in rural development areas to protect sexually active age groups, mainly women. Low efficacy vaccines can be used, considering that there are considerable health gains and benefits. Still, the elimination of STIs is very difficult and improved efficacy can be associated with diminishing returns in time. Herd immunity and its relatively low risk of infections have been previously explained (<xref rid="b0675" ref-type="bibr">Garnett and Bowden, 2000</xref>). Nevertheless, in a study done on a population with different STIs, where the group with higher levels of risk was expected to transmit the infections, it was seen that most of the infections were acquired by the low-risk population instead (<xref rid="b0680" ref-type="bibr">Garnett, 191(Supplement_1):2005</xref>). Interestingly, vaccination helped reduce the number of infections in low-risk groups and among the population with low reproductive potential (<xref rid="b0685" ref-type="bibr">Tack et al., 2017</xref>). However, some residual infections in this population may indicate that its members had been frequently exposed to infections or were prone to the highest degree of infection (<xref rid="b0685" ref-type="bibr">Tack et al., 2017</xref>). Such a population could potentially infect or transmit the infections to other individuals within the group. Then, control becomes assortative. Herd immunity may also help protect one sex, either male or female, through vaccinating the other.</p><p id="p0055">Vaccinating individuals of a single sex against STIs may be appropriate because women, as stated before, are at a higher risk of acquiring such infections. A program like this is straightforward, as vaccination can be done at the time of family planning or antenatal care (<xref rid="b0690" ref-type="bibr">Brabin et al., 2006</xref>). As heterosexually transmitted infections can be prevented by vaccinating only one sex, thereby indirectly protecting the other, it is a logical strategy to achieve herd immunity (<xref rid="b0695" ref-type="bibr">Frost et al., 2014</xref>). Herd immunity helps control the infection in the directly protected sex, allowing only few exposures in the indirectly protected sex group. In the absence of vaccines for STIs, there are many practices useful for reducing their spread. First, by reducing the duration of individual infections by antimicrobial or antibiotic treatment (<xref rid="b0700" ref-type="bibr">Dunkle et al., 2008</xref>). Second, by reducing the number of sexual partners by conducting sex education programs and informing sexually active men and women about STIs (<xref rid="b0705" ref-type="bibr">Low and Broutet, 2017</xref>). Third, by reducing STI transmission (even when having multiple partners or sexual contacts) through the use of condoms and other protection methods (<xref rid="b0710" ref-type="bibr">Lee et al., 2016</xref>). All these practices may be combined to reduce R<sub>0</sub>. Vaccines for STIs with a low degree of protection show similar effects on reducing R<sub>0</sub>. Suppose the practices mentioned above show a low efficiency in diminishing the infections, then, the combined effect of vaccines for STIs and other these practices may help eliminate the infections or further diminish their transmission among individuals (<xref rid="b0715" ref-type="bibr">Rhodes et al., 2017</xref>).</p></sec><sec id="s0035"><label>7</label><title>Advancements in vaccine development for Syphilis</title><p id="p0060">Administration of Penicillin G is currently the only treatment at all the stages of syphilis (<xref rid="b0720" ref-type="bibr">Gottlieb et al., 2014</xref>, <xref rid="b0725" ref-type="bibr">Ganesan et al., 2014</xref>, <xref rid="b0730" ref-type="bibr">Xiao et al., 2017</xref>, <xref rid="b0735" ref-type="bibr">Cao et al., 2017</xref>). The US Centers for Disease Control and Prevention (CDC) have recommended this treatment, even for pregnant women, for the past 70&#160;years (<xref rid="b0740" ref-type="bibr">Yang et al., 2015</xref>, <xref rid="b0745" ref-type="bibr">Workowski, 2015</xref>, <xref rid="b0750" ref-type="bibr">Ghanem, 2015</xref>). Although there exists an emergence of resistant <italic toggle="yes">T. pallidum</italic> strains (<xref rid="b0755" ref-type="bibr">Manteuffel et al., 2016</xref>, <xref rid="b0760" ref-type="bibr">Arora et al., 2017</xref>, <xref rid="b0765" ref-type="bibr">Beale et al., 2021</xref>, <xref rid="b0770" ref-type="bibr">Stamm, 2015</xref>). penicillin G remains as the only effective treatment against syphilis. Therefore, <italic toggle="yes">T</italic>. <italic toggle="yes">pallidum</italic> sometimes persists after penicillin treatment. Thus, to eradicate this disease, we have been relying on public education programs about syphilis and its pathogenic nature, such as that organized by the CDC in 1999 and the National plan to eradicate syphilis, held in 2006 (<xref rid="b0770" ref-type="bibr">Stamm, 2015</xref>, <xref rid="b0775" ref-type="bibr">Smajs et al., 2015</xref>, <xref rid="b0780" ref-type="bibr">Wu et al., 2016</xref>), but the disease is still spreading. The WHO has also taken initiatives for the global eradication of syphilis, especially congenital syphilis (<italic toggle="yes">i.e.</italic>, the transmission of the infection from the mother to the fetus). This last program was a complete success; the first country to achieve this goal was Cuba (<xref rid="b0785" ref-type="bibr">Ellington, 2016</xref>). However, as per the current situation, neither treatment nor awareness education programs are reducing syphilis transmission, and there is an urgent need for the development of a vaccine against this disease (<xref rid="b0790" ref-type="bibr">World Health Organization, 2017</xref>, <xref rid="b0795" ref-type="bibr">Cameron and Lukehart, 2014</xref>, <xref rid="b0800" ref-type="bibr">Lithgow and Cameron, 2017</xref>, <xref rid="b0805" ref-type="bibr">Champredon et al., 2016</xref>). An effective vaccine for syphilis should prevent <italic toggle="yes">T</italic>. <italic toggle="yes">pallidum</italic> infections, thus preventing disease transmission among sexual partners and between infected mothers to their children; it should also provide protection from diverging <italic toggle="yes">T</italic>. <italic toggle="yes">pallidum</italic> strains and decrease reinfection frequency. By eliminating reinfection, penicillin may endure as an effective syphilis control method (<xref rid="b0810" ref-type="bibr">Garnett, 2014</xref>). All this information and requirements should be helpful for designing an effective vaccine for syphilis, in our way to eradicate this infection.</p><p id="p0065">Compared to other pathogens, only a limited number of studies exist on the development of a vaccine for syphilis (<xref rid="b0815" ref-type="bibr">Peterman; T.A. and B.W. Furness, 2015</xref>). This is because only a few scientists are working on this area and because the pathogenesis of <italic toggle="yes">T. pallidum</italic> and its morphological structure are still not completely understood. In addition, there are no studies about the genetic modifications among <italic toggle="yes">T. pallidum</italic> that could be important for vaccine development (<xref rid="b0820" ref-type="bibr">Tong et al., 2017</xref>).</p><p id="p0070">Metzger did the first vaccination studies for syphilis. <italic toggle="yes">T. pallidum</italic> strains were attenuated, by storing them at 4&#160;&#176;C for a short time (<xref rid="b0825" ref-type="bibr">Zuckerman and Harper, 2016</xref>), and used to inoculate rabbits by the intramuscular route. This gave good results, and further lesions in the rabbits were not noticed. This historical investigation results led Miller to work on it further by inoculating rabbits with bacteria attenuated by &#947;-irradiation (<xref rid="b0830" ref-type="bibr">Metzger and Smogor, 1969</xref>). This method resulted in a labile surface antigen content in rabbits and thus in an attenuated infection. From this study, Miller concluded (a) that the development of protective immunity was based on the presence of intact bacteria and that the bacterial surface should not be disturbed during attenuation (<xref rid="b0835" ref-type="bibr">Miller, 1973</xref>); (b) that prolonged immunization was necessary to get good results given that the number of proteins in the outer membrane of <italic toggle="yes">T. pallidum</italic> is smaller than that in other bacteria; and (c) that achieved protection was long-lasting. The study also concluded that the rabbit model was suitable for this kind of studies.</p><p id="p0075"><italic toggle="yes">T</italic>. <italic toggle="yes">pallidum</italic> can develop chancres (<xref rid="b0840" ref-type="bibr">Hoffman et al., 2002</xref>) at the site of infection, resulting in repeated reinfections and the establishment of latency despite the immune response produced by the vaccine. Therefore, this phenomenon should be considered a key element in designing a successful vaccine for syphilis. An effective vaccine should prevent chancre development and treponemal persistence and should avoid reinfection (<xref rid="b0840" ref-type="bibr">Hoffman et al., 2002</xref>). This could help eliminate the disease symptoms in infected individuals and prevent its transmission in the population. Key considerations for developing a successful vaccine for syphilis at the pre-clinical level are the number of vaccine doses needed for obtaining the best immunity, vaccination administration methods, duration of post immunity, optimization of a multivalent vaccine, and adjuvant selection (<xref rid="b0845" ref-type="bibr">Fukuda et al., 2015</xref>).</p><p id="p0080">There has also been some advancements in syphilis pre-clinical trials using quantitative real-time PCR (RT-qPCR) (<xref rid="b0850" ref-type="bibr">Dodet, 2014</xref>). This allows us to find and detect the sensitive <italic toggle="yes">T</italic>. <italic toggle="yes">pallidum</italic> DNA at distal sites in the rabbit. However, there are some limitations with RT-qPCR. This led to the use of fluorescence <italic toggle="yes">in situ</italic> hybridization (FISH) to detect <italic toggle="yes">T</italic>. <italic toggle="yes">Pallidum</italic> in human and animal model infected tissues (<xref rid="b0855" ref-type="bibr">Kotloff</xref>).</p><p id="p0085">This also led to further investigations for the design of an effective vaccine for syphilis. However, the development of such vaccine was understudied as only a specific group of scientists were working towards <italic toggle="yes">T. pallidum</italic> pathogenesis. Further, conducting many awareness programs about <italic toggle="yes">T. pallidum</italic> in particular geographical locations where the infection and transmission rates are high may improve sexual habits among the population, providing better results (<xref rid="b0755" ref-type="bibr">Manteuffel et al., 2016</xref>, <xref rid="b0760" ref-type="bibr">Arora et al., 2017</xref>). Therefore, government and private funding agencies should focus in investing in projects for developing a new vaccine for syphilis for the betterment of humankind. In addition, developing a vaccine for both syphilis and any another STI may yield good profits and broaden the market for the syphilis vaccine (<xref rid="b0860" ref-type="bibr">Petrich et al., 2015</xref>). In conclusion, an effective vaccine for syphilis will protect humankind from infectious and congenital syphilis.</p></sec><sec id="s0040"><label>8</label><title>Advancements in vaccine development against <italic toggle="yes">Neisseria gonorrhoeae</italic> (Gonococcus)</title><p id="p0090">Gonococcus is considered as one of the most dangerous human pathogens since ancient days. Gonococcal infections in humans are transmitted through direct contact (<xref rid="b0965" ref-type="bibr">Best and Pa, 2015</xref>, <xref rid="b0970" ref-type="bibr">Lister et al., 2003</xref>). The major transmission routes involve sexual contact, by touching mucosal membranes of the male and female genitals (<xref rid="b0975" ref-type="bibr">Rice et al., 2017</xref>), through the anal canal (either between heterosexual (<xref rid="b0980" ref-type="bibr">Golden et al., 2005</xref>) or homosexual partners (<xref rid="b0985" ref-type="bibr">Kent et al., 2003</xref>), or though the oropharynx (<xref rid="b0990" ref-type="bibr">Fingerhuth et al., 2016</xref>, <xref rid="b0995" ref-type="bibr">Bernstein et al., 2017</xref>, <xref rid="b1000" ref-type="bibr">Yang et al., Sextrans-2017.</xref>, <xref rid="b1005" ref-type="bibr">Zhang et al., 2017</xref>, <xref rid="b1010" ref-type="bibr">Zhang et al., 2017</xref>, <xref rid="b1015" ref-type="bibr">Lewis, 2015</xref>, <xref rid="b1020" ref-type="bibr">Chow et al., 2016</xref>); it may even be transmitted, rarely, through eye contact (<xref rid="b1025" ref-type="bibr">Nakashima et al., 2014</xref>, <xref rid="b1030" ref-type="bibr">Kreisel et al., 2017</xref>). Except for that involving eye contact, any other mode of transmission may be restricted by conducting multiple education programs to the population at reproductive age. Such sex education programs, including safety measures for those with multiple sex partners and/or homosexual habits, might work at the highest level for eradicating gonococcal infections throughout the world, especially in the western countries (<xref rid="b1035" ref-type="bibr">De Silva et al., 2016</xref>, <xref rid="b1040" ref-type="bibr">Sarkar et al., 2016</xref>, <xref rid="b1045" ref-type="bibr">Huneeus et al., 2018</xref>, <xref rid="b1050" ref-type="bibr">Eldredge et al., 2016</xref>, <xref rid="b1055" ref-type="bibr">Pelligrino et al., 2017</xref>, <xref rid="b1060" ref-type="bibr">Yeung et al., 2017</xref>). Gonococcal infections lead to cervicitis (<xref rid="b1065" ref-type="bibr">Gonzalez et al., 2017</xref>, <xref rid="b1070" ref-type="bibr">Lama and Kayastha, 2017</xref>, <xref rid="b1075" ref-type="bibr">Gorgos et al., 2017</xref>, <xref rid="b1080" ref-type="bibr">Igietseme et al., 2015</xref>) in women and urethritis (<xref rid="b1085" ref-type="bibr">Bautista et al., 2016</xref>, <xref rid="b1090" ref-type="bibr">Horner et al., 2016</xref>, <xref rid="b1095" ref-type="bibr">Priest et al., 2017</xref>, <xref rid="b1100" ref-type="bibr">Bachmann et al., 2015</xref>) in men, but they may be cured if medical treatment is immediately sought. Mainly, asymptomatic men are responsible for the high transmission rates of the disease through sexual contact (<xref rid="b1105" ref-type="bibr">Dudhipala et al., 2017</xref>, <xref rid="b1110" ref-type="bibr">Ong et al., 2018</xref>), therefore, finding the correct symptoms for gonococcus infection is necessary for restricting the transmission (<xref rid="b1115" ref-type="bibr">Pattanasin et al., 2017</xref>). Although most women are found asymptomatic, if untreated, there is a chance for developing pelvic inflammatory disease, especially salpingitis (<xref rid="b1120" ref-type="bibr">Handsfield, 1972</xref>), and even infertility (<xref rid="b1125" ref-type="bibr">Fein et al., 2015</xref>). There is also a chance of ectopic pregnancy, which is highly painful for women. In some untreated men and women, gonococcus might enter the bloodstream and cause meningitis.</p><p id="p0095">The CDC officially announced that gonorrhea is the second most threating bacterial infection in the world, with the highest transmission rates (<xref rid="b0970" ref-type="bibr">Lister et al., 2003</xref>). Importantly, there was a 27% increase in this transmission rate among individuals in the reproductive age group from 2012 to 2015. Currently, antibiotic therapy is the only way to cure the disease and stop the transmission between individuals (<xref rid="b1130" ref-type="bibr">Briceag et al., 2015</xref>). However, recently, <italic toggle="yes">N. gonorrhoeae</italic> strains have become resistant to many commercial antibiotics, those extensively used to cure gonorrhea (<xref rid="b1135" ref-type="bibr">Balashov et al., 2016</xref>). Consequently, there is a need for vaccines or antimicrobial peptide treatments to deal with these resistant strains. Third-generation cephalosporins are the antibiotics that have been used from the 1980s to present days for the treatment of gonorrhea (<xref rid="b1140" ref-type="bibr">Tuite et al., 2017</xref>), whereas sulfonamides were used from early 1938 to 1942 (<xref rid="b1145" ref-type="bibr">Regnath et al., 2016</xref>). It is now known that single nucleotide polymorphisms in the <italic toggle="yes">folP</italic> gene reduce the affinity of the resulting protein for sulfonamides, leading to bacterial resistance. Historically, for more than four decades, penicillin was the only ruler against gonorrhea, whereas tetracycline, doxycycline, and spectinomycin were also used in the treatment of gonorrhea from the 1970s to 1980s (<xref rid="b1150" ref-type="bibr">Rodriguez</xref>).</p><p id="p0100">The search for a vaccine for gonorrhea dates back to the early 20th century (<xref rid="b1155" ref-type="bibr">Washington, 1979</xref>), specifically to the 1910s, but it was not successful. However, as many antibiotics were effective for curing gonorrhea, a vaccine was not really necessary. At least, this was the mentality of the researchers at that time. However, four candidate vaccines were tested afterwards, but none of them protected individuals from acquiring the infection. Vaccine development for gonorrhea was stopped for nearly 10 or 15&#160;years for several reasons. With the emergence of multi-drug resistance strains throughout the world, the search for a gonorrhea vaccine was reactivated in early 2010 in a full-time way (<xref rid="b1160" ref-type="bibr">Abbasi, 2017</xref>).</p><p id="p0105">A surprise came for the researchers at New Zealand in the form of a meningococcal vaccine that also showed promising results against gonorrhea. It was noticed that MeNZB (<xref rid="b1165" ref-type="bibr">Petousis-Harris et al., 2017</xref>) was 31% effective in preventing gonorrhea. Though MeNZB is no longer produced, its active ingredients are present in 4CMenB. This vaccine (<xref rid="b1170" ref-type="bibr">Lennon et al., 2012</xref>) contains three genetically modified proteins and two proteins shared between <italic toggle="yes">N. meningitidis</italic> and <italic toggle="yes">N. gonorrhoeae</italic>. 4CMenB was found to be a very effective vaccine for gonorrhea in double-blind studies and in placebo-controlled trials, with approximately 31% protection against the disease. However, it is believed that it is even more effective as an 80 million cases reduction in gonorrheal infections was registered since its production began.</p><p id="p0110">The development of effective vaccine candidates for gonococcal infections is difficult because the human body's immunological protection is changing and not predictable. There is also a lack of scientists vigorously working with gonococcal infections and vaccine development (<xref rid="b1175" ref-type="bibr">Santolaya et al., 2012</xref>). Surface antigenicity for gonococcus is modifiable and utilizes phase variation (<xref rid="b1180" ref-type="bibr">Trembizki et al., 2015</xref>). This capacity has allowed gonococcal bacteria to adapt to any environment, and many changes have occurred since their origin (<xref rid="b1185" ref-type="bibr">Palmer, 2016</xref>). An effective vaccine should overcome or bypass these adaptations, which should also be of concern for the development of new vaccines. Adaptive immune mechanisms of gonococcal antigens during infection do not eliciting a long-lasting protective immune response, therefore, there is a chance for reinfection.</p><p id="p0115">Two vaccines against gonococcal infections were designed. One of them was based in whole-cell bacteria and the other included a single antigen. Both yielded attention to the developers, but they practically failed in giving any protection against gonococcal infections (<xref rid="b0890" ref-type="bibr">Zielke et al., 2016</xref>). Vaccines for <italic toggle="yes">N. gonorrhoeae</italic> using bacterial antibody activity directed towards gonococcal infections are being assessed. Theoretically, bacterial antibodies would directly kill gonococci and promote phagocyte binding through complement receptors and the designed FC, helping to eliminate the infecting organisms (<xref rid="b1190" ref-type="bibr">Lam, 2017</xref>, <xref rid="b1195" ref-type="bibr">Edwards et al., 2016</xref>, <xref rid="b1200" ref-type="bibr">Piekarowicz et al., 2016</xref>, <xref rid="b1205" ref-type="bibr">Lao and Bonavida, 2016</xref>, <xref rid="b1210" ref-type="bibr">Butler et al., 2018</xref>). The most frequently used antibodies are Por and LOS, which bind to their antigenic targets on gonococci outer membrane through complement receptors. Many ideas and knowledge can be shared at the theoretical level, but gonococci have demolished practically all this scientific knowledge towards effective vaccine development in numerous ways. Nevertheless, researchers are still working with gonococci surface antigens or complement receptors that elicit antibodies and that might be excellent targets and vaccine candidates (<xref rid="b1215" ref-type="bibr">Gulati et al., 2015</xref>, <xref rid="b1220" ref-type="bibr">Semchenko et al., 2017</xref>, <xref rid="b1225" ref-type="bibr">Shewell et al., 2017</xref>). Interestingly, some important antigenic sites that would not elicit any immune response or antibodies in natural infection, might also be potential targets for vaccine development (<xref rid="b1230" ref-type="bibr">Gunderson and Seifert, 2015</xref>, <xref rid="b1235" ref-type="bibr">Rotman and Seifert, 2015</xref>). Transcriptome analyses from the genital tract of infected men and women will pave the way for effective vaccine design.</p><p id="p0120">There is an urgent need for a gonorrhea vaccine owing to the rapidly developing multi-drug resistant <italic toggle="yes">N. gonorrhoeae</italic> strains<italic toggle="yes">.</italic> These changes occur through various mechanisms, such as plasmid acquisition, point mutation, and naked DNA uptake from other gonococcal strains. Currently, there is no reliable antibiotic or empirical treatment for this disease as well (<xref rid="b1240" ref-type="bibr">Zhang et al., 2016</xref>). The absence of robust animal models for mimicking the prototypic disease and its variants also challenges immune response predictions (<xref rid="b1245" ref-type="bibr">Vincent and Jerse, 2018</xref>). Therefore, new discoveries in the horizon of vaccine development are a welcome step. First among them is the finding that <italic toggle="yes">N. gonorrhoeae</italic>, for its benefit, manipulates the host system. Second, new developments in an animal model for pre-clinical evaluation of gonococcal vaccines are needed. Third, to tap conserved surface antigens of <italic toggle="yes">N. gonorrhoeae</italic> for vaccine development. Recently, vaccines, such as MeNZB and Bexsero, have been developed for gonorrhea (<xref rid="b1250" ref-type="bibr">Edwards et al., 2018</xref>).</p><p id="p0125">Gonorrhea not only threatens the general public but also military personnel. Thus, the US military has strongly recommended vaccine research and development (<xref rid="b1255" ref-type="bibr">Russell, 2018</xref>). <italic toggle="yes">In vitro</italic> and clinical studies, proteomics-driven antigen discovery, and comprehensive bioinformatics strategies will help make informed and rational decisions on vaccine development. Pertaining to gonorrhea, structural vaccinology is in its infancy and the response should be public alarm; consequently, research on vaccine development for gonorrhea is urgently needed (<xref rid="b1260" ref-type="bibr">Ratto-Kim et al., 2018</xref>).</p></sec><sec id="s0045"><label>9</label><title>Current status of STD vaccines</title><p id="p0130">The current status of the vaccines for STDs and their administration is tremendously different depending on each region and its demographic characteristics. It is mostly influenced by the awareness of the disease and the cultural acceptability of vaccines in every specific area. Most of the vaccines associated with STDs still have to pass some key checkpoints before landing up into the market space. The successful achievement of endpoints in clinical trials and the validation of surrogate endpoints is crucial. Regulatory routes need to be determined well for licensing. Systems to monitor vaccine responses in advance are always appreciated and sought after in great demand.</p></sec><sec id="s0050"><label>10</label><title>HPV vaccine</title><p id="p0135">A bivalent form of vaccination is actively used against HPV16 and 18; it is commercially known as Cervarix, and it was approved in 2007. Gardasil 9 was approved in 2016; it is actively administered against HPV6, 18, 11, and 16. This nonavalent vaccine is the only one offered in the United States. The dosage has been reduced to 2 from 3 (<xref rid="b1270" ref-type="bibr">Dobson et al., 2013</xref>). For women nearly 45, three doses are recommended, followed by immunosuppressants. The latter may be given to any person, regardless of gender and age. The prevalence and distribution of HPV types differ by geographic region (<xref rid="b1275" ref-type="bibr">Stanley et al., 2012</xref>). All three prophylactic combination vaccines contain L1 in its purified form and recombinant HPV empty shells (<xref rid="b1275" ref-type="bibr">Stanley et al., 2012</xref>). The levels of vaccine content in the serum of the patients varies with age with maximum seropositivity seen for ages between 15 and 25&#160;years. Serum levels reduce a bit as patients grow older (<xref rid="b1280" ref-type="bibr">Dadar et al., 2018</xref>). Even a vaccine-based therapy is available for HPV, which triggers the cell-mediated immunity. The nonavalent prophylactic vaccine is the best vaccine for HPV in the present-day scenario (<xref rid="b1285" ref-type="bibr">Anna Rosa Garbuglia</xref>).</p></sec><sec id="s0055"><label>11</label><title><italic toggle="yes">N. Meningitidis</italic> &amp; Syphilis vaccine</title><p id="p0140">Group B OMV (outer membrane vesicle) vaccines against <italic toggle="yes">Neisseria gonorrhoeae</italic> have been developed. But the pathway and mode of action are still very unclear. Hurdles like the relation between pelvic inflammation and infection, biomarker development, and specific tests for upper genital tract ailments are seen during clinical trials. The male urethral model is also a serious challenge that is still stuck at clinical trials phase II. In the upcoming years, the effect of 4CMenB against gonorrhea deserves special attention (<xref rid="b1290" ref-type="bibr">Registry, 2020</xref>). The first prototype vaccine for syphilis was designed in 1973 (<xref rid="b1295" ref-type="bibr">Miller, 1973</xref>). Animal models administered with <italic toggle="yes">T. pallidum</italic> treated with &#947; radiation showed protection against the disease for 1&#160;year (<xref rid="b0795" ref-type="bibr">Cameron; C.E. and S.A. Lukehart, 2014</xref>). Subsequently, <italic toggle="yes">Borrelia burgdorferi</italic> based carrier and <italic toggle="yes">T. pallidum</italic> flagellin encoding plasmid were proposed as candidate vaccines, but these are still in experimental stages (<xref rid="b1300" ref-type="bibr">Parveen et al., 2019</xref>, <xref rid="b1305" ref-type="bibr">Zheng et al., 2018</xref>). Due to ethical reasons and safety concerns of the subjects under clinical trials, the vaccine for syphilis has not completed human trials yet (<xref rid="b1310" ref-type="bibr">Centre for Disease Control and Prevention. The Tuskegee timeline, https://www.cdc.gov/tuskegee/ timeline.htm. (accessed 13 August 2019</xref>).</p></sec><sec id="s0060"><label>12</label><title><italic toggle="yes">Chlamydia</italic> vaccine</title><p id="p0145">Modelling studies have suggested that partial protection of <italic toggle="yes">C. trachomatis</italic> (Ct) could be a cost-effective vaccine. But the burden of treating Ct-associated diseases, especially in developing and underdeveloped countries, makes potential vaccination inevitably necessary. Trials are still being completed in humans for Ct vaccines as endpoints for the efficacy are still under research. Scientists are currently working on biomarker identification associated with inflammation for upper genital tract and the role of antibodies (CD4 T cells generated by Ct specific vaccine). There are several potential vaccines available today for Ct which are administered in combination by practitioners; they include NanoBio Corp&#8217;s Intranasal MOMP nanoemulsion with Fattom, Statens Serum Institut&#8217;s MOMP-VD4 neutralizing antibodies, Pan-Provincial Vaccine Enterprise Inc. and British Columbia CDC&#8217;s MOMP&#160;+&#160;Pmps, Selecta Biosciences&#8217;s cSAP TLR7 agonist with UV-killed Chlamydia, Prokarium&#8217;s Vaxonella platform, and NIH/NIAID plasmid-deficient trachoma vaccine (<xref rid="b1315" ref-type="bibr">Olsen et al., 2015</xref>, <xref rid="b1320" ref-type="bibr">B&#248;je et al., 2016</xref>, <xref rid="b1325" ref-type="bibr">Olsen et al., 2017</xref>, <xref rid="b1330" ref-type="bibr">Fattom, 2019</xref>, <xref rid="b1335" ref-type="bibr">Karunakaran et al., 2015</xref>, <xref rid="b1340" ref-type="bibr">Stary et al., 2015</xref>, <xref rid="b1345" ref-type="bibr">Garmory et al., 2005</xref>, <xref rid="b1350" ref-type="bibr">Kari et al., 2011</xref>).</p></sec><sec id="s0065"><label>13</label><title>HSV vaccine &amp; HIV vaccine</title><p id="p0150">Preclinical forms for HSV treatment and prevention are mutated forms of HSV-1, HSV-2, glycoprotein B lentiviral vector with HSV-1, MPL/alum in HSV-2, intranasal recombinant of HSV-1&#160;g, and trivalent glycoprotein. Although mice and guinea pig models are not reliable for human responses for this specific disease, these models have reported enhanced viral clearance and reduction recurrence of the ailment due to the vaccine (<xref rid="b1355" ref-type="bibr">Corey et al., 1999</xref>, <xref rid="b1360" ref-type="bibr">Mascola, 1999</xref>, <xref rid="b1365" ref-type="bibr">Strasser et al., 2000</xref>). The vaccines that are underway for simplex virus associated with humans are Profectus BioSciences, gD2/ICP4, GEN-003 Genocea, HerpV Agenus, HSP, QS-21 with 32 to 35-mer peptides and polynucleotides, gD2+/&#8211;UL46 Vaxfectin, and HSV529 Sanofi Replicated attenuated HSV-2X (<xref rid="b1370" ref-type="bibr">Johnston et al., 2016</xref>). These are generally therapeutic vaccines that might surface in the coming years as all of them have reached phase II of clinical trials except for HSV529 Sanofi Replicated attenuated HSV-2X. NIAID of the NIH, US Army Medical Research and Development Command, Janssen, and the HIV Vaccine Trials Network has been working on an acceptable vaccine model which addresses the genetic diversity of HIV (<xref rid="b1375" ref-type="bibr">ClinicalTrials.gov. Identifier NCT0, 2019</xref>). The steps that need to be rendered in the subsequent years should be the completion of clinical trials of mosaic and prime boost approach vaccines. Few similar therapies like vaccines available today for HIV are immunogen stimulating germlines, passive immunization antibodies, envelope domains, envelope trimers, and genetic delivery by viral vectors and replicating viral vectors (<xref rid="b1380" ref-type="bibr">Rerks-Ngarm et al., 2009</xref>, <xref rid="b1385" ref-type="bibr">Jardine et al., 2013</xref>, <xref rid="b1390" ref-type="bibr">Moldt et al., 2012</xref>, <xref rid="b1395" ref-type="bibr">Lewis et al., 2002</xref>, <xref rid="b1400" ref-type="bibr">Parks et al., 2013</xref>).</p></sec><sec id="s0070"><label>14</label><title>Zika virus vaccine</title><p id="p0155">In the early months of 2020, zika virus was found to be dormant but the cohort presence of the viral strain in infants infected between 2015 and 2017 is still a medical issue that needs addressing (<xref rid="b1405" ref-type="bibr">Staples et al., 2020</xref>). The viral RNA has been found to be prevalent in the semen of symptomatic patients for up to 6&#160;months (<xref rid="b1410" ref-type="bibr">Counotte et al., 2018</xref>). The WHO is currently working on a set of vaccines for tackling zika virus, to name a few, AGS-v with salivary proteins, mRNA-1325, ZIKV, PIZV or TAK-426, VRC-ZKADNA085-00-VP, GLS-5700 DNA prME, and MV-Zika (<xref rid="b1415" ref-type="bibr">World Health Organization, 2019</xref>, <xref rid="b1420" ref-type="bibr">Sakkas et al., 2018</xref>).</p></sec><sec id="s0075"><label>15</label><title>Conclusion and future perspectives</title><p id="p0160">Integrative approaches with advancements in proteomics, immunomics, and immunogenomics will help in the development of a well-suited contraceptive vaccine for the next millennium. There is an imperative need to control the population growth rate throughout the world, utilizing innovation in contraception. In developing countries, between the first and second pregnancies, women undergo frequent abortions due to a lack of knowledge about contraception, affordability, and even failure when using existing contraceptive measures. Besides, contraceptive measures should be one of the main focuses of the next millennium, as 46 million abortions are being done yearly in developed nations. To our knowledge, contraceptive vaccines could be the choice to overcome the drawbacks in the existing contraception, <italic toggle="yes">e.g.</italic>, those related to condom usage. Fortunately, many contraceptive vaccines are being formulated, and some have been successful in animal models and are soon expected to undergo clinical trials. But still, we hope that advancements in integrative approaches with multi-omics techniques may come a practice to humankind in the near future. Before the development of vaccines for STIs, to understand the mechanism of transmission of organisms between individuals and the nature of STIs causing organisms is a must. If the transmission is clear, the vaccine development against each STI becomes easy and straightforward. Even though we have vaccines for hepatitis B, and HPV, the prevalence of these infections is still at an alarming stage. This is because of a lack of knowledge about STIs in rural areas and because government agencies are not conducting frequent awareness programs about STI vaccines. A lot of groundwork is in need for implementing the vaccines against STIs for prevention and control. Hopefully, vaccines for contraception and vaccines against STIs will be available in the market for the betterment of humankind in the near future. In a clinical context, a safe contraception vaccine, with no side effects, and reversible is crucial; however, it is also difficult to develop because human immune responses after immunization are hard to understand and sometimes inevitable.</p></sec><sec id="s0080"><title>Author contributions</title><p id="p0165">All the authors substantially contributed to the conception, compilation of data, checking and approving the final version of the manuscript, and agree to be accountable for its contents.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0175">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Golden</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Scholes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kerani</surname><given-names>R.P.</given-names></name></person-group><article-title>Assessing trends in chlamydia positivity and gonorrhea incidence and their associations with the incidence of pelvic inflammatory disease and ectopic pregnancy in Washington state 1988&#8211;2010</article-title><source>Sex. Transm. Dis.</source><volume>43</volume><issue>1</issue><year>2016</year><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">26656441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/OLQ.0000000000000352</pub-id></element-citation></ref><ref id="b0010"><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name name-style="western"><surname>Uniyal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paliwal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kaphaliya</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R.K.</given-names></name></person-group><article-title>Human Overpopulation: Impact on Environment</article-title><source>Environ. Issues Surrounding Hum. Overpopulation.</source><volume>738(632):1</volume><year>2016</year></element-citation></ref><ref id="b0015"><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name name-style="western"><surname>Pohjoranta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Suhonen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gissler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ikonen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mentula</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heikinheimo</surname><given-names>O.</given-names></name></person-group><article-title>Early provision of intrauterine contraception as part of abortion care&#8212;5-year results of a randomised controlled trial</article-title><source>Hum. Reprod.</source><volume>35</volume><issue>4</issue><year>2020</year><fpage>796</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">32266392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/humrep/deaa031</pub-id></element-citation></ref><ref id="b0020"><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name name-style="western"><surname>Ganatra</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gerdts</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rossier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Johnson Jr</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Tun&#231;alp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Assifi</surname><given-names>A.</given-names></name></person-group><article-title>Global, regional, and subregional classification of abortions by safety, 2010&#8211;14: estimates from a Bayesian hierarchical model</article-title><source>The Lancet</source><volume>390</volume><issue>10110</issue><year>2017</year><fpage>2372</fpage><lpage>2381</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)31794-4</pub-id><pub-id pub-id-type="pmcid">PMC5711001</pub-id><pub-id pub-id-type="pmid">28964589</pub-id></element-citation></ref><ref id="b0025"><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name name-style="western"><surname>Dahal</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Khatiwada</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>S.</given-names></name></person-group><article-title>Female Temporary Contraceptive Method: Availability and Its Effects</article-title><source>J. Community Med. Health. Care</source><volume>2</volume><issue>1</issue><year>2017</year><fpage>1005</fpage></element-citation></ref><ref id="b0030"><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name name-style="western"><surname>Kidan</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Azeze</surname><given-names>B.</given-names></name></person-group><article-title>Survey of condom use among college students</article-title><source>Ethiopian J. Health Devel, (EJHD)</source><volume>9</volume><issue>1</issue><year>2017</year></element-citation></ref><ref id="b0035"><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name name-style="western"><surname>Girma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Assefa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tushunie</surname><given-names>K.</given-names></name></person-group><article-title>Determinants of condom use among Agaro High School students using behavioral models</article-title><source>Ethiopi. J. Heal. Devel, (EJHD)</source><volume>18</volume><issue>1</issue><year>2017</year></element-citation></ref><ref id="b0040"><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name name-style="western"><surname>Magnani</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Seiber</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>E.Z.</given-names></name><name name-style="western"><surname>Vereau</surname><given-names>D.</given-names></name></person-group><article-title>Correlates of sexual activity and condom use among secondary-school students in urban Peru</article-title><source>Stud. Fam. Plann.</source><volume>32</volume><issue>1</issue><year>2007</year><fpage>53</fpage><lpage>66</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1728-4465.2001.00053.x</pub-id><pub-id pub-id-type="pmid">11326457</pub-id></element-citation></ref><ref id="b0045"><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name name-style="western"><surname>Barroso</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Babanto</surname><given-names>R.R.</given-names></name></person-group><article-title>Unwanted Teenage Pregnancies: Sociological Model Based on Agents. <italic toggle="yes">Asia Pacifi</italic></article-title><source>J. Soci. Behavi. Sci.</source><year>2016</year><fpage>13</fpage></element-citation></ref><ref id="b0050"><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name name-style="western"><surname>Cromer</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Dwyer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>R.T.</given-names></name></person-group><article-title>A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception</article-title><source>Pediatrics</source><volume>94</volume><issue>5</issue><year>1994</year><fpage>687</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">7936897</pub-id></element-citation></ref><ref id="b0055"><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name name-style="western"><surname>Hampton</surname><given-names>T.</given-names></name></person-group><article-title>Birth Control Patch</article-title><source>JAMA</source><volume>296</volume><issue>16</issue><year>2016</year><fpage>1958</fpage></element-citation></ref><ref id="b0060"><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name name-style="western"><surname>Kuehn</surname><given-names>B.M.</given-names></name></person-group><article-title>Birth control patch</article-title><source>JAMA</source><volume>299</volume><issue>8</issue><year>2008</year><fpage>890</fpage></element-citation></ref><ref id="b0065"><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name name-style="western"><surname>Delavande</surname><given-names>A.</given-names></name></person-group><article-title>Pill, patch, or shot? Subjective expectations and birth control choice</article-title><source>Int. Econ. Rev.</source><volume>49</volume><issue>3</issue><year>2008</year><fpage>999</fpage><lpage>1042</lpage></element-citation></ref><ref id="b0070"><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name name-style="western"><surname>Jayaraman</surname><given-names>K.</given-names></name></person-group><article-title>A shot at contraception. In India, a nonagenarian renews testing of a birth control vaccine</article-title><source>Nat Med.</source><volume>24</volume><issue>2</issue><year>2018</year><fpage>118</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">29414934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm0218-118</pub-id></element-citation></ref><ref id="b0075"><element-citation publication-type="book" id="h0075"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>J.</given-names></name></person-group><part-title>The birth control movement and American society: From private vice to public virtue</part-title><year>2014</year><publisher-name>Princeton University Press</publisher-name></element-citation></ref><ref id="b0080"><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>P.</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Blanda</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Controlling levonorgestrel binding and release in a multi-purpose prevention technology vaginal ring device</article-title><source>J. Cont. Release</source><volume>226</volume><year>2016</year><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2016.02.020</pub-id><pub-id pub-id-type="pmid">26878974</pub-id></element-citation></ref><ref id="b0085"><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name name-style="western"><surname>Houv&#232;ssou</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Far&#237;as-Ant&#250;nez</surname><given-names>S.</given-names></name><name name-style="western"><surname>da Silveira</surname><given-names>M.F.</given-names></name></person-group><article-title>Combined hormonal contraceptives use among women with contraindications according to the who criteria: A systematic review</article-title><source>Sex. Reproductive Healthcare</source><year>2020</year><object-id pub-id-type="publisher-id">100587</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.srhc.2020.100587</pub-id><pub-id pub-id-type="pmid">33545506</pub-id></element-citation></ref><ref id="b0090"><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name name-style="western"><surname>Zapata</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Murtaza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Whiteman</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Marchbanks</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>D'Angelo</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>K.M.</given-names></name></person-group><article-title>Contraceptive counseling and postpartum contraceptive use</article-title><source>Am. J. Obstetr. Gynecol.</source><volume>212</volume><issue>2</issue><year>2015</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2014.07.059</pub-id><pub-id pub-id-type="pmcid">PMC4470255</pub-id><pub-id pub-id-type="pmid">25093946</pub-id></element-citation></ref><ref id="b0095"><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Crengle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sheridan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>E.</given-names></name></person-group><article-title>Factors associated with consistent contraception and condom use among M&#257;ori secondary school students in New Zealand</article-title><source>J. Paediat. Child Health</source><volume>50</volume><issue>4</issue><year>2014</year><fpage>258</fpage><lpage>265</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jpc.12450</pub-id><pub-id pub-id-type="pmid">24372724</pub-id></element-citation></ref><ref id="b0100"><mixed-citation publication-type="other" id="h0100">Beksinska, M., 2016. Expanding contraceptive options for women: the SILCS diaphragm.</mixed-citation></ref><ref id="b0105"><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name name-style="western"><surname>Wiyeh</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Mome</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Mahasha</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Kongnyuy</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Wiysonge</surname><given-names>C.S.</given-names></name></person-group><article-title>Effectiveness of the female condom in preventing HIV and sexually transmitted infections: a systematic review and meta-analysis</article-title><source>BMC Public Health</source><volume>20</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">32164652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-020-8384-7</pub-id><pub-id pub-id-type="pmcid">PMC7068875</pub-id></element-citation></ref><ref id="b0110"><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name name-style="western"><surname>Malarcher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Spieler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fabic</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Starbird</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Kenon</surname><given-names>C.</given-names></name></person-group><article-title>Fertility awareness methods: distinctive modern contraceptives</article-title><source>Global Health: Sci. Pract.</source><volume>4</volume><issue>1</issue><year>2016</year><fpage>13</fpage><lpage>15</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.9745/GHSP-D-15-00297</pub-id><pub-id pub-id-type="pmcid">PMC4807745</pub-id><pub-id pub-id-type="pmid">27016540</pub-id></element-citation></ref><ref id="b0115"><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Bernholc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hubacher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>G.</given-names></name><name name-style="western"><surname>Van Vliet</surname><given-names>H.A.</given-names></name></person-group><article-title>Immediate postpartum insertion of intrauterine device for contraception</article-title><source>The Cochrane Library</source><year>2015</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD003036.pub3</pub-id><pub-id pub-id-type="pmcid">PMC10777269</pub-id><pub-id pub-id-type="pmid">26115018</pub-id></element-citation></ref><ref id="b0120"><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name name-style="western"><surname>Bakaroudis</surname><given-names>M.</given-names></name></person-group><article-title>Outercourse: Exploring nonpenetrative forms of pleasurable safer sex</article-title><source>Am. J. Sexual. Educat.</source><volume>9</volume><issue>3</issue><year>2014</year><fpage>381</fpage><lpage>397</lpage></element-citation></ref><ref id="b0125"><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name name-style="western"><surname>Susmiarsih</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Shari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ratri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pujianto</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Bachtiar</surname><given-names>E.W.</given-names></name></person-group><article-title>Anti-VDAC3 recombinant antibody decreased human sperm motility and membrane integrity: A potential spermicide for contraception</article-title><source>As. Paci. J. Reprod.</source><volume>6</volume><issue>6</issue><year>2017</year><fpage>257</fpage></element-citation></ref><ref id="b0130"><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name name-style="western"><surname>Mandell</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D.L.</given-names></name></person-group><article-title>Safer Conception and Family Planning Knowledge, Attitudes, and Practices Among Postpartum Women with HIV in Rural South Africa</article-title><source>Open Access J. Contraception</source><volume>12</volume><year>2021</year><fpage>17</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OAJC.S288569</pub-id><pub-id pub-id-type="pmcid">PMC7882456</pub-id><pub-id pub-id-type="pmid">33603508</pub-id></element-citation></ref><ref id="b0135"><mixed-citation publication-type="other" id="h0135">Edet, S.I., N.E. Samuel, A.E. Etim. Impact of Overpopulation on the Biological Diversity Conservation in Boki Local Government Area of Cross River State, Nigeria. Am. J. Environ. Eng., 20144(5) 94-8.</mixed-citation></ref><ref id="b0140"><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name name-style="western"><surname>Hanna</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cuellar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>J.</given-names></name></person-group><article-title>A progressive elimination strategy for screening meiotic inhibitors as novel contraceptives</article-title><source>Fertili. Sterili.</source><volume>106</volume><issue>3</issue><year>2016</year><object-id pub-id-type="publisher-id">e7</object-id></element-citation></ref><ref id="b0145"><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name name-style="western"><surname>Rubin</surname><given-names>R.</given-names></name></person-group><article-title>Work Progresses on Male Contraceptives, but Hurdles Remain</article-title><source>JAMA</source><volume>318</volume><issue>13</issue><year>2017</year><fpage>1208</fpage><lpage>1210</lpage><pub-id pub-id-type="pmid">28910430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.10302</pub-id></element-citation></ref><ref id="b0150"><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name name-style="western"><surname>Talwar</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Rulli</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Nand</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Bandivdekar</surname><given-names>A.H.</given-names></name><etal/></person-group><article-title>Advances in development of a contraceptive vaccine against human chorionic gonadotropin</article-title><source>Expert Opin. Biolo Therapy</source><volume>15</volume><issue>8</issue><year>2015</year><fpage>1183</fpage><lpage>1190</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2015.1049943</pub-id><pub-id pub-id-type="pmid">26160491</pub-id></element-citation></ref><ref id="b0155"><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name name-style="western"><surname>Samoylova</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Braden</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bartol</surname><given-names>F.F.</given-names></name></person-group><article-title>Immunocontraception: Filamentous Bacteriophage as a Platform for Vaccine Development</article-title><source>Curr. Medi. Chem.</source><volume>24</volume><issue>35</issue><year>2017</year><fpage>3907</fpage><lpage>3920</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929867324666170911160426</pub-id><pub-id pub-id-type="pmcid">PMC5738698</pub-id><pub-id pub-id-type="pmid">28901276</pub-id></element-citation></ref><ref id="b0160"><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name name-style="western"><surname>Steiner</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Liddon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Swartzendruber</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Rasberry</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Sales</surname><given-names>J.M.</given-names></name></person-group><article-title>Long-acting reversible contraception and condom use among female US high school students: implications for sexually transmitted infection prevention</article-title><source>JAMA Pediatr.</source><volume>170</volume><issue>5</issue><year>2016</year><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">26974492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapediatrics.2016.0007</pub-id><pub-id pub-id-type="pmcid">PMC9125406</pub-id></element-citation></ref><ref id="b0165"><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name name-style="western"><surname>Brotman</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Ravel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bavoil</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Gravitt</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Ghanem</surname><given-names>K.G.</given-names></name></person-group><article-title>Microbiome, sex hormones, and immune responses in the reproductive tract: challenges for vaccine development against sexually transmitted infections</article-title><source>Vaccine</source><volume>32</volume><issue>14</issue><year>2014</year><fpage>1543</fpage><lpage>1552</lpage><pub-id pub-id-type="pmid">24135572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.10.010</pub-id><pub-id pub-id-type="pmcid">PMC3964794</pub-id></element-citation></ref><ref id="b0170"><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>O.</given-names></name></person-group><article-title>Nasal vaccines against Hepatitis B: An update</article-title><source>Curr. Pharm. Biotechnol.</source><volume>16</volume><issue>10</issue><year>2015</year><fpage>882</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">25941886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389201016666150505122422</pub-id></element-citation></ref><ref id="b0175"><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name name-style="western"><surname>Strauss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>R.A.</given-names></name></person-group><article-title>Therapeutic vaccines for prostate cancer: recent advances and future directions</article-title><source>Expert Rev. Vaccines</source><volume>15</volume><issue>7</issue><year>2016</year><fpage>907</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">26889831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2016.1155988</pub-id></element-citation></ref><ref id="b0180"><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name name-style="western"><surname>Dominiak</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huras</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kr&#281;cisz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Krzeszowski</surname><given-names>W.</given-names></name><name name-style="western"><surname>Szyma&#324;ski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Czarnecka</surname><given-names>K.</given-names></name></person-group><article-title>Promising results in development of male contraception</article-title><source>Bioorg. Med. Chem. Lett.</source><volume>128005</volume><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmcl.2021.128005</pub-id><pub-id pub-id-type="pmid">33798701</pub-id></element-citation></ref><ref id="b0185"><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name name-style="western"><surname>Hull</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Glazener</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Conway</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Hinton</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Population study of causes, treatment, and outcome of infertility</article-title><source>Br. Med. J. (Clin. Res. Ed.)</source><volume>291</volume><issue>6510</issue><year>1985</year><fpage>1693</fpage><lpage>1697</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.291.6510.1693</pub-id><pub-id pub-id-type="pmcid">PMC1418755</pub-id><pub-id pub-id-type="pmid">3935248</pub-id></element-citation></ref><ref id="b0190"><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name name-style="western"><surname>Lea</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Adoyo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>G.O.</given-names></name></person-group><article-title>Autoimmunogenicity of the human sperm protein Sp17 in vasectomised men and identification of linear B cell epitopes</article-title><source>Fertil. Steril.</source><volume>67</volume><issue>2</issue><year>1997</year><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">9022615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0015-0282(97)81923-1</pub-id></element-citation></ref><ref id="b0195"><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name name-style="western"><surname>Mortazavi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fard</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Karkhane</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Shokrpoor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heidari</surname><given-names>F.</given-names></name></person-group><article-title>Evaluation of multi-epitope recombinant protein as a candidate for a contraceptive vaccine</article-title><source>J. Reprod. Immunol.</source><volume>103325</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jri.2021.103325</pub-id><pub-id pub-id-type="pmid">33930667</pub-id></element-citation></ref><ref id="b0200"><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name name-style="western"><surname>Diekman</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Herr</surname><given-names>J.C.</given-names></name></person-group><article-title>Sperm antigens and their use in the development of an immunocontraceptive</article-title><source>Am. J. Reprod. Immunol.</source><volume>37</volume><issue>1</issue><year>1997</year><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">9138444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0897.1997.tb00199.x</pub-id></element-citation></ref><ref id="b0205"><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name name-style="western"><surname>O'Donnell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rebourcet</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dagley</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Sgaier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Infusini</surname><given-names>G.</given-names></name><name name-style="western"><surname>O'Shaughnessy</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Chalmel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fietz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weidner</surname><given-names>W.</given-names></name><name name-style="western"><surname>Legrand</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hobbs</surname><given-names>R.M.</given-names></name></person-group><article-title>Sperm proteins and cancer-testis antigens are released by the seminiferous tubules in mice and men</article-title><source>FASEB J.</source><volume>35</volume><issue>3</issue><year>2021</year><object-id pub-id-type="publisher-id">e21397</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.202002484R</pub-id><pub-id pub-id-type="pmcid">PMC7898903</pub-id><pub-id pub-id-type="pmid">33565176</pub-id></element-citation></ref><ref id="b0210"><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name name-style="western"><surname>Mirandola</surname><given-names>L.</given-names></name><name name-style="western"><surname>Figueroa</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Phan</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Grizzi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>R.L.</given-names></name></person-group><article-title>Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets</article-title><source>Oncotarget</source><volume>6</volume><issue>5</issue><year>2015</year><fpage>2812</fpage><pub-id pub-id-type="pmid">25739119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.2802</pub-id><pub-id pub-id-type="pmcid">PMC4413619</pub-id></element-citation></ref><ref id="b0215"><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name name-style="western"><surname>Mortazavi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fard</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Karkhane</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Shokrpoor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heidari</surname><given-names>F.</given-names></name></person-group><article-title>Evaluation of multi-epitope recombinant protein as a candidate for a contraceptive vaccine</article-title><source>J. Reprod. Immunol.</source><volume>2021</volume><year>2021</year><object-id pub-id-type="publisher-id">103325</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jri.2021.103325</pub-id><pub-id pub-id-type="pmid">33930667</pub-id></element-citation></ref><ref id="b0220"><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name name-style="western"><surname>Bleil</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Wassarman</surname><given-names>P.M.</given-names></name></person-group><article-title>Identification of a ZP3-binding protein on acrosome-intact mouse sperm by photoaffinity crosslinking</article-title><source>Proceed. Nat. Acad Sci.</source><volume>87</volume><issue>14</issue><year>1990</year><fpage>5563</fpage><lpage>5567</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.87.14.5563</pub-id><pub-id pub-id-type="pmcid">PMC54365</pub-id><pub-id pub-id-type="pmid">2371290</pub-id></element-citation></ref><ref id="b0225"><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name name-style="western"><surname>Frayne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>L.</given-names></name></person-group><article-title>The potential use of sperm antigens as targets for immunocontraception; past, present and future</article-title><source>J. Reprod. Immunol.</source><volume>43</volume><issue>1</issue><year>1999</year><fpage>1</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">10392779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0165-0378(99)00005-4</pub-id></element-citation></ref><ref id="b0230"><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name name-style="western"><surname>Jalalvandi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amorim</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Petri</surname><given-names>D.F.S.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shavandi</surname><given-names>A.</given-names></name></person-group><article-title>Vaginal Administration of Contraceptives</article-title><source>Scientia Pharmaceutica</source><volume>89</volume><issue>1</issue><year>2021</year><fpage>3</fpage></element-citation></ref><ref id="b0235"><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name name-style="western"><surname>Naz</surname><given-names>R.K.</given-names></name></person-group><article-title>Contraceptive vaccines</article-title><source>Drugs</source><volume>65</volume><issue>5</issue><year>2005</year><fpage>593</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">15748095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003495-200565050-00002</pub-id></element-citation></ref><ref id="b0240"><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name name-style="western"><surname>Kerr</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>R.J.</given-names></name></person-group><article-title>Molecular basis of sperm&#8211;egg interaction and the prospects for immunocontraception</article-title><source>J. Reprod. Immunol.</source><volume>40</volume><issue>2</issue><year>1998</year><fpage>103</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">9881739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0165-0378(98)00039-4</pub-id></element-citation></ref><ref id="b0245"><element-citation publication-type="book" id="h0245"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name></person-group><source>The Sperm</source><year>2017</year><publisher-name>Springer</publisher-name><publisher-loc>Singapore</publisher-loc><fpage>171</fpage><lpage>204</lpage></element-citation></ref><ref id="b0250"><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>The antibody against a nuclear autoantigenic sperm protein can result in reproductive failure</article-title><source>Asian J. Androl.</source><volume>11</volume><issue>2</issue><year>2009</year><fpage>183</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">19219058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/aja.2008.59</pub-id><pub-id pub-id-type="pmcid">PMC3735017</pub-id></element-citation></ref><ref id="b0255"><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name name-style="western"><surname>Nagatomo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kohri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Akizawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hoshino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kono</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Requirement for nuclear autoantigenic sperm protein mRNA expression in bovine preimplantation development</article-title><source>Ani. Sci. J.</source><volume>87</volume><issue>3</issue><year>2016</year><fpage>457</fpage><lpage>461</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/asj.12538</pub-id><pub-id pub-id-type="pmid">26690724</pub-id></element-citation></ref><ref id="b0260"><element-citation publication-type="journal" id="h0260"><person-group person-group-type="author"><name name-style="western"><surname>Naz</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>D.P.</given-names></name></person-group><article-title>Antibodies to sperm-specific human FA-1 inhibiti in vitro fertilisation in rhesus monkeys: development of a simian model for testing of anti-FA-1 contraceptive vaccine</article-title><source>J. Reprod. Immunol.</source><volume>27</volume><issue>2</issue><year>1994</year><fpage>111</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">7884740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-0378(94)90027-2</pub-id></element-citation></ref><ref id="b0265"><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name name-style="western"><surname>Lefevre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martin Ruiz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chokomian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duquenne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Finaz</surname><given-names>C.</given-names></name></person-group><article-title>Characterisation and isolation of SOB2, a human sperm protein with a potential role in oocyte membrane binding</article-title><source>Mol. Hum. Reprod.</source><volume>3</volume><issue>6</issue><year>1997</year><fpage>507</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">9239740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/molehr/3.6.507</pub-id></element-citation></ref><ref id="b0270"><mixed-citation publication-type="other" id="h0270">Hay, B.A., Li, J. 2014. California Institute of Technology. Antibody-mediated immunocontraception. U.S. Patent Application 14/170,118.</mixed-citation></ref><ref id="b0275"><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name name-style="western"><surname>McLaughlin</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>R.J.</given-names></name></person-group><article-title>Contraceptive vaccines</article-title><source>Expert Opinin. Biol. Therapy</source><volume>3</volume><issue>5</issue><year>2003</year><fpage>829</fpage><lpage>841</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.3.5.829</pub-id><pub-id pub-id-type="pmid">12880382</pub-id></element-citation></ref><ref id="b0280"><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name name-style="western"><surname>Tecle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gagneux</surname><given-names>P.</given-names></name></person-group><article-title>Sugar-coated sperm: Unraveling the functions of the mammalian sperm glycocalyx</article-title><source>Mol. Reprod. Devel.</source><volume>82</volume><issue>9</issue><year>2015</year><fpage>635</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">26061344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrd.22500</pub-id><pub-id pub-id-type="pmcid">PMC4744710</pub-id></element-citation></ref><ref id="b0285"><element-citation publication-type="journal" id="h0285"><person-group person-group-type="author"><name name-style="western"><surname>Jagadish</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Selvi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Suri</surname><given-names>A.</given-names></name></person-group><article-title>Characterisation of immune response in mice to plasmid DNA encoding human sperm associated antigen 9 (SPAG9)</article-title><source>Vaccine</source><volume>4</volume><issue>17</issue><year>2006</year><fpage>3695</fpage><lpage>3703</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2005.07.007</pub-id><pub-id pub-id-type="pmid">16061308</pub-id></element-citation></ref><ref id="b0290"><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name name-style="western"><surname>Lou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Direct targeting sperm-associated antigen 9 by miR-141 influences hepatocellular carcinoma cell growth and metastasis via JNK pathway</article-title><source>J. Exp. Clin. Cancer Res.</source><volume>35(1):14</volume><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-016-0289-z</pub-id><pub-id pub-id-type="pmcid">PMC4721207</pub-id><pub-id pub-id-type="pmid">26790956</pub-id></element-citation></ref><ref id="b0295"><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name name-style="western"><surname>Archana</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Selvaraju</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arangasamy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Binsila</surname><given-names>B.</given-names></name><name name-style="western"><surname>Swathi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramya</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kumaresan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krishnappa</surname><given-names>B.</given-names></name></person-group><article-title>Seminal antigenicity affects mitochondrial membrane potential and acrosome reaction ability of the spermatozoa during cryopreservation</article-title><source>Theriogenology</source><volume>159</volume><year>2021</year><fpage>132</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">33137634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.theriogenology.2020.10.025</pub-id></element-citation></ref><ref id="b0300"><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name name-style="western"><surname>Shetty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Herr</surname><given-names>J.C.</given-names></name></person-group><article-title>Methods of analysis of sperm antigens related to fertility</article-title><source>Immune Infertil. Springer, Cham.</source><year>2017</year><fpage>23</fpage><lpage>47</lpage></element-citation></ref><ref id="b0305"><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name name-style="western"><surname>Ellerman</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Snell</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Myles</surname><given-names>D.</given-names></name><name name-style="western"><surname>Primakoff</surname><given-names>P.</given-names></name></person-group><article-title>Izumo is part of a multiprotein family whose members form large complexes on mammalian sperm</article-title><source>Mol. Reprod. Devel.</source><volume>76</volume><issue>12</issue><year>2009</year><fpage>1188</fpage><lpage>1199</lpage><pub-id pub-id-type="pmid">19658160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrd.21092</pub-id><pub-id pub-id-type="pmcid">PMC3779078</pub-id></element-citation></ref><ref id="b0310"><mixed-citation publication-type="other" id="h0310">Inoue, N.; M. Ikawa, A. Isotani and M. Okabe. The immunoglobulin superfamily protein Izumo is required for sperm to fuse with eggs. <italic toggle="yes">Nature</italic>, 2005 434(7030):234.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature03362</pub-id><pub-id pub-id-type="pmid">15759005</pub-id></mixed-citation></ref><ref id="b0315"><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name name-style="western"><surname>Naz</surname><given-names>R.K.</given-names></name></person-group><article-title>Vaccine for human contraception targeting sperm Izumo protein and YLP12 dodecamer peptide</article-title><source>Protein Sci.</source><volume>23</volume><issue>7</issue><year>2014</year><fpage>857</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">24723387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pro.2476</pub-id><pub-id pub-id-type="pmcid">PMC4088970</pub-id></element-citation></ref><ref id="b0320"><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name name-style="western"><surname>Rubinstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ziyyat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Le Naour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Boucheix</surname><given-names>C.</given-names></name></person-group><article-title>The molecular players of sperm&#8211;egg fusion in mammals. Seminars Cell</article-title><source>Dev. Biol.</source><volume>17</volume><issue>2</issue><year>2006</year><fpage>254</fpage><lpage>263</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcdb.2006.02.012</pub-id><pub-id pub-id-type="pmid">16574441</pub-id></element-citation></ref><ref id="b0325"><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wolkowicz</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Shetty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Klotz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bolling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Westbrook</surname><given-names>V.A.</given-names></name><etal/></person-group><article-title>SAMP32, a testis-specific, isoantigenic sperm acrosomal membrane-associated protein</article-title><source>Biol. Reprod</source><volume>66</volume><issue>3</issue><year>2002</year><fpage>735</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">11870081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1095/biolreprod66.3.735</pub-id></element-citation></ref><ref id="b0330"><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q.D.</given-names></name><name name-style="western"><surname>An</surname><given-names>G.</given-names></name></person-group><article-title>Investigation of recombinant mouse sperm protein izumo as a potential immunocontraceptive antigen</article-title><source>Am. J. Reprod. Immunol.</source><volume>59</volume><issue>3</issue><year>2008</year><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">18275515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0897.2007.00571.x</pub-id></element-citation></ref><ref id="b0335"><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>Immunocontraceptive potential of the Ig-like domain of Izumo</article-title><source>Mol. Reprod. Devel.</source><volume>76</volume><issue>8</issue><year>2009</year><fpage>794</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">19288544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrd.21027</pub-id></element-citation></ref><ref id="b0340"><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q.D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.Y.</given-names></name></person-group><article-title>In Vitro and In Vivo Studies Evaluating Recombinant Plasmid pCXN2-mIzumo as a Potential Immunocontraceptive Antigen</article-title><source>Am. J. Reprod. Immunol.</source><volume>61</volume><issue>3</issue><year>2009</year><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">19239425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0897.2009.00685.x</pub-id></element-citation></ref><ref id="b0345"><element-citation publication-type="journal" id="h0345"><person-group person-group-type="author"><name name-style="western"><surname>Tumova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zigo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sutovsky</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sedmikova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Postlerova</surname><given-names>P.</given-names></name></person-group><article-title>Ligands and Receptors Involved in the Sperm-Zona Pellucida Interactions in Mammals</article-title><source>Cells</source><volume>10</volume><issue>1</issue><year>2021</year><fpage>133</fpage><pub-id pub-id-type="pmid">33445482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10010133</pub-id><pub-id pub-id-type="pmcid">PMC7827414</pub-id></element-citation></ref><ref id="b0350"><element-citation publication-type="journal" id="h0350"><person-group person-group-type="author"><name name-style="western"><surname>Ferro</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Garside</surname><given-names>D.A.</given-names></name></person-group><article-title>Reproductive component vaccine developments for contraceptive and non-contraceptive uses</article-title><source>Expert opin. Ther Pat.</source><volume>21</volume><issue>9</issue><year>2011</year><fpage>1473</fpage><lpage>1482</lpage><pub-id pub-id-type="pmid">21675927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/13543776.2011.594042</pub-id></element-citation></ref><ref id="b0355"><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Beaton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hinds</surname><given-names>L.A.</given-names></name></person-group><article-title>Immunocontraception in mice using repeated, multi-antigen peptides: immunisation with purified recombinant antigens</article-title><source>Mol. Reprod. Devel.</source><volume>75</volume><issue>1</issue><year>2008</year><fpage>126</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">17474093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrd.20745</pub-id></element-citation></ref><ref id="b0360"><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name name-style="western"><surname>Naz</surname><given-names>R.K.</given-names></name></person-group><article-title>Antisperm contraceptive vaccines: where we are and where we are going?</article-title><source>Am. J. Reprod. Immunol.</source><volume>66</volume><issue>1</issue><year>2011</year><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">21481057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0897.2011.01000.x</pub-id><pub-id pub-id-type="pmcid">PMC3110624</pub-id></element-citation></ref><ref id="b0365"><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name name-style="western"><surname>Kurth</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Digilio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Snow</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bush</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Wolkowicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shetty</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Immunogenicity of a multi-component recombinant human acrosomal protein vaccine in female Macaca fascicularis</article-title><source>J. Reprod. Immunol.</source><volume>77</volume><issue>2</issue><year>2008</year><fpage>126</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">17643494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jri.2007.06.001</pub-id><pub-id pub-id-type="pmcid">PMC2481230</pub-id></element-citation></ref><ref id="b0370"><element-citation publication-type="journal" id="h0370"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Pooler</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Mattfeld</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Quimby</surname><given-names>F.W.</given-names></name></person-group><article-title>Comparative effects of GnRH and porcine zona pellucida (PZP) immunocontraceptive vaccines for controlling reproduction in white-tailed deer (Odocoileus virginianus)</article-title><source>Reproduction (Cambridge, England) Supplement</source><volume>60</volume><year>2002</year><fpage>131</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">12220153</pub-id></element-citation></ref><ref id="b0375"><element-citation publication-type="journal" id="h0375"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Bynum</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Rutberg</surname><given-names>A.T.</given-names></name></person-group><article-title>Porcine zona pellucida (PZP) immunocontraception of wild horses (Equus caballus) in Nevada: a 10 year study</article-title><source>Reproduction(Cambridge, England) Supplement</source><volume>60</volume><year>2002</year><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">12220157</pub-id></element-citation></ref><ref id="b0380"><element-citation publication-type="journal" id="h0380"><person-group person-group-type="author"><name name-style="western"><surname>Shideler</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Stoops</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gee</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lasley</surname><given-names>B.L.</given-names></name></person-group><article-title>Use of porcine zona pellucida (PZP) vaccine as a contraceptive agent in free-ranging tule elk (Cervus elaphus nannodes)</article-title><source>Reproduction (Cambridge, England) Supplement</source><volume>60</volume><year>2002</year><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">12220156</pub-id></element-citation></ref><ref id="b0385"><element-citation publication-type="journal" id="h0385"><person-group person-group-type="author"><name name-style="western"><surname>Kirkpatrick</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Fayrer-Hosken</surname><given-names>R.</given-names></name></person-group><article-title>Applications of pig zona pellucida immunocontraception to wildlife fertility control</article-title><source>J. Reprod. Fertil., Supplement.</source><year>1996 50,</year><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">8984182</pub-id></element-citation></ref><ref id="b0390"><element-citation publication-type="journal" id="h0390"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Hinds</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Redwood</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Shellam</surname><given-names>G.R.</given-names></name><etal/></person-group><article-title>Biological control of vertebrate pests using virally vectored immunocontraception</article-title><source>J. Reprod. Immunol.</source><volume>71</volume><issue>2</issue><year>2006</year><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">16870262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jri.2006.04.006</pub-id></element-citation></ref><ref id="b0395"><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name name-style="western"><surname>Lloyd</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Shellam</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Papadimitriou</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>M.A.</given-names></name></person-group><article-title>Immunocontraception is induced in BALB/c mice inoculated with murine cytomegalovirus expressing mouse zona pellucida 3</article-title><source>Biol. Reprod.</source><volume>68</volume><issue>6</issue><year>2003</year><fpage>2024</fpage><lpage>2032</lpage><pub-id pub-id-type="pmid">12606395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1095/biolreprod.102.012880</pub-id></element-citation></ref><ref id="b0400"><element-citation publication-type="journal" id="h0400"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>C.M.</given-names></name></person-group><article-title>Current status of virally vectored immunocontraception for biological control of mice</article-title><source>Soc. Reprod. Fertility Supplement</source><volume>63</volume><year>2007</year><fpage>495</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">17566294</pub-id></element-citation></ref><ref id="b0405"><element-citation publication-type="journal" id="h0405"><person-group person-group-type="author"><name name-style="western"><surname>Redwood</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Hinds</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>C.M.</given-names></name></person-group><article-title>Prospects for virally vectored immunocontraception in the control of wild house mice (Mus domesticus)</article-title><source>Wildlife. Res.</source><volume>34</volume><issue>7</issue><year>2008</year><fpage>530</fpage><lpage>539</lpage></element-citation></ref><ref id="b0410"><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name name-style="western"><surname>McLeod</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>G.</given-names></name><name name-style="western"><surname>Twigg</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Arthur</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hinds</surname><given-names>L.A.</given-names></name></person-group><article-title>Prospects for the future: is there a role for virally vectored immunocontraception in vertebrate pest management?</article-title><source>Wildlife Res.</source><volume>34</volume><issue>7</issue><year>2008</year><fpage>555</fpage><lpage>566</lpage></element-citation></ref><ref id="b0415"><element-citation publication-type="journal" id="h0415"><person-group person-group-type="author"><name name-style="western"><surname>Killian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rhyan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Doten</surname><given-names>H.</given-names></name></person-group><article-title>Immunocontraception of Florida Feral Swine with a Single-dose GnRH Vaccine</article-title><source>Am. J. Reprod. Immunol.</source><volume>55</volume><issue>5</issue><year>2006</year><fpage>378</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">16635212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0897.2006.00379.x</pub-id></element-citation></ref><ref id="b0420"><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Gionfriddo</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Fagerstone</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Rhyan</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Killian</surname><given-names>G.J.</given-names></name></person-group><article-title>The Single-Shot GnRH Immunocontraceptive Vaccine (GonaCon&#8482;) in White-Tailed Deer: Comparison of Several GnRH Preparations</article-title><source>Am. J. Reprod. Immunol.</source><volume>60</volume><issue>3</issue><year>2008</year><fpage>214</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">18782282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0897.2008.00616.x</pub-id></element-citation></ref><ref id="b0425"><element-citation publication-type="journal" id="h0425"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y.G.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.P.</given-names></name><name name-style="western"><surname>Ijaz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>Hepatitis B Surface Antigen S Gene is an Effective Carrier Molecule for Developing GnRH DNA Immunocastration Vaccine in Mice</article-title><source>Reprod. Domest. Animals</source><volume>51</volume><issue>3</issue><year>2016</year><fpage>445</fpage><lpage>450</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/rda.12692</pub-id><pub-id pub-id-type="pmid">27157596</pub-id></element-citation></ref><ref id="b0430"><element-citation publication-type="journal" id="h0430"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Varamini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Simerska</surname><given-names>P.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name></person-group><article-title>Design, synthesis and evaluation of a gonadotropin releasing hormone-based subunit vaccine in rams (Ovis aries)</article-title><source>Vaccine</source><volume>33</volume><issue>12</issue><year>2015</year><fpage>1453</fpage><lpage>1458</lpage><pub-id pub-id-type="pmid">25678242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.01.076</pub-id></element-citation></ref><ref id="b0435"><element-citation publication-type="journal" id="h0435"><person-group person-group-type="author"><name name-style="western"><surname>Barranco</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Fuentes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Calzada</surname><given-names>L.</given-names></name><name name-style="western"><surname>Baladr&#243;n</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pimentel</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Heberprovac, a therapeutic Gnrh based vaccine to treat advanced prostate cancer</article-title><source>Bju. International</source><year>2015</year><fpage>116:31</fpage></element-citation></ref><ref id="b0440"><element-citation publication-type="journal" id="h0440"><person-group person-group-type="author"><name name-style="western"><surname>Madbouly</surname><given-names>H.</given-names></name><name name-style="western"><surname>Korany</surname><given-names>R.</given-names></name><name name-style="western"><surname>El-Shahat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eissa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fathi</surname><given-names>M.</given-names></name></person-group><article-title>Efficacy of intratesticular glycerol injection as male cat contraception in comparison with two surgical approaches</article-title><source>Topics Companion Animal Med.</source><volume>42</volume><year>2021</year><object-id pub-id-type="publisher-id">100493</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcam.2020.100493</pub-id><pub-id pub-id-type="pmid">33152526</pub-id></element-citation></ref><ref id="b0445"><element-citation publication-type="journal" id="h0445"><person-group person-group-type="author"><name name-style="western"><surname>Pinna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schivazappa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Virgili</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parolari</surname><given-names>G.</given-names></name></person-group><article-title>Effect of vaccination against gonadotropin-releasing hormone (GnRH) in heavy male pigs for Italian typical dry-cured ham production</article-title><source>Meat Sci.</source><volume>110</volume><year>2015</year><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">26225931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.meatsci.2015.07.002</pub-id></element-citation></ref><ref id="b0450"><element-citation publication-type="journal" id="h0450"><person-group person-group-type="author"><name name-style="western"><surname>Minhas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wadhwa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.K.</given-names></name></person-group><article-title>Novel Sperm and Gonadotropin-releasing Hormone-based Recombinant Fusion Protein: Achievement of 100% Contraceptive Efficacy by Co-immunization of Male and Female Mice</article-title><source>Mol. Reprod. Devel.</source><volume>83</volume><issue>12</issue><year>2016</year><fpage>1048</fpage><lpage>1059</lpage><pub-id pub-id-type="pmid">27676172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrd.22743</pub-id></element-citation></ref><ref id="b0455"><element-citation publication-type="journal" id="h0455"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>K.</given-names></name><name name-style="western"><surname>Prabha</surname><given-names>V.</given-names></name></person-group><article-title>Immunocontraceptives: new approaches to fertility control</article-title><source>BioMed. Res. Int., Article ID</source><volume>868196</volume><year>2014</year><fpage>15 pages</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/868196</pub-id><pub-id pub-id-type="pmcid">PMC4119744</pub-id><pub-id pub-id-type="pmid">25110702</pub-id></element-citation></ref><ref id="b0460"><element-citation publication-type="journal" id="h0460"><person-group person-group-type="author"><name name-style="western"><surname>Da Ros</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Battistone</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Brukman</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Carvajal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Curci</surname><given-names>L.</given-names></name><etal/></person-group><article-title>From the epididymis to the egg: participation of CRISP proteins in mammalian fertilisation. <italic toggle="yes">Asian</italic></article-title><source>J. Androl.</source><volume>17(5):711</volume><year>2015</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1008-682X.155769</pub-id><pub-id pub-id-type="pmcid">PMC4577577</pub-id><pub-id pub-id-type="pmid">26112483</pub-id></element-citation></ref><ref id="b0465"><element-citation publication-type="journal" id="h0465"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.G.</given-names></name></person-group><article-title>Construction of a catsper1 DNA vaccine and its antifertility effect on male mice</article-title><source>PLoS ONE</source><volume>10</volume><issue>5</issue><year>2015</year><object-id pub-id-type="publisher-id">e0127508</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0127508</pub-id><pub-id pub-id-type="pmcid">PMC4436331</pub-id><pub-id pub-id-type="pmid">25993432</pub-id></element-citation></ref><ref id="b0470"><element-citation publication-type="journal" id="h0470"><person-group person-group-type="author"><name name-style="western"><surname>Ellerman</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Brantua</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Conesa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cuasnic&#250;</surname><given-names>P.S.</given-names></name></person-group><article-title>Potential contraceptive use of epididymal proteins: immunisation of male rats with epididymal protein DE inhibits sperm fusion ability</article-title><source>Biol. Reprod.</source><volume>59</volume><issue>5</issue><year>1998</year><fpage>1029</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">9780306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1095/biolreprod59.5.1029</pub-id></element-citation></ref><ref id="b0475"><element-citation publication-type="journal" id="h0475"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Widgren</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Orand</surname><given-names>M.G.</given-names></name></person-group><article-title>Eppin: a molecular strategy for male contraception</article-title><source>Soci. Reprod. Fertil. Suppl.</source><volume>65</volume><year>2007</year><fpage>535</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">17644992</pub-id></element-citation></ref><ref id="b0480"><element-citation publication-type="journal" id="h0480"><person-group person-group-type="author"><name name-style="western"><surname>O'rand</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Widgren</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>R.T.</given-names></name></person-group><article-title>Eppin: an effective target for male contraception</article-title><source>Mol. Cell. Endocrinol.</source><volume>250</volume><issue>1&#8211;2</issue><year>2006</year><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">16423450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mce.2005.12.039</pub-id></element-citation></ref><ref id="b0485"><element-citation publication-type="journal" id="h0485"><person-group person-group-type="author"><name name-style="western"><surname>O'rand</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Widgren</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Sivashanmugam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>French</surname><given-names>F.S.</given-names></name></person-group><article-title>Reversible immunocontraception in male monkeys immunised with eppin</article-title><source>Science</source><volume>306</volume><issue>5699</issue><year>2004</year><fpage>1189</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">15539605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1099743</pub-id></element-citation></ref><ref id="b0490"><element-citation publication-type="journal" id="h0490"><person-group person-group-type="author"><name name-style="western"><surname>O'Rand</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Widgren</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Beyler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>R.T.</given-names></name></person-group><article-title>Inhibition of human sperm motility by contraceptive anti-eppin antibodies from infertile male monkeys: effect on cyclic adenosine monophosphate</article-title><source>Biol. Reprod.</source><volume>80</volume><issue>2</issue><year>2009</year><fpage>279</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">18945989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1095/biolreprod.108.072942</pub-id><pub-id pub-id-type="pmcid">PMC2630362</pub-id></element-citation></ref><ref id="b0495"><element-citation publication-type="journal" id="h0495"><person-group person-group-type="author"><name name-style="western"><surname>Michael</surname><given-names>G.O.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Hami</surname><given-names>K.G.</given-names></name></person-group><article-title>Non-hormonal male contraception: A review and development of an Eppin based contraceptive</article-title><source>Pharmacol. Therapeut.</source><volume>157</volume><year>2016</year><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2015.11.004</pub-id><pub-id pub-id-type="pmcid">PMC4703502</pub-id><pub-id pub-id-type="pmid">26593445</pub-id></element-citation></ref><ref id="b0500"><mixed-citation publication-type="other" id="h0500">Nieschlag, E., Henke, A. Hopes for male contraception. The Lancet, 365(9459) 554-6.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(05)17924-0</pub-id><pub-id pub-id-type="pmid">15708085</pub-id></mixed-citation></ref><ref id="b0505"><element-citation publication-type="journal" id="h0505"><person-group person-group-type="author"><name name-style="western"><surname>Persani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rossetti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cacciatore</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fabre</surname><given-names>S.</given-names></name></person-group><article-title>The fundamental role of bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders</article-title><source>Hum. Reprod. Update</source><volume>20</volume><issue>6</issue><year>2014</year><fpage>869</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">24980253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/humupd/dmu036</pub-id></element-citation></ref><ref id="b0510"><element-citation publication-type="journal" id="h0510"><person-group person-group-type="author"><name name-style="western"><surname>Otsuka</surname><given-names>F.</given-names></name><name name-style="western"><surname>McTavish</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Shimasaki</surname><given-names>S.</given-names></name></person-group><article-title>Integral role of GDF-9 and BMP-15 in ovarian function</article-title><source>Mol. Reprod. Devel.</source><volume>78</volume><issue>1</issue><year>2011</year><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">21226076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrd.21265</pub-id><pub-id pub-id-type="pmcid">PMC3051839</pub-id></element-citation></ref><ref id="b0515"><element-citation publication-type="book" id="h0515"><person-group person-group-type="author"><name name-style="western"><surname>Marconi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weidner</surname><given-names>W.</given-names></name></person-group><part-title>Site and risk factors of antisperm antibodies production in the male population</part-title><year>2017</year><publisher-name>Springer, Cham</publisher-name><publisher-loc>In Immune Infertility</publisher-loc><fpage>133</fpage><lpage>147</lpage></element-citation></ref><ref id="b0520"><element-citation publication-type="journal" id="h0520"><person-group person-group-type="author"><name name-style="western"><surname>Brubaker</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Eisenberg</surname><given-names>M.L.</given-names></name></person-group><article-title>Increased risk of autoimmune disorders in infertile men: analysis of US claims data</article-title><source>Andrology</source><volume>6</volume><issue>1</issue><year>2018</year><fpage>94</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">29179258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/andr.12436</pub-id></element-citation></ref><ref id="b0525"><element-citation publication-type="journal" id="h0525"><person-group person-group-type="author"><name name-style="western"><surname>Shrestha</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Motamedi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Swope</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>H.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>M.B.</given-names></name></person-group><article-title>Hexavalent Sperm-Binding IgG Antibody Released from Self-Dissolving Vaginal Film Enables Potent, On-Demand Non-Hormonal Female Contraception</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2107832118</pub-id><pub-id pub-id-type="pmcid">PMC8640842</pub-id><pub-id pub-id-type="pmid">34815336</pub-id></element-citation></ref><ref id="b0530"><element-citation publication-type="journal" id="h0530"><person-group person-group-type="author"><name name-style="western"><surname>Sturm</surname><given-names>A.W.</given-names></name></person-group><article-title>Ureaplasma urealyticum and infertility</article-title><source>Antonie Van Leeuwenhoek</source><volume>44</volume><issue>3</issue><year>1978</year></element-citation></ref><ref id="b0535"><element-citation publication-type="journal" id="h0535"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Screening of an antigen target for immunocontraceptives from cross-reactive antigens between human sperm and Ureaplasma urealyticum</article-title><source>Infect. Immunt.</source><volume>75</volume><issue>4</issue><year>2007</year><fpage>2004</fpage><lpage>2011</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.01171-06</pub-id><pub-id pub-id-type="pmcid">PMC1865700</pub-id><pub-id pub-id-type="pmid">17283099</pub-id></element-citation></ref><ref id="b0540"><element-citation publication-type="book" id="h0540"><person-group person-group-type="author"><name name-style="western"><surname>Weissenbacher</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mylonas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Klinik f&#252;r Geburtshilfe</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Ledger</surname></name><name name-style="western"><surname>Witkin</surname><given-names>S.S.</given-names></name></person-group><part-title>Immunology of the female genital tract</part-title><year>2014</year><publisher-name>Springer</publisher-name><publisher-loc>Berlin Heidelberg</publisher-loc></element-citation></ref><ref id="b0545"><element-citation publication-type="journal" id="h0545"><person-group person-group-type="author"><name name-style="western"><surname>Beagley</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.L.</given-names></name><name name-style="western"><surname>Pomering</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.C.</given-names></name></person-group><article-title>Immune responses in the epididymis: implications for immunocontraception</article-title><source>J. Reprod. Fertil.-Supp.</source><year>1998</year><fpage>235</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">10645283</pub-id></element-citation></ref><ref id="b0550"><element-citation publication-type="journal" id="h0550"><person-group person-group-type="author"><name name-style="western"><surname>Taylor-Robinson</surname><given-names>D.</given-names></name></person-group><article-title>Evaluation of the role of Ureaplasma urealyticum in infertility</article-title><source>Pediatr. Infect. Dis.</source><volume>5</volume><issue>6 Suppl</issue><year>1986</year><fpage>S262</fpage><lpage>S265</lpage><pub-id pub-id-type="pmid">3540899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00006454-198611010-00012</pub-id></element-citation></ref><ref id="b0555"><element-citation publication-type="journal" id="h0555"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>C.</given-names></name></person-group><article-title>Future prospects for new vaccines against sexually transmitted infections</article-title><source>Curr. Opin. Infect. Dis.</source><volume>30</volume><issue>1</issue><year>2017</year><fpage>77</fpage><pub-id pub-id-type="pmid">27922851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QCO.0000000000000343</pub-id><pub-id pub-id-type="pmcid">PMC5325242</pub-id></element-citation></ref><ref id="b0560"><element-citation publication-type="journal" id="h0560"><person-group person-group-type="author"><name name-style="western"><surname>Velan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yadgar</surname><given-names>Y.</given-names></name></person-group><article-title>On the implications of desexualising vaccines against sexually transmitted diseases: health policy challenges in a multicultural society</article-title><source>Israel J. Health Policy Res.</source><volume>6</volume><issue>1</issue><year>2017</year><fpage>30</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13584-017-0153-4</pub-id><pub-id pub-id-type="pmcid">PMC5493887</pub-id><pub-id pub-id-type="pmid">28666469</pub-id></element-citation></ref><ref id="b0565"><element-citation publication-type="journal" id="h0565"><person-group person-group-type="author"><name name-style="western"><surname>Kahle</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Meites</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sineath</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Nasrullah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bowles</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>DiNenno</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Sexually Transmitted Disease Testing and Uptake of Human Papillomavirus Vaccine in a Large Online Survey of US Men Who Have Sex With Men at Risk for HIV Infection</article-title><source>Sex. Transm. Dis.</source><volume>44</volume><issue>1</issue><year>2012</year><fpage>62</fpage><lpage>66</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/OLQ.0000000000000545</pub-id><pub-id pub-id-type="pmcid">PMC5283388</pub-id><pub-id pub-id-type="pmid">27898576</pub-id></element-citation></ref><ref id="b0570"><element-citation publication-type="journal" id="h0570"><person-group person-group-type="author"><name name-style="western"><surname>Korenromp</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Wi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Resch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stover</surname><given-names>J.</given-names></name><name name-style="western"><surname>Broutet</surname><given-names>N.</given-names></name></person-group><article-title>Costing of National STI Program implementation for the global STI control strategy for the health sector, 2016&#8211;2021</article-title><source>PloS One</source><volume>12</volume><issue>1</issue><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0170773</pub-id><pub-id pub-id-type="pmcid">PMC5271339</pub-id><pub-id pub-id-type="pmid">28129372</pub-id></element-citation></ref><ref id="b0575"><element-citation publication-type="journal" id="h0575"><person-group person-group-type="author"><name name-style="western"><surname>Low</surname><given-names>N.</given-names></name><name name-style="western"><surname>Broutet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>R.</given-names></name></person-group><article-title>A Collection on the prevention, diagnosis, and treatment of sexually transmitted infections: Call for research papers</article-title><source>PLoS Med.</source><volume>14</volume><issue>6</issue><year>2017</year><object-id pub-id-type="publisher-id">e1002333</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1002333</pub-id><pub-id pub-id-type="pmcid">PMC5486959</pub-id><pub-id pub-id-type="pmid">28654648</pub-id></element-citation></ref><ref id="b0580"><element-citation publication-type="journal" id="h0580"><person-group person-group-type="author"><name name-style="western"><surname>Kurosky</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Galindo</surname><given-names>C.M.</given-names></name></person-group><article-title>Effect of combination vaccines on Hepatitis B vaccine compliance in children in the United States</article-title><source>Pediatr. Infect. Dis. J.</source><volume>36</volume><issue>7</issue><year>2017</year><fpage>e189</fpage><lpage>e196</lpage><pub-id pub-id-type="pmid">28106622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/INF.0000000000001548</pub-id></element-citation></ref><ref id="b0585"><element-citation publication-type="journal" id="h0585"><person-group person-group-type="author"><name name-style="western"><surname>Van Damme</surname><given-names>P.</given-names></name></person-group><source>Hepatitis A Vaccines. Pediatr. Vaccines Vaccinat.</source><year>2017</year><fpage>99</fpage><lpage>108</lpage><comment>Springer, Cham</comment></element-citation></ref><ref id="b0590"><element-citation publication-type="journal" id="h0590"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>R.</given-names></name></person-group><article-title>Prevalent vaccination practices among Indian Allopathic non-pediatrician doctors for their own children: A proxy indicator of updated knowledge about childhood immunisation</article-title><source>Al. Ameen. J. Med. Sci.</source><volume>10</volume><issue>4</issue><year>2017</year><fpage>256</fpage><lpage>260</lpage></element-citation></ref><ref id="b0595"><element-citation publication-type="journal" id="h0595"><person-group person-group-type="author"><name name-style="western"><surname>Borch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolster</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gluud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gluud</surname><given-names>L.L.</given-names></name></person-group><article-title>Vaccines for preventing hepatitis B in healthcare workers (an updated protocol). <italic toggle="yes">The Cochrane</italic></article-title><source>Library.</source><year>2017</year></element-citation></ref><ref id="b0600"><element-citation publication-type="book" id="h0600"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>A.</given-names></name></person-group><part-title>A 2-Part Study Examining; Hepatitis B Vaccination Rates Among High-risk Adults and the Influence of Education on Knowledge and Awareness of Hepatitis B and the Use of Vaccines as a Safe, Preventative Measure Among University of MS Students</part-title><year>2017</year><publisher-name>University of Mississippi)</publisher-name><comment>Doctoral dissertation</comment></element-citation></ref><ref id="b0605"><element-citation publication-type="journal" id="h0605"><person-group person-group-type="author"><name name-style="western"><surname>Hasan</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Khaleque</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Shejuti</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Wasi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>S.</given-names></name></person-group><article-title>Prevalence of Hepatitis B Virus Seromarkers and Associated Risk Factors in Young Healthy Individuals in Bangladesh: Implications for Preventive Strategies</article-title><source>Hepatitis Monthly</source><volume>17</volume><issue>6</issue><year>2017</year></element-citation></ref><ref id="b0610"><element-citation publication-type="journal" id="h0610"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Deal</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Giersing</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rees</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bolan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps</article-title><source>Vaccine</source><volume>34</volume><issue>26</issue><year>2016</year><fpage>2939</fpage><lpage>2947</lpage><pub-id pub-id-type="pmid">27105564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.03.111</pub-id><pub-id pub-id-type="pmcid">PMC6759054</pub-id></element-citation></ref><ref id="b0615"><mixed-citation publication-type="other" id="h0615">Nahmias, A.J., Keyserlin, H., Lee, F.K. Herpes simplex viruses 1 and 2. In Viral infections of humans. Springer, Boston, MA. 1989 393-417.</mixed-citation></ref><ref id="b0620"><element-citation publication-type="journal" id="h0620"><person-group person-group-type="author"><name name-style="western"><surname>Looker</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Garnett</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>G.P.</given-names></name></person-group><article-title>An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection</article-title><source>Bull. World Health Organ.</source><volume>86</volume><issue>10</issue><year>2008</year><fpage>805</fpage><lpage>812A</lpage><pub-id pub-id-type="pmid">18949218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2471/BLT.07.046128</pub-id><pub-id pub-id-type="pmcid">PMC2649511</pub-id></element-citation></ref><ref id="b0625"><element-citation publication-type="journal" id="h0625"><person-group person-group-type="author"><name name-style="western"><surname>Stingley</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Simmen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sandri-Goldin</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Ghazal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.K.</given-names></name></person-group><article-title>Global analysis of herpes simplex virus type 1 transcription using an oligonucleotide-based DNA microarray</article-title><source>J. Virol.</source><volume>74</volume><issue>21</issue><year>2000</year><fpage>9916</fpage><lpage>9927</lpage><pub-id pub-id-type="pmid">11024119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.74.21.9916-9927.2000</pub-id><pub-id pub-id-type="pmcid">PMC102029</pub-id></element-citation></ref><ref id="b0630"><element-citation publication-type="journal" id="h0630"><person-group person-group-type="author"><name name-style="western"><surname>Moncada</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Holden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hook</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Gaydos</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Schachter</surname><given-names>J.</given-names></name></person-group><article-title>Stability studies on dry swabs and wet mailed swabs for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Aptima assays</article-title><source>J. Clin. Microbiol.</source><volume>55</volume><issue>3</issue><year>2017</year><fpage>971</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">28077695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JCM.02235-16</pub-id><pub-id pub-id-type="pmcid">PMC5328466</pub-id></element-citation></ref><ref id="b0635"><element-citation publication-type="journal" id="h0635"><person-group person-group-type="author"><name name-style="western"><surname>Smolak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nagelkerke</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kassebaum</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Chico</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Korenromp</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Abu-Raddad</surname><given-names>L.J.</given-names></name></person-group><article-title>Trends and predictors of syphilis prevalence in the general population: Global pooled analyses of 1103 prevalence measures including 136 million syphilis tests</article-title><source>Clin. Infect. Dis.</source><volume>66</volume><issue>8</issue><year>2017</year><fpage>1184</fpage><lpage>1191</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cix975</pub-id><pub-id pub-id-type="pmcid">PMC5888928</pub-id><pub-id pub-id-type="pmid">29136161</pub-id></element-citation></ref><ref id="b0640"><element-citation publication-type="book" id="h0640"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>May</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>B.</given-names></name></person-group><part-title>Infectious diseases of humans: dynamics and control</part-title><year>1992</year><publisher-name>Oxford University Press</publisher-name><publisher-loc>Oxford</publisher-loc></element-citation></ref><ref id="b0645"><element-citation publication-type="journal" id="h0645"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Fine</surname><given-names>P.E.</given-names></name></person-group><article-title>Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies</article-title><source>Int. J. Epidemiol.</source><volume>13</volume><issue>1</issue><year>1984</year><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">6698708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/13.1.87</pub-id></element-citation></ref><ref id="b0650"><element-citation publication-type="journal" id="h0650"><person-group person-group-type="author"><name name-style="western"><surname>Garnett</surname><given-names>G.P.</given-names></name></person-group><article-title>The geographical and temporal evolution of sexually transmitted disease epidemics</article-title><source>Sex. Transm. Infect.</source><volume>78</volume><issue>suppl 1</issue><year>2002</year><fpage>i14</fpage><lpage>i19</lpage><pub-id pub-id-type="pmid">12083434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/sti.78.suppl_1.i14</pub-id><pub-id pub-id-type="pmcid">PMC1765811</pub-id></element-citation></ref><ref id="b0655"><element-citation publication-type="journal" id="h0655"><person-group person-group-type="author"><name name-style="western"><surname>McLean</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Blower</surname><given-names>S.M.</given-names></name></person-group><article-title>Modelling HIV vaccination</article-title><source>Trends <italic toggle="yes">Microbiol.</italic></source><volume>3</volume><issue>12</issue><year>1995</year><fpage>458</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">8800836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0966-842x(00)89010-1</pub-id></element-citation></ref><ref id="b0660"><mixed-citation publication-type="other" id="h0660">Linares, L.O., Shankar, V., Diaz, A.; Nucci-Sack, A., Strickler H.D., Peake, K. The Association between Cumulative Psychosocial Risk and Cervical HPV Infection Among Female Adolescents in a Free Vaccination Program. J. Develop. Behavi. Pediatr. (JDBP), 36(8):620.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/DBP.0000000000000178</pub-id><pub-id pub-id-type="pmcid">PMC4868125</pub-id><pub-id pub-id-type="pmid">25985216</pub-id></mixed-citation></ref><ref id="b0665"><element-citation publication-type="journal" id="h0665"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>M.</given-names></name></person-group><article-title>The racial disparities in STI in the US: Concurrency, STI prevalence, and heterogeneity in partner selection</article-title><source>Epidemics</source><volume>11</volume><year>2015</year><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">25979282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.epidem.2015.02.003</pub-id><pub-id pub-id-type="pmcid">PMC4435828</pub-id></element-citation></ref><ref id="b0670"><element-citation publication-type="journal" id="h0670"><person-group person-group-type="author"><name name-style="western"><surname>Badawi</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Elkafrawy</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Yehia</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Attia</surname><given-names>D.A.</given-names></name></person-group><article-title>Clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrence</article-title><source>Drug Delivery</source><volume>28</volume><issue>1</issue><year>2021</year><fpage>814</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">33899634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10717544.2021.1912211</pub-id><pub-id pub-id-type="pmcid">PMC8086592</pub-id></element-citation></ref><ref id="b0675"><element-citation publication-type="journal" id="h0675"><person-group person-group-type="author"><name name-style="western"><surname>Garnett</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>F.J.</given-names></name></person-group><article-title>The epidemiology of bacterial sexually transmitted disease: the problems and opportunities of a cure</article-title><source>Sex. Transm. Dis.</source><volume>27</volume><year>2000</year><fpage>588</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">11099074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007435-200011000-00007</pub-id></element-citation></ref><ref id="b0680"><element-citation publication-type="journal" id="h0680"><person-group person-group-type="author"><name name-style="western"><surname>Garnett</surname><given-names>G.P.</given-names></name></person-group><article-title>Role of herd immunity in determining the effect of vaccines against sexually transmitted disease</article-title><source>J. infect. Diseases</source><volume>191</volume><issue>Supplement_1</issue><year>2005</year><comment>S97-106.68</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/425271</pub-id><pub-id pub-id-type="pmid">15627236</pub-id></element-citation></ref><ref id="b0685"><element-citation publication-type="journal" id="h0685"><person-group person-group-type="author"><name name-style="western"><surname>Tack</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Noon</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Strybos</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fedy</surname><given-names>B.C.</given-names></name></person-group><article-title>No substitute for survival: Perturbation analyses using a Golden Eagle population model reveal limits to managing for take</article-title><source>J. Raptor Res.</source><volume>51</volume><issue>3</issue><year>2017</year><fpage>258</fpage><lpage>272</lpage></element-citation></ref><ref id="b0690"><element-citation publication-type="journal" id="h0690"><person-group person-group-type="author"><name name-style="western"><surname>Brabin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Farzaneh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kitchener</surname><given-names>H.C.</given-names></name></person-group><article-title>Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes</article-title><source>Vaccine</source><volume>24</volume><issue>16</issue><year>2006</year><fpage>3087</fpage><lpage>3094</lpage><pub-id pub-id-type="pmid">16500736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2006.01.048</pub-id></element-citation></ref><ref id="b0695"><element-citation publication-type="journal" id="h0695"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Sonfield</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zolna</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Finer</surname><given-names>L.B.</given-names></name></person-group><article-title>Return on investment: a fuller assessment of the benefits and cost savings of the US publicly funded family planning program</article-title><source>The Milbank Quarterly</source><volume>92</volume><issue>4</issue><year>2014</year><fpage>696</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">25314928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1468-0009.12080</pub-id><pub-id pub-id-type="pmcid">PMC4266172</pub-id></element-citation></ref><ref id="b0700"><element-citation publication-type="journal" id="h0700"><person-group person-group-type="author"><name name-style="western"><surname>Dunkle</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Karita</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chomba</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kayitenkore</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vwalika</surname><given-names>C.</given-names></name><etal/></person-group><article-title>New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data</article-title><source>Lancet</source><volume>371</volume><issue>9631</issue><year>2008</year><fpage>2183</fpage><lpage>2191</lpage><pub-id pub-id-type="pmid">18586173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(08)60953-8</pub-id></element-citation></ref><ref id="b0705"><element-citation publication-type="journal" id="h0705"><person-group person-group-type="author"><name name-style="western"><surname>Low</surname><given-names>N.</given-names></name><name name-style="western"><surname>Broutet</surname><given-names>N.J.</given-names></name></person-group><article-title>Sexually transmitted infections-Research priorities for new challenges</article-title><source>PLoS Med.</source><volume>14</volume><issue>12</issue><year>2017</year><object-id pub-id-type="publisher-id">e1002481</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1002481</pub-id><pub-id pub-id-type="pmcid">PMC5744906</pub-id><pub-id pub-id-type="pmid">29281640</pub-id></element-citation></ref><ref id="b0710"><element-citation publication-type="journal" id="h0710"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Florez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>K.</given-names></name><name name-style="western"><surname>Horwitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>R.</given-names></name></person-group><article-title>Latino adolescent perspectives toward sexually transmitted infection educational programs</article-title><source>Int. J. Nur. Knowl.</source><volume>27</volume><issue>1</issue><year>2016</year><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/2047-3095.12074</pub-id><pub-id pub-id-type="pmid">25640090</pub-id></element-citation></ref><ref id="b0715"><element-citation publication-type="journal" id="h0715"><person-group person-group-type="author"><name name-style="western"><surname>Rhodes</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Alonzo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Song</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Arellano</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Small-group randomised controlled trial to increase condom use and HIV testing among Hispanic/Latino gay, bisexual, and other men who have sex with men</article-title><source>Am. J. Public Healt.</source><volume>107</volume><issue>6</issue><year>2017</year><fpage>969</fpage><lpage>976</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2105/AJPH.2017.303814</pub-id><pub-id pub-id-type="pmcid">PMC5425903</pub-id><pub-id pub-id-type="pmid">28426301</pub-id></element-citation></ref><ref id="b0720"><element-citation publication-type="journal" id="h0720"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Low</surname><given-names>N.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Bolan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kamb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Broutet</surname><given-names>N.</given-names></name></person-group><article-title>Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines</article-title><source>Vaccine</source><volume>32</volume><issue>14</issue><year>2014</year><fpage>1527</fpage><lpage>1535</lpage><pub-id pub-id-type="pmid">24581979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.07.087</pub-id><pub-id pub-id-type="pmcid">PMC6794147</pub-id></element-citation></ref><ref id="b0725"><element-citation publication-type="journal" id="h0725"><person-group person-group-type="author"><name name-style="western"><surname>Ganesan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mesner</surname><given-names>O.</given-names></name><name name-style="western"><surname>Okulicz</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>O&#8217;Bryan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deiss</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Lalani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Whitman</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Weintrob</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Macalino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Agan</surname><given-names>B.K.</given-names></name><etal/></person-group><article-title>A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis</article-title><source>Clin. Infect. Diseases</source><volume>60</volume><issue>4</issue><year>2014</year><fpage>653</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">25389249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciu888</pub-id><pub-id pub-id-type="pmcid">PMC6477935</pub-id></element-citation></ref><ref id="b0730"><element-citation publication-type="journal" id="h0730"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name></person-group><article-title>Comparison of doxycycline and benzathine penicillin G for the treatment of early syphilis</article-title><source>Acta dermatovenerologica Croatica.</source><volume>25</volume><issue>2</issue><year>2017</year><fpage>107</fpage><pub-id pub-id-type="pmid">28871924</pub-id></element-citation></ref><ref id="b0735"><element-citation publication-type="journal" id="h0735"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A multicenter study evaluating ceftriaxone and benzathine penicillin G as treatment agents for early syphilis in Jiangsu, China</article-title><source>Clin. Infect. Dis.</source><volume>65</volume><issue>10</issue><year>2017</year><fpage>1683</fpage><lpage>1688</lpage><pub-id pub-id-type="pmid">29020150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cix611</pub-id></element-citation></ref><ref id="b0740"><element-citation publication-type="journal" id="h0740"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.T.</given-names></name><etal/></person-group><article-title>Comparison of serological responses to single-dose azithromycin (2 g) versus benzathine penicillin G in the treatment of early syphilis in HIV-infected patients in an area of low prevalence of macrolide-resistant Treponema pallidum infection</article-title><source>J. Antimicrob. Chemother.</source><volume>71</volume><issue>3</issue><year>2015</year><fpage>775</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">26604241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkv379</pub-id></element-citation></ref><ref id="b0745"><element-citation publication-type="journal" id="h0745"><person-group person-group-type="author"><name name-style="western"><surname>Workowski</surname><given-names>K.A.</given-names></name></person-group><article-title>Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines</article-title><source>Clin. Infect. Dis.</source><volume>61</volume><issue>suppl8</issue><year>2015</year><fpage>S759</fpage><lpage>S762</lpage><pub-id pub-id-type="pmid">26602614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/civ771</pub-id></element-citation></ref><ref id="b0750"><element-citation publication-type="journal" id="h0750"><person-group person-group-type="author"><name name-style="western"><surname>Ghanem</surname><given-names>K.G.</given-names></name></person-group><article-title>Management of adult syphilis: key questions to inform the2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines</article-title><source>Clin. Infect. Dis.</source><volume>61</volume><issue>suppl_8</issue><year>2015</year><fpage>S818</fpage><lpage>S836</lpage><pub-id pub-id-type="pmid">26602620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/civ714</pub-id></element-citation></ref><ref id="b0755"><element-citation publication-type="journal" id="h0755"><person-group person-group-type="author"><name name-style="western"><surname>Manteuffel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Markowitz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ham</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Slezak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perrotta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>P.J.</given-names></name></person-group><article-title>Implementation of an Emergency Department Syphilis and HIV Point-of-Care Screening Process During an Outbreak of Syphilis in Detroit, MI in Collaboration With the Infectious Disease Department and the Centers for Disease Control and Prevention</article-title><source>Ann. Emergen. Medi.</source><volume>68</volume><issue>4</issue><year>2016</year><fpage>S148</fpage></element-citation></ref><ref id="b0760"><element-citation publication-type="journal" id="h0760"><person-group person-group-type="author"><name name-style="western"><surname>Arora</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schuenemann</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Jager</surname><given-names>G.</given-names></name><name name-style="western"><surname>Peltzer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Herbig</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Origin of modern syphilis and emergence of a pandemic Treponema pallidum cluster</article-title><source>Nature Microbiol.</source><volume>2</volume><issue>1</issue><year>2017</year><fpage>16245</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmicrobiol.2016.245</pub-id><pub-id pub-id-type="pmid">27918528</pub-id></element-citation></ref><ref id="b0765"><element-citation publication-type="journal" id="h0765"><person-group person-group-type="author"><name name-style="western"><surname>Beale</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Pitt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ruis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Balla</surname><given-names>E.</given-names></name><name name-style="western"><surname>Crucitti</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ewens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Naval</surname><given-names>C.</given-names></name><name name-style="western"><surname>Grankvist</surname><given-names>A.</given-names></name></person-group><article-title>Contemporary syphilis is characterised by rapid global spread of pandemic Treponema pallidum lineages</article-title><source>medRxiv.</source><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-021-01000-z</pub-id><pub-id pub-id-type="pmcid">PMC8612932</pub-id><pub-id pub-id-type="pmid">34819643</pub-id></element-citation></ref><ref id="b0770"><element-citation publication-type="journal" id="h0770"><person-group person-group-type="author"><name name-style="western"><surname>Stamm</surname><given-names>L.V.</given-names></name></person-group><article-title>Syphilis: antibiotic treatment and resistance</article-title><source>Epidemiol. Infect.</source><volume>143</volume><issue>8</issue><year>2015</year><fpage>1567</fpage><lpage>1574</lpage><pub-id pub-id-type="pmid">25358292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0950268814002830</pub-id><pub-id pub-id-type="pmcid">PMC9507240</pub-id></element-citation></ref><ref id="b0775"><element-citation publication-type="journal" id="h0775"><person-group person-group-type="author"><name name-style="western"><surname>Smajs</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pastekova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grillova</surname><given-names>L.</given-names></name></person-group><article-title>Macrolide resistance in the syphilis spirochete, Treponema pallidum ssp. pallidum: Can we also expect macrolide-resistant yaws strains?</article-title><source>Am. J. Tropic. Medi. Hygiene</source><volume>93</volume><issue>4</issue><year>2015</year><fpage>678</fpage><lpage>683</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.15-0316</pub-id><pub-id pub-id-type="pmcid">PMC4596581</pub-id><pub-id pub-id-type="pmid">26217043</pub-id></element-citation></ref><ref id="b0780"><element-citation publication-type="journal" id="h0780"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>Poor awareness of syphilis prevention and treatment knowledge among six different populations in south China</article-title><source>BMC Public Health</source><volume>16</volume><issue>1</issue><year>2016</year><fpage>287</fpage><pub-id pub-id-type="pmid">27020405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-016-2966-4</pub-id><pub-id pub-id-type="pmcid">PMC4810517</pub-id></element-citation></ref><ref id="b0785"><mixed-citation publication-type="other" id="h0785">Ellington, R.D., 2016 Sexual Health Education Policy: Influences on the Implementation of Sexual Health Education Programs (Doctoral dissertation, Walden University).</mixed-citation></ref><ref id="b0790"><mixed-citation publication-type="other" id="h0790">World Health Organization, 2017. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV and syphilis.</mixed-citation></ref><ref id="b0795"><element-citation publication-type="journal" id="h0795"><person-group person-group-type="author"><name name-style="western"><surname>Cameron</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Lukehart</surname><given-names>S.A.</given-names></name></person-group><article-title>Current status of syphilis vaccine development: need, challenges, prospects</article-title><source>Vaccine</source><volume>32</volume><issue>14</issue><year>2014</year><fpage>1602</fpage><lpage>1609</lpage><pub-id pub-id-type="pmid">24135571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.09.053</pub-id><pub-id pub-id-type="pmcid">PMC3951677</pub-id></element-citation></ref><ref id="b0800"><element-citation publication-type="journal" id="h0800"><person-group person-group-type="author"><name name-style="western"><surname>Lithgow</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>C.E.</given-names></name></person-group><article-title>Vaccine development for syphilis</article-title><source>Expert Rev. Vaccines</source><volume>16</volume><issue>1</issue><year>2017</year><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">27328030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14760584.2016.1203262</pub-id><pub-id pub-id-type="pmcid">PMC5513191</pub-id></element-citation></ref><ref id="b0805"><element-citation publication-type="journal" id="h0805"><person-group person-group-type="author"><name name-style="western"><surname>Champredon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Smieja</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dushoff</surname><given-names>J.</given-names></name></person-group><article-title>Epidemiological impact of a syphilis vaccine: a simulation study</article-title><source>Epidemiol. Infect.</source><volume>144</volume><issue>15</issue><year>2016</year><fpage>3244</fpage><lpage>3252</lpage><pub-id pub-id-type="pmid">27477823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0950268816001643</pub-id><pub-id pub-id-type="pmcid">PMC5080673</pub-id></element-citation></ref><ref id="b0810"><element-citation publication-type="journal" id="h0810"><person-group person-group-type="author"><name name-style="western"><surname>Garnett</surname><given-names>G.P.</given-names></name></person-group><article-title>The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease</article-title><source>Vaccine</source><volume>32</volume><issue>14</issue><year>2014</year><fpage>1536</fpage><lpage>1542</lpage><pub-id pub-id-type="pmid">24606635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.11.007</pub-id></element-citation></ref><ref id="b0815"><element-citation publication-type="journal" id="h0815"><person-group person-group-type="author"><name name-style="western"><surname>Peterman</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Furness</surname><given-names>B.W.</given-names></name></person-group><article-title>Public health interventions to control syphilis</article-title><source>Sex. Health</source><volume>12</volume><issue>2</issue><year>2015</year><fpage>126</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">25588031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1071/SH14156</pub-id><pub-id pub-id-type="pmcid">PMC6746170</pub-id></element-citation></ref><ref id="b0820"><element-citation publication-type="journal" id="h0820"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.Z.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.L.</given-names></name><etal/></person-group><article-title>Re-evaluating the sensitivity of the rabbit infectivity test for Treponema pallidum in modern era</article-title><source>Clin. Chimi. Acta.</source><volume>464</volume><year>2017</year><fpage>136</fpage><lpage>141</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2016.11.031</pub-id><pub-id pub-id-type="pmid">27876463</pub-id></element-citation></ref><ref id="b0825"><element-citation publication-type="journal" id="h0825"><person-group person-group-type="author"><name name-style="western"><surname>Zuckerman</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>K.N.</given-names></name></person-group><article-title>Paleoepidemiological and biocultural approaches to ancient disease: the origin and antiquity of syphilis</article-title><source>New Directions in Biocultural Anthropol.</source><year>2016</year></element-citation></ref><ref id="b0830"><element-citation publication-type="journal" id="h0830"><person-group person-group-type="author"><name name-style="western"><surname>Metzger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smogor</surname><given-names>W.</given-names></name></person-group><article-title>Artificial immunisation of rabbits against syphilis. I. Effect of increasing doses of treponemes given by the intramuscular route</article-title><source>British J. Vener. Dis.</source><volume>45</volume><issue>4</issue><year>1969</year><fpage>308</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/sti.45.4.308</pub-id><pub-id pub-id-type="pmcid">PMC1047999</pub-id><pub-id pub-id-type="pmid">4902287</pub-id></element-citation></ref><ref id="b0835"><element-citation publication-type="journal" id="h0835"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>J.N.</given-names></name></person-group><article-title>Immunity in Experimental Syphilis: VI. Successful Vaccination of Rabbits with Treponema Pallidum, Nichols Strain, Attenuated by &#947;-Irradiation</article-title><source>J. Immunol.</source><volume>110</volume><issue>5</issue><year>1973</year><fpage>1206</fpage><lpage>1215</lpage><pub-id pub-id-type="pmid">4572631</pub-id></element-citation></ref><ref id="b0840"><element-citation publication-type="journal" id="h0840"><person-group person-group-type="author"><name name-style="western"><surname>Hoffman</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Luke</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>I.</given-names></name><name name-style="western"><surname>Le</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Doolan</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Protection of humans against malaria by immunisation with radiation-attenuated Plasmodium falciparum sporozoites</article-title><source>J. Infect. Dis.</source><volume>185</volume><issue>8</issue><year>2002</year><fpage>1155</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">11930326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/339409</pub-id></element-citation></ref><ref id="b0845"><element-citation publication-type="journal" id="h0845"><person-group person-group-type="author"><name name-style="western"><surname>Fukuda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Oharaseki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>H.</given-names></name></person-group><article-title>Multiple primary syphilis on the lip, nipple&#8211;areola and penis: An immunohistochemical examination of Treponema pallidum localisation using an anti-T. pallidum antibody</article-title><source>J. Dermatol.</source><volume>42</volume><issue>5</issue><year>2015</year><fpage>515</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">25708895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1346-8138.12818</pub-id></element-citation></ref><ref id="b0850"><element-citation publication-type="journal" id="h0850"><person-group person-group-type="author"><name name-style="western"><surname>Dodet</surname><given-names>B.</given-names></name></person-group><article-title>Current barriers, challenges and opportunities for the development of effective STI vaccines: Point of view of vaccine producers, biotech companies and funding agencies</article-title><source>Vaccine</source><volume>32</volume><issue>14</issue><year>2014</year><fpage>1624</fpage><lpage>1629</lpage><pub-id pub-id-type="pmid">23994377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.08.032</pub-id></element-citation></ref><ref id="b0855"><mixed-citation publication-type="other" id="h0855">Kotloff, K.L., Platts-Mills, J.A., Nasrin, D., Roose, A., Blackwelder, W.C. and Levine, M.M. Global burden of diarrheal diseases among children in developing countries: Incidence, etiology, and insights from new molecular diagnostic techniques. Vaccine, 35(49):6783-9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.07.036</pub-id><pub-id pub-id-type="pmid">28765005</pub-id></mixed-citation></ref><ref id="b0860"><element-citation publication-type="journal" id="h0860"><person-group person-group-type="author"><name name-style="western"><surname>Petrich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loddenkemper</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giacani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Fluorescence in situ hybridisation for the identification of Treponema pallidum in tissue sections</article-title><source>Int. J. Medi. Microbiol.</source><volume>305</volume><issue>7</issue><year>2015</year><fpage>709</fpage><lpage>718</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijmm.2015.08.022</pub-id><pub-id pub-id-type="pmid">26365167</pub-id></element-citation></ref><ref id="b0865"><element-citation publication-type="journal" id="h0865"><person-group person-group-type="author"><name name-style="western"><surname>Sood</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Workowski</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Lockwood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>S.</given-names></name></person-group><article-title>Combined Intravitreal and Systemic Antibiotic Therapy in a Patient with Syphilitic Uveitis</article-title><source>Ocular Immunol. Inflammat.</source><volume>22</volume><year>2017</year><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09273948.2017.1385817</pub-id><pub-id pub-id-type="pmid">29053397</pub-id></element-citation></ref><ref id="b0870"><element-citation publication-type="journal" id="h0870"><person-group person-group-type="author"><name name-style="western"><surname>Kersh</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Lukehart</surname><given-names>S.A.</given-names></name></person-group><article-title>Biomedical Research Priorities for Modern Syphilis Clinical Management, Diagnosis, and Vaccines: Overview and Commentary for Unit 1</article-title><source>Sex. Transm. Dis.</source><year>2018</year><pub-id pub-id-type="doi">10.1097/OLQ.0000000000000830</pub-id><pub-id pub-id-type="pmcid">PMC6089653</pub-id><pub-id pub-id-type="pmid">29528993</pub-id></element-citation></ref><ref id="b0875"><element-citation publication-type="journal" id="h0875"><person-group person-group-type="author"><name name-style="western"><surname>Ambrose</surname><given-names>C.T.</given-names></name></person-group><article-title>Vaccines and the looming threat of syphilis</article-title><source>Glob. Vaccines <italic toggle="yes">Immunol.</italic></source><volume>1</volume><issue>1</issue><year>2016</year><fpage>8</fpage></element-citation></ref><ref id="b0880"><element-citation publication-type="journal" id="h0880"><person-group person-group-type="author"><name name-style="western"><surname>Lithgow</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Hof</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wetherell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>D.</given-names></name><name name-style="western"><surname>Houston</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>C.E.</given-names></name></person-group><article-title>A defined syphilis vaccine candidate inhibits dissemination of Treponema pallidum subspecies pallidum. <italic toggle="yes">Nature</italic></article-title><source>Communications</source><year>2017</year><fpage>8:14273</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms14273</pub-id><pub-id pub-id-type="pmcid">PMC5296639</pub-id><pub-id pub-id-type="pmid">28145405</pub-id></element-citation></ref><ref id="b0885"><element-citation publication-type="journal" id="h0885"><person-group person-group-type="author"><name name-style="western"><surname>Jerse</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Bash</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>M.V.</given-names></name></person-group><article-title>Vaccines against Gonorrhea: current status and future challenges</article-title><source>Vaccine</source><volume>32</volume><issue>14</issue><year>2014</year><fpage>1579</fpage><lpage>1587</lpage><pub-id pub-id-type="pmid">24016806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.08.067</pub-id><pub-id pub-id-type="pmcid">PMC4682887</pub-id></element-citation></ref><ref id="b0890"><element-citation publication-type="journal" id="h0890"><person-group person-group-type="author"><name name-style="western"><surname>Zielke</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Wierzbicki</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Baarda</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Gafken</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Soge</surname><given-names>O.O.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>K.K.</given-names></name></person-group><article-title>Proteomics-driven antigen discovery for development of vaccines against Gonorrhea</article-title><source>Mol. Cell. Proteom.</source><volume>15</volume><issue>7</issue><year>2016</year><fpage>2338</fpage><lpage>2355</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/mcp.M116.058800</pub-id><pub-id pub-id-type="pmcid">PMC4937508</pub-id><pub-id pub-id-type="pmid">27141096</pub-id></element-citation></ref><ref id="b0895"><element-citation publication-type="journal" id="h0895"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>M.W.</given-names></name></person-group><article-title>Could vaccination against Neisseria gonorrhoeae be on the horizon?</article-title><source>Future Microbiol.</source><volume>13</volume><issue>5</issue><year>2018</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fmb-2017-0262</pub-id><pub-id pub-id-type="pmid">29517283</pub-id></element-citation></ref><ref id="b0900"><element-citation publication-type="journal" id="h0900"><person-group person-group-type="author"><name name-style="western"><surname>Wetzler</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Feavers</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Gray-Owen</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Jerse</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Deal</surname><given-names>C.D.</given-names></name></person-group><article-title>Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop &#8220;Gonorrhea Vaccines: the Way Forward&#8221;</article-title><source>Clin. Vaccine Immunol.</source><volume>23</volume><issue>8</issue><year>2016</year><fpage>656</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">27335384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CVI.00230-16</pub-id><pub-id pub-id-type="pmcid">PMC4979170</pub-id></element-citation></ref><ref id="b0905"><mixed-citation publication-type="other" id="h0905">Dubensky, T.W.; N.A. Hosken; S.H. Robbins and M.D. Moore. Inventors; IMMUNE DESIGN CORP, assignee. <italic toggle="yes">Vaccines for HSV-2. United States patent</italic> 2018 US 9,895,435.20.</mixed-citation></ref><ref id="b0910"><mixed-citation publication-type="other" id="h0910">Dubensky, Jr.,T.W., Hosken, N.A., Robbins, S.H., Moore, M.D. Inventors; IMMUNE DESIGN CORP, assignee. <italic toggle="yes">Vaccines for HSV-2</italic>. <italic toggle="yes">United States patent 2017</italic> US 9,555,099.31.</mixed-citation></ref><ref id="b0915"><element-citation publication-type="journal" id="h0915"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Wald</surname><given-names>A.</given-names></name></person-group><article-title>Status of vaccine research and development of vaccines for herpes simplex virus</article-title><source>Vaccine</source><volume>34</volume><issue>26</issue><year>2016</year><fpage>2948</fpage><lpage>2952</lpage><pub-id pub-id-type="pmid">26973067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.12.076</pub-id></element-citation></ref><ref id="b0920"><mixed-citation publication-type="other" id="h0920">Long, D., Flechtner, J., Skoberne, M. Siber, G.R. Inventors; Genocea Biosciences Inc, assignee. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response. United States patent US 9,895,436.</mixed-citation></ref><ref id="b0925"><element-citation publication-type="journal" id="h0925"><person-group person-group-type="author"><name name-style="western"><surname>Hensel</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Dorwart</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Heeke</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tummala</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Prophylactic herpes simplex virus 2 (HSV-2) vaccines adjuvanted with stable emulsion and toll-like receptor 9 agonist induce a robust HSV-2-specific cell-mediated immune response, protect against symptomatic disease, and reduce the latent viral reservoir</article-title><source>J. Virol.</source><volume>91</volume><issue>9</issue><year>2017</year><fpage>e02257</fpage><lpage>e2316</lpage><pub-id pub-id-type="pmid">28228587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02257-16</pub-id><pub-id pub-id-type="pmcid">PMC5391472</pub-id></element-citation></ref><ref id="b0930"><element-citation publication-type="journal" id="h0930"><person-group person-group-type="author"><name name-style="western"><surname>Dooling</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>K.</given-names></name><name name-style="western"><surname>Belongia</surname><given-names>E.A.</given-names></name><etal/></person-group><article-title>Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines</article-title><source>Am. J. Transplant.</source><volume>18</volume><issue>3</issue><year>2018</year><fpage>756</fpage><lpage>762</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6703a5</pub-id><pub-id pub-id-type="pmcid">PMC5812314</pub-id><pub-id pub-id-type="pmid">29370152</pub-id></element-citation></ref><ref id="b0935"><mixed-citation publication-type="other" id="h0935">Brekke, O.H., Fredriksen, A.B., Areffard, A., Lindeberg, M.M., 2018. Inventors; Vaccibody As, assignee. Vaccines against hpv. United States patent US 9,901,635.27.</mixed-citation></ref><ref id="b0940"><mixed-citation publication-type="other" id="h0940">Di Mario, S., Basevi, V., Lopalco, P.L., Balduzzi, S., D&#8217;Amico, R. and Magrini, N., 2015. Are the two human papillomavirus vaccines really similar? A systematic review of available evidence: efficacy of the two vaccines against HPV. J. Immunol. Res., Article ID 435141:13.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/435141</pub-id><pub-id pub-id-type="pmcid">PMC4562171</pub-id><pub-id pub-id-type="pmid">26380321</pub-id></mixed-citation></ref><ref id="b0945"><element-citation publication-type="journal" id="h0945"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Brotherton</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>A.A.</given-names></name></person-group><article-title>Hepatitis B Vaccines and HPV Vaccines Have Been Hailed as Major Public Health Achievements in Preventing Cancer&#8212;Could a Schistosomiasis Vaccine be the Third? PLoS Negl</article-title><source>Tropic. Dis.</source><volume>9</volume><issue>5</issue><year>2015</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0003598</pub-id><pub-id pub-id-type="pmcid">PMC4447425</pub-id><pub-id pub-id-type="pmid">26020953</pub-id></element-citation></ref><ref id="b0950"><element-citation publication-type="journal" id="h0950"><person-group person-group-type="author"><name name-style="western"><surname>Schiller</surname><given-names>J.T.</given-names></name></person-group><article-title>The potential benefits of HPV vaccination in previously infected women</article-title><source>EBioMedicine</source><volume>10</volume><year>2016</year><fpage>5</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">27515688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2016.08.005</pub-id><pub-id pub-id-type="pmcid">PMC5006803</pub-id></element-citation></ref><ref id="b0955"><mixed-citation publication-type="other" id="h0955">Agarwal, M., Trimble, C. Cancer Vaccines for HPV Malignancies. InOncoimmunology, 2018, pp. 263-274. Springer, Cham.</mixed-citation></ref><ref id="b0960"><mixed-citation publication-type="other" id="h0960">Oh, S., Zurawski, S., Zurawski, G. Inventors; Baylor Research Institute, assignee. Novel vaccines against hpv and hpv-related diseases. United States patent application US 15/111,357.</mixed-citation></ref><ref id="b0965"><mixed-citation publication-type="other" id="h0965">Best, S.R, S.I. Pa. The Role of Vaccines for HPV-Related Head and Neck Cancers. InHPV and Head and Neck Cancers, Springer, New Delhi, 2015 99-110.</mixed-citation></ref><ref id="b0970"><element-citation publication-type="journal" id="h0970"><person-group person-group-type="author"><name name-style="western"><surname>Lister</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tabrizi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Medland</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Garland</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fairley</surname><given-names>C.K.</given-names></name></person-group><article-title>Screening for Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men at male-only saunas</article-title><source>Sex. Transm. Dis.</source><volume>30</volume><issue>12</issue><year>2003</year><fpage>886</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">14646635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.OLQ.0000099160.26205.22</pub-id></element-citation></ref><ref id="b0975"><element-citation publication-type="journal" id="h0975"><person-group person-group-type="author"><name name-style="western"><surname>Rice</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Shafer</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Ram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jerse</surname><given-names>A.E.</given-names></name></person-group><article-title>Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development</article-title><source>Ann. Rev. Microbiol.</source><volume>71</volume><year>2017</year><fpage>665</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">28886683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-micro-090816-093530</pub-id></element-citation></ref><ref id="b0980"><element-citation publication-type="journal" id="h0980"><person-group person-group-type="author"><name name-style="western"><surname>Golden</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Whittington</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Handsfield</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Stamm</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Hogben</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Effect of expedited treatment of sex partners on recurrent or persistent Gonorrhea or chlamydial infection</article-title><source>New Eng. J. Medi.</source><volume>352</volume><issue>7</issue><year>2005</year><fpage>676</fpage><lpage>685</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa041681</pub-id><pub-id pub-id-type="pmid">15716561</pub-id></element-citation></ref><ref id="b0985"><element-citation publication-type="journal" id="h0985"><person-group person-group-type="author"><name name-style="western"><surname>Kent</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Chaw</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liska</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Prevalence of rectal, urethral, and pharyngeal chlamydia and Gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003</article-title><source>Clin. Infect. Dis.</source><volume>41</volume><issue>1</issue><year>2005</year><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">15937765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/430704</pub-id></element-citation></ref><ref id="b0990"><element-citation publication-type="journal" id="h0990"><person-group person-group-type="author"><name name-style="western"><surname>Fingerhuth</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Bonhoeffer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Low</surname><given-names>N.</given-names></name><name name-style="western"><surname>Althaus</surname><given-names>C.L.</given-names></name></person-group><article-title>Antibiotic-resistant Neisseria gonorrhoeae spread faster with more treatment, not more sexual partners</article-title><source>PLoS Pathogens</source><volume>12</volume><issue>5</issue><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1005611</pub-id><pub-id pub-id-type="pmcid">PMC4872991</pub-id><pub-id pub-id-type="pmid">27196299</pub-id></element-citation></ref><ref id="b0995"><element-citation publication-type="journal" id="h0995"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Chesson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kirkcaldy</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Marcus</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Gift</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Aral</surname><given-names>S.O.</given-names></name></person-group><article-title>Limited Empirical Data on Oropharyngeal Neisseria gonorrhoeae Among Men Who Have Sex With Men and Implications for Modeling</article-title><source>Sex. Transm. Dis.</source><volume>44</volume><issue>10</issue><year>2017</year><fpage>596</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">28910265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/OLQ.0000000000000709</pub-id><pub-id pub-id-type="pmcid">PMC5967843</pub-id></element-citation></ref><ref id="b1000"><element-citation publication-type="journal" id="h1000"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>T.Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Read</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Needleman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bradshaw</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Fortune</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Sampling technique and detection rates of oropharyngeal and anorectal gonorrhoea using nucleic acid amplification tests in men who have sex with men</article-title><source>Sex. Transm. Infect. Sextrans</source><year>2017</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/sextrans-2017-053339</pub-id><pub-id pub-id-type="pmid">29133523</pub-id></element-citation></ref><ref id="b1005"><element-citation publication-type="journal" id="h1005"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Regan</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Gambhir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cornelisse</surname><given-names>V.</given-names></name><name name-style="western"><surname>Grulich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Neisseria gonorrhoeae transmission among men who have sex with men: an anatomical site-specific mathematical model evaluating the potential preventive impact of mouthwash</article-title><source>Sex. Transm. Dis.</source><volume>44</volume><issue>10</issue><year>2017</year><fpage>586</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">28876289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/OLQ.0000000000000661</pub-id></element-citation></ref><ref id="b1010"><mixed-citation publication-type="other" id="h1010">Zhang, L., Regan, D.G., Chow, E.P., Gambhir, M., Cornelisse, V., Grulich, A., et al., 2017. O14. 4 Oropharyngeal transmission of neisseria gonorrhoeae among men who have sex with men and potential impacts of mouthwash A32-A33.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/OLQ.0000000000000661</pub-id><pub-id pub-id-type="pmid">28876289</pub-id></mixed-citation></ref><ref id="b1015"><element-citation publication-type="journal" id="h1015"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>D.A.</given-names></name></person-group><article-title>Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains?</article-title><source>Sex. Transm. Infect.</source><volume>91</volume><issue>4</issue><year>2015</year><fpage>234</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">25911525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/sextrans-2014-051731</pub-id></element-citation></ref><ref id="b1020"><element-citation publication-type="journal" id="h1020"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Tabrizi</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bradshaw</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.Y.</given-names></name><etal/></person-group><article-title>Neisseria gonorrhoeae bacterial DNA load in the pharynges and saliva of men who have sex with men</article-title><source>J. Clin. Microbiol.</source><volume>54</volume><issue>10</issue><year>2016</year><fpage>2485</fpage><lpage>2490</lpage><pub-id pub-id-type="pmid">27413195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JCM.01186-16</pub-id><pub-id pub-id-type="pmcid">PMC5035428</pub-id></element-citation></ref><ref id="b1025"><element-citation publication-type="journal" id="h1025"><person-group person-group-type="author"><name name-style="western"><surname>Nakashima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shigehara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wakatsuki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kobori</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Prevalence of human papillomavirus infection in the oropharynx and urine among sexually active men: a comparative study of infection by papillomavirus and other organisms, including Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma spp., and Ureaplasma spp</article-title><source>BMC Infect. Dis.</source><volume>14</volume><issue>1</issue><year>2014</year><fpage>43</fpage><pub-id pub-id-type="pmid">24468054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2334-14-43</pub-id><pub-id pub-id-type="pmcid">PMC3907364</pub-id></element-citation></ref><ref id="b1030"><element-citation publication-type="journal" id="h1030"><person-group person-group-type="author"><name name-style="western"><surname>Kreisel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weston</surname><given-names>E.</given-names></name><name name-style="western"><surname>Braxton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Llata</surname><given-names>E.</given-names></name><name name-style="western"><surname>Torrone</surname><given-names>E.</given-names></name></person-group><article-title>Keeping an Eye on Chlamydia and Gonorrhea Conjunctivitis in Infants in the United States, 2010&#8211;2015</article-title><source>Sex. Transm. Dis.</source><volume>44</volume><issue>6</issue><year>2017</year><fpage>356</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">28499285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/OLQ.0000000000000613</pub-id><pub-id pub-id-type="pmcid">PMC5527667</pub-id></element-citation></ref><ref id="b1035"><element-citation publication-type="journal" id="h1035"><person-group person-group-type="author"><name name-style="western"><surname>De Silva</surname><given-names>D.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Whole-genome sequencing to determine transmission of Neisseria gonorrhoeae: an observational study</article-title><source>Lancet Infect. Diseases</source><volume>16</volume><issue>11</issue><year>2016</year><fpage>1295</fpage><lpage>1303</lpage><pub-id pub-id-type="pmid">27427203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(16)30157-8</pub-id><pub-id pub-id-type="pmcid">PMC5086424</pub-id></element-citation></ref><ref id="b1040"><element-citation publication-type="journal" id="h1040"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>N.</given-names></name><name name-style="western"><surname>McKenney</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schillinger</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blank</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>M.E.</given-names></name></person-group><article-title>Predictors of Chlamydia trachomatis and Neisseria gonorrhea screening acceptance in a New York City school-based STD program</article-title><source>Sex. Transm. Dis.</source><volume>43</volume><year>2016</year></element-citation></ref><ref id="b1045"><element-citation publication-type="journal" id="h1045"><person-group person-group-type="author"><name name-style="western"><surname>Huneeus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>M.I.</given-names></name></person-group><article-title>Prevalence of Chlamydia Trachomatis, Neisseria Gonorrhoeae, and Trichomonas Vaginalis Infection in Chilean Adolescents and Young Adults</article-title><source>J. Pediat. Adol. Gynecol.</source><volume>S1083&#8211;3188</volume><issue>18</issue><year>2018</year><fpage>30011</fpage><lpage>30021</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpag.2018.01.003</pub-id><pub-id pub-id-type="pmid">29409759</pub-id></element-citation></ref><ref id="b1050"><element-citation publication-type="journal" id="h1050"><person-group person-group-type="author"><name name-style="western"><surname>Eldredge</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Markham</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ruiter</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Kok</surname><given-names>G.</given-names></name><name name-style="western"><surname>Parcel</surname><given-names>G.S.</given-names></name></person-group><article-title>Planning health promotion programs: an intervention mapping approach</article-title><source>John Wiley &amp; Sons.</source><year>2016</year></element-citation></ref><ref id="b1055"><element-citation publication-type="journal" id="h1055"><person-group person-group-type="author"><name name-style="western"><surname>Pelligrino</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zaitzow</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Sothern</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scribner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Phillippi</surname><given-names>S.</given-names></name></person-group><article-title>Incarcerated black women in the Southern USA: a narrative review of STI and HIV risk and implications for future public health research, practice, and policy</article-title><source>J. Racial Ethn. Health. Disparities</source><volume>4</volume><issue>1</issue><year>2017</year><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">26823063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40615-015-0194-8</pub-id></element-citation></ref><ref id="b1060"><element-citation publication-type="journal" id="h1060"><person-group person-group-type="author"><name name-style="western"><surname>Yeung</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aggleton</surname><given-names>P.</given-names></name><name name-style="western"><surname>Richters</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grulich</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Visser</surname><given-names>R.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rissel</surname><given-names>C.</given-names></name></person-group><article-title>Sex education: findings from the Second Australian Study of Health and Relationships</article-title><source>Sex. Health.</source><volume>14</volume><issue>3</issue><year>2017</year><fpage>293</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">28259201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1071/SH16215</pub-id></element-citation></ref><ref id="b1065"><element-citation publication-type="journal" id="h1065"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Karczmarczyk</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Douress</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>M.M.</given-names></name></person-group><article-title>Sex Education Policy: Need for a Standard Definition of Medically Accurate Information</article-title><source>Pedagogy Health Promot.</source><volume>3</volume><issue>4</issue><year>2017</year><fpage>221</fpage><lpage>227</lpage></element-citation></ref><ref id="b1070"><element-citation publication-type="journal" id="h1070"><person-group person-group-type="author"><name name-style="western"><surname>Lama</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kayastha</surname><given-names>B.M.</given-names></name></person-group><article-title>Gonococcal culture and drug sensitivity pattern in patients with urethral discharge and vaginal discharge with cervicitis</article-title><source>Post-Graduate Medical J. NAMS.</source><volume>13</volume><issue>2</issue><year>2017</year></element-citation></ref><ref id="b1075"><element-citation publication-type="journal" id="h1075"><person-group person-group-type="author"><name name-style="western"><surname>Gorgos</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Sycuro</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fiedler</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Balkus</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Relationship of specific bacteria in the cervical and vaginal microbiotas with cervicitis</article-title><source>Sex. Transm. Diseases</source><year>2017</year><fpage>42(9):475</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/OLQ.0000000000000318</pub-id><pub-id pub-id-type="pmcid">PMC4590771</pub-id><pub-id pub-id-type="pmid">26267872</pub-id></element-citation></ref><ref id="b1080"><element-citation publication-type="journal" id="h1080"><person-group person-group-type="author"><name name-style="western"><surname>Igietseme</surname><given-names>J.U.</given-names></name><name name-style="western"><surname>Omosun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Black</surname><given-names>C.M.</given-names></name></person-group><article-title>Bacterial Sexually Transmitted Infections (STIs): A Clinical Overview** Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention</article-title><source>Mol. Med. Microbiol. (Second Edition)</source><volume>1403&#8211;1420</volume><year>2015</year></element-citation></ref><ref id="b1085"><element-citation publication-type="journal" id="h1085"><person-group person-group-type="author"><name name-style="western"><surname>Bautista</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Wurapa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sateren</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hollingsworth</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>J.L.</given-names></name></person-group><article-title>Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections</article-title><source>Milit. Medi. Res.</source><volume>3</volume><issue>1</issue><year>2016</year><fpage>4</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40779-016-0074-5</pub-id><pub-id pub-id-type="pmcid">PMC4752809</pub-id><pub-id pub-id-type="pmid">26877884</pub-id></element-citation></ref><ref id="b1090"><element-citation publication-type="journal" id="h1090"><person-group person-group-type="author"><name name-style="western"><surname>Horner</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Blee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Falk</surname><given-names>L.</given-names></name><name name-style="western"><surname>van der Meijden</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moi</surname><given-names>H.</given-names></name></person-group><article-title>European guideline on the management of non-gonococcal urethritis</article-title><source>Int. J. STD AIDS</source><volume>27</volume><issue>11</issue><year>2016</year><fpage>928</fpage><lpage>937</lpage><pub-id pub-id-type="pmid">27147267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0956462416648585</pub-id></element-citation></ref><ref id="b1095"><element-citation publication-type="journal" id="h1095"><person-group person-group-type="author"><name name-style="western"><surname>Priest</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Tabrizi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bissessor</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Neisseria gonorrhoeae DNA bacterial load in men with symptomatic and asymptomatic gonococcal urethritis</article-title><source>Sex. Transm. Infect.</source><volume>93</volume><issue>7</issue><year>2017</year><fpage>478</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">28148678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/sextrans-2016-052950</pub-id></element-citation></ref><ref id="b1100"><element-citation publication-type="journal" id="h1100"><person-group person-group-type="author"><name name-style="western"><surname>Bachmann</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Manhart</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Sena</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Dimitrakoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Advances in the understanding and treatment of male urethritis</article-title><source>Clin. Infect. Diseases</source><volume>61</volume><issue>8</issue><year>2015</year><fpage>S763</fpage><lpage>S769</lpage><pub-id pub-id-type="pmid">26602615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/civ755</pub-id></element-citation></ref><ref id="b1105"><element-citation publication-type="journal" id="h1105"><person-group person-group-type="author"><name name-style="western"><surname>Dudhipala</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Kishore</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Godha</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Ananthula</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Pinjala</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A study of co-infection with neisseria gonorrhoeae and chlamydia trachomatis in male urethritis</article-title><source>J Evol Medi Dent Sci.</source><volume>6</volume><issue>49</issue><year>2017</year><fpage>3746</fpage><lpage>3751</lpage></element-citation></ref><ref id="b1110"><element-citation publication-type="journal" id="h1110"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>De Petra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pelatosis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Howden</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Should asymptomatic men who have sex with men be screened for oropharyngeal chlamydia? Clinical outcomes from a cross-sectional study</article-title><source>Sex. Transm. Dis.</source><volume>45</volume><issue>2</issue><year>2018</year><fpage>103</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">29329179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/OLQ.0000000000000718</pub-id></element-citation></ref><ref id="b1115"><element-citation publication-type="journal" id="h1115"><person-group person-group-type="author"><name name-style="western"><surname>Pattanasin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dunne</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Wasinrapee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tongtoyai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chonwattana</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sriporn</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Screening for Chlamydia trachomatis and Neisseria gonorrhoeae infection among asymptomatic men who have sex with men in Bangkok, Thailand</article-title><source>Int. J. STD &amp; AIDS</source><year>2017</year><comment>0956462417744904</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0956462417744904</pub-id><pub-id pub-id-type="pmcid">PMC6409203</pub-id><pub-id pub-id-type="pmid">29198179</pub-id></element-citation></ref><ref id="b1120"><element-citation publication-type="journal" id="h1120"><person-group person-group-type="author"><name name-style="western"><surname>Handsfield</surname><given-names>H.H.</given-names></name></person-group><article-title>Treatment of Gonorrhea</article-title><source>JAMA</source><volume>220</volume><issue>3</issue><year>1972</year><fpage>419</fpage><lpage>420</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.1972.03200030077032</pub-id><pub-id pub-id-type="pmid">5067118</pub-id></element-citation></ref><ref id="b1125"><element-citation publication-type="journal" id="h1125"><person-group person-group-type="author"><name name-style="western"><surname>Fein</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Sellinger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>M.J.</given-names></name></person-group><article-title>Acute Salpingitis in a Nonsexually Active Adolescent</article-title><source>Pediat. Emergen. Care</source><volume>31</volume><issue>12</issue><year>2015</year><fpage>853</fpage><lpage>855</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PEC.0000000000000631</pub-id><pub-id pub-id-type="pmid">26626893</pub-id></element-citation></ref><ref id="b1130"><element-citation publication-type="journal" id="h1130"><person-group person-group-type="author"><name name-style="western"><surname>Briceag</surname><given-names>I.</given-names></name><name name-style="western"><surname>Costache</surname><given-names>A.</given-names></name><name name-style="western"><surname>Purcarea</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Cergan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dumitru</surname><given-names>M.</given-names></name><name name-style="western"><surname>Briceag</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Fallopian tubes&#8211;literature review of anatomy and etiology in female infertility</article-title><source>J. Medi Life</source><volume>8</volume><issue>2</issue><year>2015</year><fpage>129</fpage><pub-id pub-id-type="pmcid">PMC4392087</pub-id><pub-id pub-id-type="pmid">25866566</pub-id></element-citation></ref><ref id="b1135"><element-citation publication-type="journal" id="h1135"><person-group person-group-type="author"><name name-style="western"><surname>Balashov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mordechai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Adelson</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gyga</surname><given-names>S.E.</given-names></name></person-group><article-title>Inventors; Medical Diagnostic Laboratories LLC, assignee. Antibiotic resistance profile for Neisseria gonorrhoeae and use of same in diagnosis and treatment of Gonorrhea</article-title><source>United States patent US</source><volume>9</volume><issue>297</issue><year>2016</year><fpage>048</fpage></element-citation></ref><ref id="b1140"><element-citation publication-type="journal" id="h1140"><person-group person-group-type="author"><name name-style="western"><surname>Tuite</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Gift</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Chesson</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Salomon</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Grad</surname><given-names>Y.H.</given-names></name></person-group><article-title>Impact of rapid susceptibility testing and antibiotic selection strategy on the emergence and spread of antibiotic resistance in Gonorrhea</article-title><source>J. Infect. Dis.</source><volume>216</volume><issue>9</issue><year>2017</year><fpage>1141</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">28968710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jix450</pub-id><pub-id pub-id-type="pmcid">PMC5853443</pub-id></element-citation></ref><ref id="b1145"><element-citation publication-type="journal" id="h1145"><person-group person-group-type="author"><name name-style="western"><surname>Regnath</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mertes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ignatius</surname><given-names>R.</given-names></name></person-group><article-title>Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, 2004 to 2015: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation cephalosporins</article-title><source>Eurosurveillance</source><volume>21</volume><issue>36</issue><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2016.21.36.30335</pub-id><pub-id pub-id-type="pmcid">PMC5048714</pub-id><pub-id pub-id-type="pmid">27632642</pub-id></element-citation></ref><ref id="b1150"><mixed-citation publication-type="other" id="h1150">Rodriguez, C.A. Geographical Incidence of Antimicrobial Resistant Gonorrhea. Winter 12-16-2016.</mixed-citation></ref><ref id="b1155"><element-citation publication-type="journal" id="h1155"><person-group person-group-type="author"><name name-style="western"><surname>Washington</surname><given-names>A.E.</given-names></name></person-group><article-title>Experience with various antibiotics for treatment of anorectal Gonorrhea</article-title><source>Sex. Transm. Dis.</source><volume>6</volume><issue>2</issue><year>1979</year><fpage>148</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">386538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007435-197904000-00020</pub-id></element-citation></ref><ref id="b1160"><element-citation publication-type="journal" id="h1160"><person-group person-group-type="author"><name name-style="western"><surname>Abbasi</surname><given-names>J.</given-names></name></person-group><article-title>New Hope for a Gonorrhea Vaccine</article-title><source>JAMA</source><volume>318</volume><issue>10</issue><year>2017</year><fpage>894</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">28832870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.11037</pub-id></element-citation></ref><ref id="b1165"><element-citation publication-type="journal" id="h1165"><person-group person-group-type="author"><name name-style="western"><surname>Petousis-Harris</surname><given-names>H.</given-names></name><name name-style="western"><surname>Paynter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saxton</surname><given-names>P.</given-names></name><name name-style="western"><surname>McArdle</surname><given-names>B.</given-names></name><name name-style="western"><surname>Goodyear-Smith</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study</article-title><source>The Lancet</source><volume>390</volume><issue>10102</issue><year>2017</year><fpage>1603</fpage><lpage>1610</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)31449-6</pub-id><pub-id pub-id-type="pmid">28705462</pub-id></element-citation></ref><ref id="b1170"><element-citation publication-type="journal" id="h1170"><person-group person-group-type="author"><name name-style="western"><surname>Lennon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crengle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Percival</surname><given-names>T.</given-names></name></person-group><article-title>Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic</article-title><source>J. Paediatr. Child Healt.</source><volume>48</volume><issue>3</issue><year>2012</year><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1440-1754.2010.01969.x</pub-id><pub-id pub-id-type="pmid">21996021</pub-id></element-citation></ref><ref id="b1175"><element-citation publication-type="journal" id="h1175"><person-group person-group-type="author"><name name-style="western"><surname>Santolaya</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Oryan</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Valenzuela</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Prado</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vergara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Toneatto</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study</article-title><source>The Lancet</source><volume>379</volume><issue>9816</issue><year>2012</year><fpage>617</fpage><lpage>624</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(11)61713-3</pub-id><pub-id pub-id-type="pmid">22260988</pub-id></element-citation></ref><ref id="b1180"><element-citation publication-type="journal" id="h1180"><person-group person-group-type="author"><name name-style="western"><surname>Trembizki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>C.</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jennison</surname><given-names>A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bates</surname><given-names>J.</given-names></name></person-group><article-title>Estimating the prevalence of mixed-type gonococcal infections in Queensland, Australia</article-title><source>Sex. Health</source><volume>12</volume><issue>5</issue><year>2015</year><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">26145099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1071/SH15009</pub-id></element-citation></ref><ref id="b1185"><element-citation publication-type="journal" id="h1185"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Bankhead</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>H.S.</given-names></name></person-group><article-title>Antigenic variation in bacterial pathogens</article-title><source>Microbiol. Spectrum</source><volume>4</volume><issue>1</issue><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/microbiolspec.VMBF-0005-2015</pub-id><pub-id pub-id-type="pmcid">PMC4806564</pub-id><pub-id pub-id-type="pmid">26999387</pub-id></element-citation></ref><ref id="b1190"><mixed-citation publication-type="other" id="h1190">Lam, J. Genetic adaptation contributing to increased gonococcal fitness during vaginal infection of CEACAM-humanized mice (Doctoral dissertation, University of Toronto (Canada) 2017.</mixed-citation></ref><ref id="b1195"><element-citation publication-type="journal" id="h1195"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Apicella</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Seib</surname><given-names>K.L.</given-names></name></person-group><article-title>Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development</article-title><source>Crit. Rev. Microbiol.</source><volume>42</volume><issue>6</issue><year>2016</year><fpage>928</fpage><lpage>941</lpage><pub-id pub-id-type="pmid">26805040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/1040841X.2015.1105782</pub-id><pub-id pub-id-type="pmcid">PMC4958600</pub-id></element-citation></ref><ref id="b1200"><element-citation publication-type="journal" id="h1200"><person-group person-group-type="author"><name name-style="western"><surname>Piekarowicz</surname><given-names>A.</given-names></name><name name-style="western"><surname>K&#322;yz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Majchrzak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>D.C.</given-names></name></person-group><article-title>Oral Immunisation of Rabbits with S. enterica Typhimurium Expressing Neisseria gonorrhoeae Filamentous Phage &#934;6 Induces Bactericidal Antibodies Against N. gonorrhoeae</article-title><source>Sci. Rep.</source><year>2016</year><fpage>6:22549</fpage><pub-id pub-id-type="pmid">26939573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep22549</pub-id><pub-id pub-id-type="pmcid">PMC4778046</pub-id></element-citation></ref><ref id="b1205"><mixed-citation publication-type="other" id="h1205">Lao, A.H., Bonavida, B., 2016. Gonorrhea: Immune Escape and Immunotherapeutic Strategies. FIDT, 7(3-4), Begel House Inc.</mixed-citation></ref><ref id="b1210"><element-citation publication-type="journal" id="h1210"><person-group person-group-type="author"><name name-style="western"><surname>Butler</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Waidyarachchi</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Jerse</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R.E.</given-names></name><etal/></person-group><article-title>Aminomethyl spectinomycins as therapeutics for drug-resistant Gonorrhea and chlamydial co-infections</article-title><source>Antimicrob. Agents Chemotherapy</source><year>2018</year><fpage>26</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00325-18</pub-id><pub-id pub-id-type="pmcid">PMC5923137</pub-id><pub-id pub-id-type="pmid">29483122</pub-id></element-citation></ref><ref id="b1215"><element-citation publication-type="journal" id="h1215"><person-group person-group-type="author"><name name-style="western"><surname>Gulati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Ram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>P.A.</given-names></name></person-group><article-title>Antibody to reduction modifiable protein increases the bacterial burden and the duration of gonococcal infection in a mouse model</article-title><source>J. Infect. Dis.</source><volume>212</volume><issue>2</issue><year>2015</year><fpage>311</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">25596304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiv024</pub-id><pub-id pub-id-type="pmcid">PMC4565997</pub-id></element-citation></ref><ref id="b1220"><element-citation publication-type="journal" id="h1220"><person-group person-group-type="author"><name name-style="western"><surname>Semchenko</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Day</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Seib</surname><given-names>K.L.</given-names></name></person-group><article-title>MetQ of Neisseria gonorrhoeae is a surface-expressed antigen that elicits bactericidal and functional blocking antibodies</article-title><source>Infect. Immun.</source><volume>85</volume><issue>2</issue><year>2017</year><fpage>e00898</fpage><lpage>e916</lpage><pub-id pub-id-type="pmid">27895130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00898-16</pub-id><pub-id pub-id-type="pmcid">PMC5278169</pub-id></element-citation></ref><ref id="b1225"><element-citation publication-type="journal" id="h1225"><person-group person-group-type="author"><name name-style="western"><surname>Shewell</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Jen</surname><given-names>F.E.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>M.P.</given-names></name></person-group><article-title>Refinement of immunising antigens to produce functional blocking antibodies against the AniA nitrite reductase of Neisseria gonorrhoeae</article-title><source>PloS one</source><volume>12</volume><issue>8</issue><year>2017</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0182555</pub-id><pub-id pub-id-type="pmcid">PMC5542605</pub-id><pub-id pub-id-type="pmid">28771632</pub-id></element-citation></ref><ref id="b1230"><element-citation publication-type="journal" id="h1230"><person-group person-group-type="author"><name name-style="western"><surname>Gunderson</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>H.S.</given-names></name></person-group><article-title>Neisseria gonorrhoeae elicits extracellular traps in primary neutrophil culture while suppressing the oxidative burst</article-title><source>MBio.</source><volume>6</volume><issue>1</issue><year>2015</year><fpage>e02452</fpage><lpage>e2514</lpage><pub-id pub-id-type="pmid">25670773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.02452-14</pub-id><pub-id pub-id-type="pmcid">PMC4337578</pub-id></element-citation></ref><ref id="b1235"><element-citation publication-type="journal" id="h1235"><person-group person-group-type="author"><name name-style="western"><surname>Rotman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>H.S.</given-names></name></person-group><article-title>Neisseria gonorrhoeae MutS affects pilin antigenic variation through mismatch correction and not by pilE guanine quartet binding</article-title><source>J. Bacteriol.</source><volume>197</volume><issue>10</issue><year>2015</year><fpage>1828</fpage><lpage>1838</lpage><pub-id pub-id-type="pmid">25777677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JB.02594-14</pub-id><pub-id pub-id-type="pmcid">PMC4402387</pub-id></element-citation></ref><ref id="b1240"><element-citation publication-type="journal" id="h1240"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.X.</given-names></name><etal/></person-group><article-title>Opacity proteins of neisseria gonorrhoeae in lipooligosaccharide mutants lost ability to interact with neutrophil-restricted CEACAM3 (CD66d)</article-title><source>J. Huazhong Univ. Sci. Technol., [Med. Sci.]</source><volume>36</volume><issue>3</issue><year>2016</year><fpage>344</fpage><lpage>349</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11596-016-1589-4</pub-id><pub-id pub-id-type="pmid">27376801</pub-id></element-citation></ref><ref id="b1245"><element-citation publication-type="journal" id="h1245"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Jerse</surname><given-names>A.E.</given-names></name></person-group><article-title>Biological feasibility and importance of a gonorrhea vaccine for global public health</article-title><source>Vaccine</source><year>2018</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.02.081</pub-id><pub-id pub-id-type="pmcid">PMC6892272</pub-id><pub-id pub-id-type="pmid">29680200</pub-id></element-citation></ref><ref id="b1250"><element-citation publication-type="journal" id="h1250"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Seib</surname><given-names>K.L.</given-names></name></person-group><article-title>Neisseria gonorrhoeae vaccine development: hope on the horizon?</article-title><source>Curr. Opinion Infect. Dis.</source><volume>31</volume><year>2018</year><fpage>246</fpage><lpage>250</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QCO.0000000000000450</pub-id><pub-id pub-id-type="pmid">29601324</pub-id></element-citation></ref><ref id="b1255"><element-citation publication-type="journal" id="h1255"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>M.W.</given-names></name></person-group><article-title>Could vaccination against Neisseria gonorrhoeae be on the horizon?</article-title><source>Future Microbiol.</source><year>2018</year><fpage>495</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">29517283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fmb-2017-0262</pub-id></element-citation></ref><ref id="b1260"><element-citation publication-type="journal" id="h1260"><person-group person-group-type="author"><name name-style="western"><surname>Ratto-Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Paris</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Excler</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Oconnell</surname><given-names>R.J.</given-names></name></person-group><article-title>The US military commitment to vaccine development: a century of successes and challenges</article-title><source>Front. Immunol.</source><year>2018</year><fpage>9</fpage><pub-id pub-id-type="pmid">29977239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.01397</pub-id><pub-id pub-id-type="pmcid">PMC6021486</pub-id></element-citation></ref><ref id="b1270"><element-citation publication-type="journal" id="h1270"><person-group person-group-type="author"><name name-style="western"><surname>Dobson</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dionne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dawar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ogilvie</surname><given-names>G.</given-names></name><name name-style="western"><surname>Krajden</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial</article-title><source>JAMA</source><volume>309</volume><year>2013</year><fpage>1793</fpage><lpage>1802</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.1625</pub-id><pub-id pub-id-type="pmid">23632723</pub-id></element-citation></ref><ref id="b1275"><element-citation publication-type="journal" id="h1275"><person-group person-group-type="author"><name name-style="western"><surname>Stanley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Trimble</surname><given-names>C.</given-names></name></person-group><article-title>Human papillomavirus vaccines&#8212;immune responses</article-title><source>Vaccine</source><volume>30</volume><issue>Suppl. 5</issue><year>2012</year><fpage>F83</fpage><lpage>F87</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.106</pub-id><pub-id pub-id-type="pmid">23199968</pub-id></element-citation></ref><ref id="b1280"><element-citation publication-type="journal" id="h1280"><person-group person-group-type="author"><name name-style="western"><surname>Dadar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khandia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chaicumpa</surname><given-names>W.</given-names></name></person-group><article-title>Advances in designing and developing vaccines, drugs and therapeutic approaches to counter human papilloma virus</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>2478</fpage><pub-id pub-id-type="pmid">30483247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.02478</pub-id><pub-id pub-id-type="pmcid">PMC6240620</pub-id></element-citation></ref><ref id="b1285"><mixed-citation publication-type="other" id="h1285">Anna Rosa Garbuglia, Daniele Lapa, Catia Sias , Maria Rosaria Capobianchi and Paola Del Porto. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. Front. Immunol. 20 11:188.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00188</pub-id><pub-id pub-id-type="pmcid">PMC7040023</pub-id><pub-id pub-id-type="pmid">32133000</pub-id></mixed-citation></ref><ref id="b1290"><mixed-citation publication-type="other" id="h1290">Australian New Zealand Clinical Trials Registry. ANZTR identifier ACTRN12619001478101. Therapeutic Advances in Vaccines and Immunotherapy 8 MenGO: does the licensed meningococcal vaccine Bexsero&#174; provide cross-protection against gonorrhoea in gay and bisexual men? https://www. anzctr.org.au/Trial/Registration/TrialReview. aspx?id=376715. (accessed 31 October 2020).</mixed-citation></ref><ref id="b1295"><element-citation publication-type="journal" id="h1295"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>J.N.</given-names></name></person-group><article-title>Immunity in experimental syphilis. VI. Successful vaccination of rabbits with Treponema pallidum, Nichols strain, attenuated by irradiation</article-title><source>J. Immunol.</source><volume>110</volume><year>1973</year><fpage>1206</fpage><lpage>1215</lpage><pub-id pub-id-type="pmid">4572631</pub-id></element-citation></ref><ref id="b1300"><element-citation publication-type="journal" id="h1300"><person-group person-group-type="author"><name name-style="western"><surname>Parveen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Non-pathogenic borrelia burgdorferi expressing Treponema pallidum TprK and Tp0435 antigens as a novel approach to evaluate syphilis vaccine candidates</article-title><source>Vaccine</source><volume>37</volume><year>2019</year><fpage>1807</fpage><lpage>1818</lpage><pub-id pub-id-type="pmid">30797635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.02.022</pub-id><pub-id pub-id-type="pmcid">PMC6414260</pub-id></element-citation></ref><ref id="b1305"><element-citation publication-type="journal" id="h1305"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Immunogenicity and protective efficacy against Treponema pallidum in New Zealand rabbits immunized with plasmid DNA encoding flagellin</article-title><source>Emerg Microbes Infect</source><volume>7</volume><year>2018</year><fpage>177</fpage><pub-id pub-id-type="pmid">30405111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41426-018-0176-0</pub-id><pub-id pub-id-type="pmcid">PMC6220273</pub-id></element-citation></ref><ref id="b1310"><mixed-citation publication-type="other" id="h1310">Centre for Disease Control and Prevention. The Tuskegee timeline, https://www.cdc.gov/tuskegee/ timeline.htm. (accessed 13 August 2019).</mixed-citation></ref><ref id="b1315"><element-citation publication-type="journal" id="h1315"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Follmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Erneholm</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Protection against Chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein</article-title><source>J. Infect. Dis.</source><volume>212</volume><year>2015</year><fpage>978</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">25748320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiv137</pub-id></element-citation></ref><ref id="b1320"><element-citation publication-type="journal" id="h1320"><person-group person-group-type="author"><name name-style="western"><surname>B&#248;je</surname><given-names>S.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Erneholm</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A multisubunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-&#655;+ CMI responses protects against a genital infection in minipigs</article-title><source>Immunol. Cell Biol.</source><volume>94</volume><year>2016</year><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">26268662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/icb.2015.79</pub-id><pub-id pub-id-type="pmcid">PMC4748142</pub-id></element-citation></ref><ref id="b1325"><element-citation publication-type="journal" id="h1325"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Lorenzen</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Rosenkrands</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Protective effect of the vaccine promoted neutralizing antibodies against the intracellular pathogen Chlamydia trachomatis</article-title><source>Front. Immunol.</source><volume>8</volume><year>2017</year><fpage>1652</fpage><pub-id pub-id-type="pmid">29312283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.01652</pub-id><pub-id pub-id-type="pmcid">PMC5732375</pub-id></element-citation></ref><ref id="b1330"><mixed-citation publication-type="other" id="h1330">Fattom AI. Development of a nanoemulsion based vaccine for Chlamydia infection. http:// grantome.com/grant/NIH/R43-AI134168-01A1. (accessed 9 September 2019).</mixed-citation></ref><ref id="b1335"><element-citation publication-type="journal" id="h1335"><person-group person-group-type="author"><name name-style="western"><surname>Karunakaran</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine</article-title><source>Vaccine</source><volume>33</volume><year>2015</year><fpage>2159</fpage><lpage>2166</lpage><pub-id pub-id-type="pmid">25738816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.02.055</pub-id><pub-id pub-id-type="pmcid">PMC4390527</pub-id></element-citation></ref><ref id="b1340"><element-citation publication-type="journal" id="h1340"><person-group person-group-type="author"><name name-style="western"><surname>Stary</surname><given-names>G.</given-names></name><name name-style="western"><surname>Olive</surname><given-names>A.</given-names></name><name name-style="western"><surname>Radovic-Moreno</surname><given-names>A.F.</given-names></name><etal/></person-group><article-title>A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells</article-title><source>Science</source><volume>348</volume><year>2015</year><fpage>aaa8205</fpage><pub-id pub-id-type="pmid">26089520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaa8205</pub-id><pub-id pub-id-type="pmcid">PMC4605428</pub-id></element-citation></ref><ref id="b1345"><element-citation publication-type="journal" id="h1345"><person-group person-group-type="author"><name name-style="western"><surname>Garmory</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Leckenby</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>K.F.</given-names></name><etal/></person-group><article-title>Antibiotic-free plasmid stabilization by operator repressor titration for vaccine delivery by using live Salmonella enterica serovar typhimurium</article-title><source>Infect Immun</source><volume>73</volume><year>2005</year><fpage>2005</fpage><lpage>2011</lpage><pub-id pub-id-type="pmid">15784541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.73.4.2005-2011.2005</pub-id><pub-id pub-id-type="pmcid">PMC1087430</pub-id></element-citation></ref><ref id="b1350"><element-citation publication-type="journal" id="h1350"><person-group person-group-type="author"><name name-style="western"><surname>Kari</surname><given-names>L.</given-names></name><name name-style="western"><surname>Whitmire</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Olivares-Zavaleta</surname><given-names>N.</given-names></name><etal/></person-group><article-title>A live-attenuated Chlamydial vaccine protects against trachoma in non-human primates</article-title><source>J. Exp. Med.</source><volume>208</volume><year>2011</year><fpage>2217</fpage><lpage>2223</lpage><pub-id pub-id-type="pmid">21987657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20111266</pub-id><pub-id pub-id-type="pmcid">PMC3201208</pub-id></element-citation></ref><ref id="b1355"><element-citation publication-type="journal" id="h1355"><person-group person-group-type="author"><name name-style="western"><surname>Corey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Langenberg</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection. Two randomized controlled trials</article-title><source>JAMA</source><volume>282</volume><year>1999</year><fpage>331</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">10432030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.282.4.331</pub-id></element-citation></ref><ref id="b1360"><element-citation publication-type="journal" id="h1360"><person-group person-group-type="author"><name name-style="western"><surname>Mascola</surname><given-names>J.R.</given-names></name></person-group><article-title>Herpes simplex virus vaccines &#8211; why don&#8217;t antibodies protect?</article-title><source>JAMA</source><volume>282</volume><year>1999</year><fpage>379</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">10432037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.282.4.379</pub-id></element-citation></ref><ref id="b1365"><element-citation publication-type="journal" id="h1365"><person-group person-group-type="author"><name name-style="western"><surname>Strasser</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Pachuk</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs</article-title><source>J. Infect Dis.</source><volume>182</volume><year>2000</year><fpage>1304</fpage><lpage>11210</lpage><pub-id pub-id-type="pmid">11023454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/315878</pub-id></element-citation></ref><ref id="b1370"><element-citation publication-type="journal" id="h1370"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Wald</surname><given-names>A.</given-names></name></person-group><article-title>Status of vaccine research and development of vaccines for herpes simplex virus</article-title><source>Vaccine</source><volume>34</volume><year>2016</year><fpage>2948</fpage><lpage>2952</lpage><pub-id pub-id-type="pmid">26973067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.12.076</pub-id></element-citation></ref><ref id="b1375"><mixed-citation publication-type="other" id="h1375">ClinicalTrials.gov. Identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02919306">NCT02919306</ext-link>. Safety and efficacy study of vaccine schedule with Ad26.Mos.HIV and MVA-Mosaic in human immunodeficiency virus (HIV)-infected adults,https://clinicaltrials.gov/ct2/show/<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02919306">NCT02919306</ext-link>?term=vaccine&amp;cond=Human+Immunodeficien cy+Virus&amp;draw=2&amp;rank=1. (accessed 20 March 2019).</mixed-citation></ref><ref id="b1380"><element-citation publication-type="journal" id="h1380"><person-group person-group-type="author"><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nitayaphan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Vaccination with Alvac and AIDSVAX to prevent HIV-1 infection in Thailand</article-title><source>New Engl J. Med.</source><volume>361</volume><year>2009</year><fpage>2209</fpage><lpage>2220</lpage><pub-id pub-id-type="pmid">19843557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0908492</pub-id></element-citation></ref><ref id="b1385"><element-citation publication-type="journal" id="h1385"><person-group person-group-type="author"><name name-style="western"><surname>Jardine</surname><given-names>J.</given-names></name><name name-style="western"><surname>Julien</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Menis</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Rational HIV immunogen design to target specific germline B cell receptors</article-title><source>Science</source><volume>340</volume><year>2013</year><fpage>711</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">23539181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1234150</pub-id><pub-id pub-id-type="pmcid">PMC3689846</pub-id></element-citation></ref><ref id="b1390"><element-citation publication-type="journal" id="h1390"><person-group person-group-type="author"><name name-style="western"><surname>Moldt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rakasz</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo</article-title><source>Proc Natl Acad Sci USA</source><volume>109</volume><year>2012</year><fpage>18921</fpage><lpage>18925</lpage><pub-id pub-id-type="pmid">23100539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1214785109</pub-id><pub-id pub-id-type="pmcid">PMC3503218</pub-id></element-citation></ref><ref id="b1395"><element-citation publication-type="journal" id="h1395"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer</article-title><source>J. Virol.</source><volume>76</volume><year>2002</year><fpage>8769</fpage><lpage>8775</lpage><pub-id pub-id-type="pmid">12163597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.76.17.8769-8775.2002</pub-id><pub-id pub-id-type="pmcid">PMC136414</pub-id></element-citation></ref><ref id="b1400"><element-citation publication-type="journal" id="h1400"><person-group person-group-type="author"><name name-style="western"><surname>Parks</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Picker</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>King</surname><given-names>C.R.</given-names></name></person-group><article-title>Development of replication-competent viral vectors for HIV vaccine delivery</article-title><source>Curr. Opin. HIV AIDS</source><volume>8</volume><year>2013</year><fpage>402</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">23925000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/COH.0b013e328363d389</pub-id><pub-id pub-id-type="pmcid">PMC4040527</pub-id></element-citation></ref><ref id="b1405"><mixed-citation publication-type="other" id="h1405">Staples, J.E., Martin, S.W., Fischer M. Zika, 2019. Travel-related infections. In: Brunette, G.W., Nemhauser, J.B. (Eds.) CDC Yellow Book 2020: Health Information for International Travel New York: Oxford University Press.</mixed-citation></ref><ref id="b1410"><element-citation publication-type="journal" id="h1410"><person-group person-group-type="author"><name name-style="western"><surname>Counotte</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Sexual transmission of Zika virus and other flaviviruses a living systematic review</article-title><source>PLoS Med</source><volume>15</volume><year>2018</year><object-id pub-id-type="publisher-id">e1002611</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1002611</pub-id><pub-id pub-id-type="pmcid">PMC6057622</pub-id><pub-id pub-id-type="pmid">30040845</pub-id></element-citation></ref><ref id="b1415"><mixed-citation publication-type="other" id="h1415">World Health Organization. Welcome to the WHO vaccine trial tracker, https://docs.google. com/spreadsheets/d/19otvINcayJURCMg76xWO4KvuyedYbMZDcXqbyJGdcZM/pubhtml (2019). (accessed 9 September 2020).</mixed-citation></ref><ref id="b1420"><mixed-citation publication-type="other" id="h1420">Sakkas, H., Bozidis, P., Giannakopoulos, X., et al. An update on sexual transmission of Zika virus. Pathogens 2018; 7: pii: E66.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens7030066</pub-id><pub-id pub-id-type="pmcid">PMC6161238</pub-id><pub-id pub-id-type="pmid">30081445</pub-id></mixed-citation></ref></ref-list><ack id="ak005"><sec id="s0090"><title>Acknowledgements</title><p id="p0180">All the authors acknowledge and thank their respective Institutes and Universities.</p></sec><sec id="s0095"><title>Funding</title><p id="p0185">This compilation is a review article written by its authors and required no substantial funding to be stated.</p></sec></ack><fn-group><fn id="d35e300"><p id="np005">Peer review under responsibility of King Saud University.</p></fn></fn-group></back></article></pmc-articleset>